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ABSTRACT 
Assessment of Micronutrient Status in Pregnant Malawian Women Before and After 
Treatment for Moderate Malnutrition 
 
Cambria M. Glosz 
 
Background: Multiple micronutrient deficiencies are prevalent in pregnant women in 
developing countries and can result in adverse effects to both the mother and infant. 
Multiple micronutrient supplements or supplementary foods may be a way to combat 
micronutrient deficiencies.  
Objective: To assess change in micronutrient and protein levels in moderately 
malnourished pregnant Malawian women after receiving one of three nutritional 
interventions.  
Methods: Serum retinol, 25-hydroxyvitamin D, ferritin, vitamin B12, folate, zinc, albumin 
and C-reactive protein concentrations were measured in pregnant women with MUAC 
>20.6 cm and <23.0 cm at baseline (n=343) and after 10 weeks (n=229) of receiving 
either: 1) macro- and micronutrient fortified, peanut-based, ready-to-use supplementary 
food (RUSF), 2) corn-soy blended flour with a prenatal multiple micronutrient 
supplement (CSB-UNIMMAP), or 3) corn-soy blended flour with iron and folic acid 
(CSB-IFA). Each provides approximately double the RDA of most micronutrients and 
900 kcal/day. Percentages of deficiency were assessed using chi-square testing for 
proportions. Mean changes in concentrations were found using repeated measures 
MANOVA or ANOVA. Variables were transformed logarithmically if they were not on 
v 
 
the normal distribution. Covariates included inflammatory status (measured by CRP), 
gestational age at baseline, HIV status, parity, fasting status, and MUAC at baseline.  
Results: Baseline micronutrient concentrations indicated high rates of deficiency in zinc 
(29-39%) and albumin (37-46%), and marginal status of retinol (26-37%) and vitamin D 
(31-32%). Adjusted mean changes in vitamin B12 concentrations from week 0 to week 10 
were -17.1, -36.1, and -52.9 pg/mL for RUSF, CSB-UNIMMAP, and CSB-IFA, 
respectively (p=0.007). Adjusted mean changes in vitamin D concentrations from week 0 
to week 10 were 6.1, 3.1, and 1.7 ng/mL for RUSF, CSB-UNIMMAP, and CSB-IFA, 
respectively (p=0.007). Adjusted mean changes in folate concentrations from week 0 to 
week 10 were 2.2, 1.7, and 4.0 ng/mL for RUSF, CSB-UNIMMAP, and CSB-IFA, 
respectively (p=0.37 for effect of treatment; p=0.06 for the interaction effect of 
time*treatment). Changes in ferritin, zinc, albumin, retinol, and CRP were not 
significantly different between treatment groups.  
Conclusions: Deficiencies in zinc and albumin, and marginal status of vitamin D and 
retinol, are common among this population of moderately malnourished pregnant 
Malawian women. Significant changes in vitamin D and vitamin B12were observed from 
week 0 to week 10, with the RUSF group having the greatest improvements compared to 
the CSB-UNIMMAP and CSB-IFA treatments.   
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CHAPTER 1: INTRODUCTION 
 Malnutrition is a global problem, especially in developing countries, with 
pregnant women being particularly vulnerable to becoming undernourished. Pregnancy 
greatly increases requirements for many nutrients (Lartey, 2008). An environment of 
poverty and food shortages results in increased prevalence of maternal malnutrition, 
which can cause short-term and long-term health consequences to both a mother and her 
child. Poor birth outcomes such as low birth weight (LBW) infants, stillbirths, preterm 
delivery, and neonatal mortality are common in undernourished mothers (Ahmed, 
Hossain, & Sanin, 2012; Lartey, 2008).  
Infectious diseases, such as HIV and malaria, are common in African women and 
can further worsen nutritional status (Lartey, 2008). Malawi is a low-income country in 
sub-Saharan Africa that has one of the highest rates of maternal mortality worldwide, at 
634 deaths per 100,000 live births (The World Bank, 2015). Similar to other resource-
limited countries, Malawian women are afflicted with a combination of chronic lack of 
energy intake, insufficient weight gain during pregnancy, anemia, and micronutrient 
deficiencies (Ahmed et al., 2012).  
 Malnourished women have a higher rate of mortality during pregnancy and 
childbirth than women who are properly nourished (Ahmed et al., 2012). Micronutrient 
deficiencies are common in those who are malnourished, and even moderate deficiencies 
can have severe negative effects on the mother and fetus. Children who are born in an 
undernourished state are at increased risk of having stunting and malnutrition later in life. 
Malnutrition can become an intergenerational vicious cycle that is difficult to recover 
from (Ahmed et al., 2012).  
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 The most common micronutrient deficiencies worldwide are iron, vitamin A, 
iodine, and zinc (Ahmed et al., 2012). Deficiencies in these nutrients during pregnancy, 
in addition to vitamin D, vitamin B12, and folate, can lead to a myriad of negative 
maternal consequences, including night blindness, increased susceptibility to infections, 
anemia, and preeclampsia; infant-related consequences include small for gestational age 
(SGA) and LBW newborns, increased risk of premature births and stillbirths, neural tube 
defects, and decreased fetal cognitive development (Ahmed et al., 2012; Christian, 
Schulze, Stoltzfus, & Jr, 1998; Kennedy, Nantel, & Shetty, 2003). 
 The current micronutrient supplementation standard of care for pregnant women 
in most developing countries is supplementation with iron and folic acid. Recent research 
has questioned whether multiple micronutrients would be more beneficial to maternal and 
infant nutrition than iron and folic acid alone (Bhutta, Imdad, Ramakrishnan, & 
Martorell, 2012). It is crucial to investigate the prevalence of micronutrient deficiencies 
in pregnant Malawian women and to determine if supplementation with multiple 
micronutrients or ready-to-use fortified foods during pregnancy can improve nutritional 
status greater than iron and folic acid supplements. In order to better target nutritional 
treatment, determination of micronutrient status and prevalence of deficiencies is helpful. 
In addition, monitoring change in serum micronutrient levels during treatment will help 
to determine which treatment is most effective in delivering micronutrients.  
 
   
 
 
3 
CHAPTER 2: REVIEW OF LITERATURE 
 Maternal malnutrition is a global burden that is related to millions of deaths of 
women and children each year (Ahmed et al., 2012). Maternal nutrition refers to the 
nutritional needs of a woman before pregnancy, throughout pregnancy, and during 
lactation. Pregnant women who are undernourished prior to conception are more likely to 
worsen their nutritional status due to the increased energy and nutrient demands from the 
growing fetus (Ahmed et al., 2012). Women in developing countries tend to perform hard 
physical labor throughout the entire length of their pregnancies, which further increases 
their nutrient requirements (Lartey, 2008). The additional nutrient demands during 
pregnancy and lactation can cause the woman’s tissues to become depleted, making this a 
high-risk period. In developing countries, it is common for women to have frequent 
pregnancies due to a lack of birth control (Ahmed et al., 2012). Closely spaced 
pregnancies result in insufficient time to replenish nutrient and energy stores before the 
next pregnancy (Lartey, 2008).  
Women who are malnourished during pregnancy have a higher risk of mortality 
than healthy pregnant women (Lartey, 2008). Maternal malnutrition becomes a vicious 
cycle that gets handed down to subsequent generations. A malnourished infant will often 
grow up to be a malnourished adult (Ahmed et al., 2012; Fig. 2.1).  
 
 
4 
 
Figure 2.1. The effects of maternal malnutrition, with potential causes and 
consequences throughout the life cycle. (Excerpted from Ahmed et al., 2012.) 
 
 Malnutrition in the form of micronutrient deficiency is most common among 
young children and women of reproductive age. Even moderate deficiencies during 
pregnancy can have serious adverse effects for the mother and fetus (Ahmed et al., 2012). 
Micronutrient deficiencies are sometimes referred to as “hidden hunger”, because the 
effects on the body can go unnoticed and are not as visual as protein-energy malnutrition, 
especially when the deficiency is subclinical (Kennedy et al., 2003). Almost one-third of 
the world is affected by a deficiency in one or more micronutrient (Ahmed et al., 2012). 
Improving the micronutrient status of pregnant women is one proposed method to combat 
maternal malnutrition and improve birth outcomes (Black, 2001).  
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2.1 Maternal Health in Malawi 
 Malawi is a resource-limited, landlocked country in southeastern Africa with a 
population of 16.36 million (The World Bank, 2015) (Figure 2.2). One out of every 36 
pregnant women will die during pregnancy or childbirth in Malawi, one of the highest 
rates in the world. The main causes of maternal mortality include hemorrhage, sepsis, 
hypertension, and other pregnancy complications, but the indirect causes include 
nutritional deficiencies and malaria (UNICEF, 2013). 
 
Figure 2.2. Malawi, a country in southeastern Africa. Excerpted from 
(http://commons.wikimedia.org).  
 
Another factor that further compromises maternal nutrition is infection with HIV, 
which disproportionately affects Malawian women. The average prevalence of HIV in 
Malawian adults is 12% (UNICEF, 2013); approximately 58% of the individuals with 
HIV are female (UNAIDS, 2012). High fertility rates in Malawi increase a woman’s risk 
for malnutrition, due to the inability to recover nutritionally from the previous pregnancy. 
The total fertility rate in Malawi in 2014 was 5.26 children born per woman (Central 
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Intelligence Agency, 2014). Figure 2.3 summarizes the factors involved with maternal 
malnutrition and the consequences it can have on both maternal and infant health. 
 
Figure 2.3. Factors involved in maternal malnutrition and effects on maternal and 
infant health. (Adapted from Lartey, 2008).  
 
Women of reproductive age in Malawi are at high risk of contracting infectious 
diseases, including HIV/AIDS, tuberculosis (TB), pneumonia, malaria, and parasitic 
infections. Some of these diseases and their relation to maternal malnutrition will be 
discussed in detail in later sections.  
2.1.1. Diagnosis of maternal malnutrition and body composition  
There is no international agreement on the diagnostic criteria to identify pregnant 
women as malnourished and when to enroll them in nutritional intervention programs. 
Mid-upper arm circumference (MUAC) is commonly used to classify malnutrition in all 
populations. MUAC changes very little throughout pregnancy and is not dependent on 
gestational age, unlike weight (Ververs, Antierens, Sackl, Staderini, & Captier, 2013; 
WHO, 1995). There is some inconsistency with the MUAC cut-off guidelines for 
malnutrition in pregnant women. MUAC values below 22 and 23 cm are associated with 
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moderate malnutrition and adverse effects during pregnancy, including LBW (Karim & 
Mascie-Taylor, 1997), IUGR, and premature infants (Verhoeff et al., 2001; Ververs et al., 
2013). MUAC values below 20.7 cm during pregnancy are associated with severe 
maternal malnutrition and fetal growth retardation (The Sphere Project, 2011). Guidelines 
are not yet universal in recommending specific cut-off values for enrolling pregnant 
women into nutritional feeding programs (Ververs et al., 2013).  
There are other measurements of body composition that can be used to determine 
nutritional status. A healthy pregnant woman’s arm fat area (AFA) rises in the first 
trimester and decreases in the third trimester because fat stores are being supplied to the 
fetus. Arm muscle area (AMA) of a healthy pregnant woman rises in the third trimester 
and should stay elevated until at least 8 weeks after delivery (Taggart, Holliday, 
Billewicz, Hytten, & Thomson, 1967; R. M. Thomas et al., 2013).  
Pregnant women living in resource-limited countries tend to have different 
patterns of body composition compared to pregnant women in developed countries, due 
to a combination of poor dietary intake, frequent pregnancies, high amounts of physical 
labor during pregnancy, and acute infections (R. M. Thomas et al., 2013). The rainy 
season in many African countries, including Malawi, is associated with higher rates of 
food shortages, physical labor, and malarial infections, which can lead to increased 
maternal morbidity and reduced weight gain during pregnancy (Branca, Pastore, 
Demissie, & Ferro-Luzzi, 1993; Friis et al., 2004b; R. M. Thomas et al., 2013).  
 Patterns of body composition in HIV-infected pregnant women are not as well 
understood. A longitudinal study of HIV-infected women in Malawi measured 
anthropometrics and body composition during pregnancy. Women who were pregnant 
 
 
8 
during the famine season (from August to March) experienced significant decreases in 
MUAC and AMA (Figure 2.4), as well as a lower rate of gestational weight gain and 
increased loss of AFA, compared to pregnant women who were not exposed to the 
famine season (R. M. Thomas et al., 2013). 
Figure 2.4. Values of arm muscle area throughout the pregnancies of HIV-infected 
Malawian women who were either fully exposed (all of the last 30.5 days) to famine 
season or not exposed (zero of the last 30.5 days). (Excerpted from Thomas et al., 
2013) 
 The increase of AMA during the third trimester in women not exposed to the 
famine season in the study by Thomas et al. (2013) is similar to the normal pattern seen 
in healthy pregnant women. However, the significant loss of MUAC and AMA in women 
exposed to the famine season is consistent with a study of Tanzanian HIV-infected 
pregnant women, who lost an average of 1 cm from their MUAC during the second and 
third trimesters (R. M. Thomas et al., 2013; Villamor, Saathoff, Msamanga, et al., 2005). 
Loss of AMA in HIV-infected pregnant women has been linked to increased risk of 
infection, progression of HIV, death, and possible increase in risk of mother-to-child 
transmission of HIV (Macallan, 1999b; Villamor, Saathoff, Msamanga, et al., 2005). 
 A study in HIV-infected Malawian pregnant women analyzed dietary patterns and 
anthropometrics (Ramlal et al., 2015). In this population, the mean energy intake was 
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1,378 calories per day. Based on 24-hour dietary recalls, women were placed into one of 
three diet clusters: animal-based, plant-based, or grain-based. Women consuming a grain-
based diet had the lowest wealth index and were most exposed to the famine season, 
resulting in lower intake of calories, protein, fat and iron, compared to women consuming 
the animal- or plant-based diets. Women consuming grain-based diets had significantly 
lower AFA compared to the plant-based group, however, the grain-based group had 
higher AMA compared to the animal-based group. This may be because women in the 
grain-based group would be more likely to perform manual labor, such as farming, due to 
their lower wealth index. This study provided an interesting look into Malawian dietary 
patterns and the authors conclude that this population could benefit from increased 
dietary diversity and caloric and nutrient intake, especially during pregnancy (Ramlal et 
al., 2015).   
2.1.2 Malnutrition and impact on maternal and infant health 
Malnutrition can affect maternal health by increasing a woman’s risk of anemia, 
micronutrient deficiencies, short stature, low BMI, and maternal mortality (Bhutta & Das, 
2014; Black et al., 2008). Possible consequences of micronutrient deficiency during 
pregnancy include maternal or fetal death, increased labor complications, anemia, 
abnormal fetal organ development, compromised fetal growth, and reduced immunity of 
the newborn (Black, 2001; Ramakrishnan, Manjrekar, Rivera, Gonzáles-Cossío, & 
Martorell, 1999). Over twenty percent of maternal deaths can be attributed to inadequate 
nutrition during pregnancy (Bhutta & Das, 2014). The World Health Organization 
(WHO) defines maternal mortality as the death of a woman during the pregnancy or 
 
 
10 
within 42 days after pregnancy has ended, due to a cause related to or worsened by the 
pregnancy itself (WHO, 2015b).  
Maternal malnutrition can also have a great impact on the health and nutritional 
status of her child. Low maternal BMI can contribute to intrauterine growth restriction 
(IUGR), LBW infants, and neonatal mortality (Arimond et al., 2013). There is a growing 
amount of research about the “first 1,000 days” of a child’s life (from conception to age 
two) as a crucial time to prevent childhood stunting. During this time period, maternal 
and infant undernutrition can cause irreversible damage (Arimond et al., 2013; Victora et 
al., 2008). 
Maternal anthropometrics can be predictors of infant size. A study done on 
Malawian HIV-infected pregnant women found that maternal MUAC, AFA and AMA 
strongly predicted the weight of her infant, with the strongest predictor being MUAC. In 
this study, every 1 cm increase in maternal MUAC corresponded to a 31.8 g increase in 
infant birth weight (R. Thomas et al., 2012). 
 Fetal and infant malnutrition can result in both immediate and long-term 
consequences. Proximate concerns include a higher risk of being born with LBW, small 
for gestational age (SGA), or IUGR, which then increases the likelihood of being stunted 
as a child. Mothers who have short stature or low BMI are more likely to deliver 
newborns that are LBW or SGA (Adair, 2014). These smaller infants are also more likely 
to have decreased cognitive and educational abilities, higher rates of morbidity and 
mortality, and impaired immunity (Adair, 2014; R. Thomas et al., 2012).    
Long-term consequences of fetal undernutrition include decreased cognitive 
development and motor skills, as well as a higher chance of developing chronic disease 
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later in life (Arimond et al., 2013; The World Bank, 2006). Most of the brain 
development of an infant occurs during the first 1,000 days after conception, thus, 
intrauterine life is critical. The neural tube of the fetus, which will form the brain and 
spinal cord, begins to form only 22 days after conception. The brain develops the most 
between 24 and 42 weeks gestation, making infants who are born preterm at higher risk 
of not having a fully developed neurological system (Kerac et al., 2014). The nutrients 
that are most crucial for neurodevelopment include iron, zinc, folate, vitamin A, 
selenium, iodine, and choline (Georgieff, 2007). These nutrients impact various areas of 
brain development, thus a deficiency in one may have differing effects on cognitive 
growth than another. Specific micronutrient deficiencies and their effect on fetal 
neurodevelopment are shown in Table 2.1. However, micronutrient deficiencies are 
rarely singular and it is common for pregnant women to be lacking in multiple nutrients 
(Kerac et al., 2014). Essential fatty acids (EFAs), especially docosahexaenoic acid 
(DHA), are necessary for the function of membranes and synapses, as well as 
myelination in the brain (Georgieff, 2007). Infants who are born preterm are at risk of 
EFA deficiency because the EFAs accumulate in the brain during the third trimester 
(Prado & Dewey, 2014). Other long-term consequences of fetal undernutrition include 
increased risk of chronic disease later in life, such as cardiovascular disease. This may be 
due to increased stress in the womb (Roseboom, Painter, van Abeelen, Veenendaal, & de 
Rooij, 2011). A study of individuals who were born during a famine in the Nigerian civil 
war (1967-1970) found that they had increased risk of type 2 diabetes and hypertension, 
compared to those not exposed in utero to the famine (Hult et al., 2010).  
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Table 2.1. Maternal micronutrient deficiencies and their potential impact on fetal 
and infant neurodevelopment. (Adapted from Kerac et al., 2014) 
Nutrient Deficiency Fetal and Infant Neurodevelopmental Risk 
Folate Neural tube defects 
Iron Impaired language ability and fine motor skills at age 5 
Vitamin A Anemia and auditory loss 
Zinc Autonomic and cerebellar dysfunction 
 
The perinatal period, which is defined as the period between 22 weeks gestation 
and 7 days postpartum, requires high nutrient and energy intake in order to support the 
increased growth rates of the fetus and newborn (Makrides, Anderson, Gibson, & Collins, 
2013; WHO, 2015a). Inadequate nutrient supply to the fetus can result in LBW infants, 
who are more likely to have lower cognitive abilities later in life, compared to infants of 
average birth weight. This inadequate nutrient supply could occur due to a number of 
factors, including poor maternal nutrition, preterm birth, or placental insufficiency 
leading to reduced flow of nutrients to the fetus. Preterm infants have been found to have 
reduced cognitive abilities compared to normal term babies (Makrides et al., 2013).  
2.1.3 Health care in Malawi 
 Antenatal care (ANC) in Malawi is found in both rural and urban centers. From 
2008-2012, 94.7% of pregnant women attended at least one visit to ANC. However, only 
45.5% of these women attended ANC at least four times (UNICEF, 2013). Many women 
don’t attend ANC until their second or third trimester. Seventy-three percent of women 
deliver in an institutional setting, such as a clinic or hospital (UNICEF, 2013). 
Supplementary feeding programs (SFPs) are common for severely or moderately 
malnourished children and lactating mothers, but SFPs are not currently widespread for 
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pregnant women. Records from 2008 indicate that 210 ANC centers in 28 districts of 
Malawi provided SFPs for 6,500 pregnant and lactating mothers. The current standard of 
care is iron and folic acid supplements for all pregnant women. Malnourished pregnant 
and lactating women receive a corn-soy flour blend (CSB) ration of 5 kilograms per 
fortnight at some, but not all, ANC clinics (World Food Programme, 2008b). 
 Malaria is a major health issue affecting Malawi, with especially devastating 
effects for pregnant women and children. In 2012, malaria accounted for 63 out of 
100,000 deaths in the Malawian population, while accounting for 1 out 12 deaths in 
children under five (President’s Malaria Initiative, 2015). Malaria in pregnancy can lead 
to perinatal mortality, LBW infants and premature delivery (Schantz-Dunn & Nour, 
2009). Intermittent preventive treatment in pregnancy (IPTp) gives doses of the anti-
malarial drug sulphadoxine-pyrimethamine (SP) to prevent maternal malarial infection. 
In Malawi, the first IPTp-SP dose is given as early as possible in the second trimester, 
with the second dose administered at least one month after the first dose (WHO, 2012b). 
In 2012, 53% of women received two or more doses of IPTp-SP during their previous 
pregnancy (President’s Malaria Initiative, 2015). SP is contraindicated in women 
receiving cotrimoxazole prophylaxis (for prevention of mother-to-child-transmission of 
HIV). Pregnant women also receive insecticide treatment bed nets during pregnancy to 
further reduce risk of contracting malaria (WHO, 2012b).  
2.2. Micronutrient deficiency in pregnancy  
 Vitamins and minerals, collectively called micronutrients, are essential for the 
proper growth of a fetus. Inadequate intake of micronutrients during pregnancy can result 
in problems for both the mother and fetus. Common deficiencies among pregnant women 
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worldwide are vitamins A, B6, B12, C, D, E, and folate and minerals iron, iodine, and zinc 
(Black et al., 2008; Kawai, Spiegelman, Shankar, & Fawzi, 2011).   
 There are various confounding factors that can make it difficult to determine the 
prevalence and magnitude of maternal micronutrient deficiencies, especially in 
developing countries. One is that micronutrient deficiencies tend to coexist, which can 
make it difficult to determine which deficiency is causing which outcome. There is also 
intra-individual variability in bioavailability of nutrients, which can lead to different 
nutrient requirements for different individuals (Black, 2001). The micronutrients that will 
be discussed in detail in this review are vitamins A, B12, D, and folate, and minerals zinc 
and iron. 
2.2.1 Vitamin A  
 Vitamin A, a fat-soluble nutrient, is necessary for visual function, immunity, cell 
growth, integrity of epithelial cells, lung development, production of red blood cells, and 
reproduction (Checkley et al., 2010; WHO, 2009). Retinol and its oxidation products are 
necessary for the transcription of hundreds of genes, especially within the visual and 
reproductive systems (S. S. Gropper, Smith, & Groff, 2009). A diet that is deficient in 
vitamin A will result in the inability to adequately support vision, immunity, and cellular 
processes. Some periods of the lifecycle require increased amounts of vitamin A to 
support these systems, including pregnancy, lactation, infancy and childhood (WHO, 
2009).   
 Serum retinol is a measure of the body’s reserves of vitamin A and it is controlled 
by homeostasis in the body. Serum retinol levels do not decrease until the stores in the 
body are compromised. Retinol levels are impacted by infection, protein status, and 
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levels of other micronutrients (dePee & Dary, 2002). The cut-off value for using retinol 
to determine vitamin A deficiency (VAD) is generally <0.70 µmol/L. However, some 
sources indicate that for pregnant and lactating women, a cut-off value of <1.05 µmol/L 
should be used to indicate marginal vitamin A status, with <0.70 µmol/L representing 
vitamin A deficiency. Severe VAD is characterized by retinol levels <0.35 µmol/L 
(Sommer & Davidson, 2002; WHO, 2009). Some research has indicated the use of 
different cut-off values to account for inflammation. Thurnham & McCabe (2012) 
suggest using <0.60 µmol/L to classify VAD with inflammation. See Appendix A for the 
recommended dietary allowances (RDA) and tolerable upper intake levels (UL) during 
pregnancy for vitamin A and all other micronutrients discussed in this review. There is a 
risk of excessive intake of vitamin A during pregnancy, which can cause fetal toxicity 
and birth defects. Women who are pregnant or may become pregnant should not exceed 
3,000 µg retinol equivalents (RE) per day (FAO & WHO, 1998).  
 A WHO analysis of vitamin A concentrations from 1995-2005 found that over 19 
million pregnant women worldwide are estimated to have low serum retinol, which 
represents 15.3% of pregnant women living in countries at highest risk for VAD. This 
study estimated that 13.7% of Malawian pregnant women were deficient in vitamin A, 
which categorizes Malawi as having a moderate public health problem in terms of VAD 
(WHO, 2009). 
 VAD in pregnant women is associated with severe anemia, wasting, and 
morbidity from infectious diseases. VAD and infections have a complex and bidirectional 
relationship, in that each influences and increases the risk of the other (Christian et al., 
1998). Infections can increase the risk of VAD, and individuals (especially young 
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children and pregnant women) with VAD are more susceptible to developing infectious 
diseases (Christian et al., 1998). Vitamin A is involved in the immune system via retinoic 
acid, which stimulates the activity of phagocytes and cytokines, and preserves 
concentrations of natural killer cells. Individuals with VAD are less able to fight 
infections because VAD causes reduced regeneration of mucosal epithelial cells, which 
serve as barriers against invading pathogens (S. S. Gropper et al., 2009; Stephensen, 
2001).  
 Hearing loss and ear infections are common in the developing world and may be 
related to gestational VAD (Emmett & West, 2014). Due to vitamin A’s relationship with 
infections and the immune system, a fetal environment that is deficient in vitamin A may 
lead to ear infections and hearing loss in the child. It is hypothesized that proper fetal 
development of the inner ear is dependent on adequate vitamin A status during the 
mother’s pregnancy (Emmett & West, 2014).  
 The nutrient status of a newborn is highly dependent on the mother’s nutrient 
status. A vitamin supplementation trial done on HIV-infected pregnant and lactating 
women in Tanzania found that infants born to mothers who received vitamin A had 
significantly higher serum vitamin A concentrations during their first six months of life 
compared to infants whose mothers did not receive vitamin A (Table 2.2) (Baylin, 
Villamor, Rifai, Msamanga, & Fawzi, 2005).  
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Table 2.2. Effects of supplementing HIV-infected pregnant and lactating women on 
the mean serum concentrations of retinol in their infants at 6 weeks and 6 months of 
age. (Adapted from Baylin et al., 2005).  
 
 Pregnant women who are HIV-infected with VAD are at increased risk of having 
a LBW infant and have increased risk of mother-to-child transmission (MTCT) of HIV 
(Semba et al., 1995). Infant mortality rates are also greater in women who are deficient in 
vitamin A. HIV-infected women in Malawi who were severely deficient in vitamin A 
(<0.35 µmol/L) during pregnancy experienced an infant mortality rate of 93.3% in their 
offspring, while women with the most replete vitamin A levels (>1.75 µmol/L) had a 
14.2% infant mortality rate (p<0.0001) (Semba et al., 1995). In a study in Malawi, HIV-
infected pregnant women were randomized to receive a daily dose of 10,000 IU of 
vitamin A or a placebo from 18-28 weeks gestation until delivery (Kumwenda et al., 
2002). Infants born to mothers in the vitamin A group had significantly higher birth 
weights, and weight and length at 6 weeks of age, compared to infants born into the 
placebo group.  However, by 6 months of age there were no significant differences 
between the weights and lengths of the two groups. In addition, at 6 weeks of age, infants 
in the vitamin A group had significantly higher hemoglobin levels and significantly lower 
rates of anemia, compared to infants born into the placebo group. The results from this 
study indicate that vitamin A supplementation of 10,000 IU per day during pregnancy can 
 No vitamin A Vitamin A  
 N Mean (SD) N Mean (SD) P-value 
6 weeks      
Retinol     
(µmol/L) 
297 0.43 (0.16) 297 0.52 (0.18) <0.0001 
6 months      
Retinol 
(µmol/L) 
276 0.48 (0.19) 284 0.54 (0.21) 0.0002 
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result in increased birth weight and growth at 6 weeks, and reduced prevalence of anemia 
in infants born in HIV-infected mothers (Kumwenda et al., 2002).  
 Vitamin A may have an effect on lowering anemia rates through a variety of 
possible mechanisms, including the ability to mobilize iron stores from tissues, to reduce 
anemia of infection, and to increase growth of precursor cells that differentiate into 
erythrocytes (red blood cells) (Kumwenda et al., 2002; Semba et al., 2001). A study 
involving pregnant women in Indonesia found that vitamin A combined with iron 
supplementation reduced rates of anemia more than iron on its own (Suharno, West, 
Muhilal, Karyadi, & Hautvast, 1993). Vitamin A may play a role in reducing iron 
deficiency anemia through improving resistance to infections, regulating red blood cell 
production, and influencing iron metabolism and absorption (Michelazzo, Oliveira, 
Stefanello, Luzia, & Rondó, 2013).  
 Despite evidence from singular studies showing associations between prenatal 
vitamin A supplementation and improved maternal and infant outcomes, a 2011 
Cochrane review and meta-analysis of 16 randomized controlled trials of maternal 
vitamin A supplementation (van den Broek et al., 2011) found no significant effect on the 
relative risk of maternal mortality (Green, Pindar, Davis, & Mellanby, 1931; Kirkwood et 
al., 2010; West et al., 1999), perinatal mortality (Kirkwood et al., 2010), neonatal 
mortality (Coutsoudis, Pillay, Spooner, Kuhn, & Coovadia, 1999; Kirkwood et al., 2010; 
Kumwenda et al., 2002; West et al., 1999), stillbirths (Kirkwood et al., 2010; Kumwenda 
et al., 2002; Muslimatun et al., 2001), neonatal anemia (Fawzi et al., 1998; Kumwenda et 
al., 2002), preterm births (Coutsoudis et al., 1999), or LBW infants (Cox et al., 2005; 
Kumwenda et al., 2002; Radhika, Bhaskaram, Balakrishna, & Ramalakshmi, 2003). 
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However, antenatal vitamin A supplementation did show a significant reduction in the 
risk of night blindness (West et al., 1999) and maternal anemia (Fawzi et al., 1998; 
Muslimatun et al., 2001; Semba et al., 2001; Suharno et al., 1993; West et al., 1999).  
There was a reduced risk of LBW infants from HIV-infected women when comparing 
vitamin A, iron and folate supplementation to iron and folate alone  (RR 0.67, 95% CI 
0.47, 0.96) (Kumwenda et al., 2002). Some evidence was found that vitamin A 
supplementation might reduce the risk of maternal clinical infections. These authors 
conclude that there may not be a role for antenatal vitamin A supplementation to reduce 
maternal or infant mortality, but there is strong evidence that vitamin A supplementation 
can reduce maternal anemia, especially in HIV-infected populations (van den Broek et 
al., 2011).  A 2015 Cochrane review including 19 trials found similar results and came to 
the same conclusions as the 2011 review (McCauley, van den Broek, Dou, & Othman, 
2015).  
2.2.2 Vitamin D 
 Vitamin D is a fat-soluble seco-steroid that is sometimes referred to as a pro-
hormone rather than a vitamin, because it has the ability to be synthesized under the skin 
from sunlight, therefore it is not essential to consume. Vitamin D has long been 
associated with effects on the bone and its role in maintaining calcium concentrations in 
the body. Recent research has begun to associate vitamin D with many more functions. 
During pregnancy, a wide array of diseases and complications for both mother and fetus 
have been linked to low levels of vitamin D (Christakos et al., 2013).   
 The traditional roles of vitamin D in the body involve bone health and calcium 
homeostasis. However, vitamin D has recently been discovered to have an impact on 
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almost all body systems. Vitamin D receptors (VDR) have been found in 37 human 
tissues in both the classical systems (bone, kidney, and intestine), as well as unexpected 
cells such as in the pancreas, placenta, brain, skin, cardiovascular, and immune systems. 
This means that vitamin D, or lack thereof, may have an effect on many different diseases 
and conditions (Barrett & McElduff, 2010; Christakos et al., 2013).  
 There are few naturally occurring dietary sources of vitamin D, including fatty 
fish (salmon, tuna, herring, sardines, and fish liver oils), liver, beef, veal, egg yolks, and 
cheese. In the United States, fortified vitamin D products include milk, margarine, orange 
juice, and some breads and breakfast cereals (S. S. Gropper et al., 2009). In Malawi, oils 
and skimmed milk powder are fortified with vitamin D (World Food Programme, 2008a).  
 In populations living in areas of adequate sunshine, vitamin D levels are mostly 
affected by sunlight, rather than dietary intake of vitamin D. The bioavailability and 
synthesis of vitamin D depends on various factors, including season, time of day, skin 
color, latitude, type of clothing, use of sunscreen, obesity, and other health conditions 
(Gebreegziabher & Stoecker, 2013). Individuals with darker skin need a longer time in 
the sun in order to make adequate amounts of vitamin D due to higher concentrations of 
melanin in the skin, compared to lighter skinned people. Melanin is a large polymer that 
competes with 7-dehydrocholesterol for UVB photons, thus demanding a longer time in 
the sun to generate the same amount of vitamin D in the skin (Tsiaras & Weinstock, 
2011).   
Vitamin D deficiency causes decreased calcium and phosphorus absorption, 
which stimulates parathyroid hormone (PTH) secretion to remove calcium from the bone 
in order to maintain calcium homeostasis. This results in decreased calcium in the bones 
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and secondary hyperparathyroidism (Pettifor & Prentice, 2011; Uriu-Adams, Obican, & 
Keen, 2013).  
No large-scale studies of VDD in Malawian pregnant women have been reported. 
A comparison study from 2013 assessed VDD in Malawian adults in the hospital, with or 
without tuberculosis (TB) infection (Mastala et al., 2013). The mean 25(OH)D level in 
non-TB patients was 84.2 nmol/L, which was significantly higher than the mean 
25(OH)D level of TB patients (59.7 nmol/L) (Mastala et al., 2013). Patients with TB also 
had significantly higher rates of low vitamin D levels compared to non-TB patients 
(74.5% and 47.8%, respectively) and VDD (42.2% and 16.6%, respectively). In this 
study, low BMI and antiretroviral use (in HIV patients) were associated with lower 
vitamin D levels. Low BMI may be a risk factor for VDD because the lack of adipose 
tissue may result in an inability to store vitamin D (Mastala et al., 2013).  
Assessment of VDD is complicated by the fact that there is no standardized cut-
off value for deficiency (Peragallo Urrutia & Thorp, 2012). Differing serum 
concentration categorizations of 25(OH)D are found in Table 2.3. 
Table 2.3. Serum 25(OH)D concentrations and deficiency cut-off values.  
 Sufficiency Insufficiency Deficiency  
NIH1  >20 ng/mL  
>50 nmol/L 
12-20 ng/mL 
30-50 nmol/L 
<12 ng/mL 
<30 ng/mL 
ARUP Reference 
Laboratory2 
>30 ng/mL 
>75 nmol/L 
20-29 ng/mL 
50-72 nmol/L 
<20 ng/mL 
<50 nmol/L 
Gebreegziabher, et 
al (2013)3 
 
>20 ng/mL 
>50 nmol/L 
N/A <12 ng/mL 
<30 nmol/L 
ACOG (2011)4 >20 ng/mL 
>50 nmol/L  
N/A <20 ng/mL  
<50 nmol/L 
1(National Institutes of Health, 2014) 
2ARUP Laboratories (2016) 
3(Gebreegziabher & Stoecker, 2013) 
4(ACOG Committee on Obstetric Practice, 2011) 
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 Vitamin D insufficiency during pregnancy has been linked to adverse infant 
outcomes, including LBW and SGA infants, neonatal hypocalcemia, low bone mineral 
density, and impaired growth (Barrett & McElduff, 2010). Infants born to mothers with 
VDD are more likely to develop autoimmune diseases, asthma, allergies, and wheezing 
later in life (Barrett & McElduff, 2010). A meta-analysis of 31 studies found that 
insufficient levels of vitamin D were associated with gestational diabetes, preeclampsia, 
and SGA newborns. Mothers with 25(OH)D levels below 37.5 nmol/L had lower birth 
weight infants (by an average of 131 g), compared to mothers with 25(OH)D levels 
above 37.5 nmol/L (Aghajafari et al., 2013). Another recent meta-analysis found that 
supplementing with vitamin D3 during pregnancy resulted in a 60% reduced risk of 
having a LBW newborn (RR 0.40, 95% CI 0.23-0.71) (Thorne-Lyman & Fawzi, 2013).   
 Infants who are born to mothers with inadequate levels of vitamin D are more 
likely to have increased rates of premature birth compared to infants born to mothers with 
adequate vitamin D stores (Bodnar et al., 2013). A cohort study of women with twin 
pregnancies assessed vitamin D concentrations and rates of premature deliveries. Mothers 
with 25(OH)D levels above 75 nmol/L were 60% less likely to have a preterm birth, 
compared to women with 25(OH)D levels less than 75 nmol/L (Bodnar et al., 2013). A 
trial in India randomized pregnant women to receive either one dose of 1500 µg vitamin 
D3 in their second trimester, one dose of 3000 µg vitamin D3 in both the second and third 
trimesters, or no vitamin D treatment (Kalra et al., 2012). Both of the vitamin D groups 
had infants with significantly higher birth weights, lengths, and head circumferences 
compared to the control group infants (Kalra et al., 2012). A randomized controlled trial 
in Bangladesh supplied pregnant women with 35,000 IU of vitamin D per week from the 
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third trimester until delivery or a placebo (Roth, Perumal, Al Mahmud, & Baqui, 2013). 
While there were no significant differences between the anthropometric measurements at 
birth, length-for-age Z-scores (LAZ) and growth rates at 1 month of age were 
significantly higher in the infants in the vitamin D group. For every 10 nmol/L increase in 
maternal 25(OH)D level at delivery, there was a 0.06 LAZ increase at 1 month of age. 
Inadequate linear growth during infancy can lead to childhood stunting, which has long-
term health consequences (Roth et al., 2013). Lower birth lengths and infant growth rates 
are also associated with increased risk of bone fractures in later life (Zhu et al., 2013).  
Vitamin D is known to modulate the immune system by increasing production of 
antimicrobial peptides (AMPs) and anti-inflammatory cytokines (Mehta et al., 2010). 
Cathelicidin, an AMP, is increased in the presence of adequate 25(OH)D, which can lead 
to increased antimicrobial action against pathogens. Another proposed mechanism is that 
vitamin D increases phagocytosis by macrophages and increases production of natural 
killer cells, which target invading pathogens (Mehta et al., 2010, 2011).  
 HIV-infected individuals are susceptible to contracting opportunistic infections, 
with the most common being TB (Mehta et al., 2010). Vitamin D has been shown to fight 
or prevent TB infections by the process of increasing AMPs, such as cathelicidin. TB is a 
common cause of mortality among HIV-infected individuals, thus adequate vitamin D 
status may reduce risk of mortality from opportunistic infections (Mehta et al., 2010). 
Vitamin D is crucial for proper function of many body tissues and cells, and a lack of it 
may result in increased risk of adverse maternal and neonatal outcomes.   
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2.2.3 Vitamin B12 
 Vitamin B12, or cobalamin, is actually a group of water-soluble compounds called 
corrinoids that have a cobalt molecule in the center of a corrin nucleus (FAO & WHO, 
1998). Dietary vitamin B12 is found only in animal products because no plant species 
have the required enzymes for vitamin B12 synthesis. Bacteria, algae, and mammalian 
cells have enzymes that are dependent on vitamin B12 to function. Vitamin B12 is present 
in animal products because it is synthesized in microorganisms that enter the 
gastrointestinal (GI) tract of animals, and vitamin B12 then gets absorbed and 
incorporated into their tissues (FAO & WHO, 1998). The best sources of vitamin B12 are 
meat, poultry, fish, clams, oysters and eggs. Some plant foods are fortified with vitamin 
B12 (S. S. Gropper et al., 2009).  
 Vitamin B12 plays a role in DNA synthesis by converting homocysteine to 
methionine, using methylcobalamin as the coenzyme. A lack of vitamin B12 will result in 
a buildup of homocysteine (S. S. Gropper et al., 2009). High levels of homocysteine have 
been linked to oxidative stress, increased risk of cardiovascular disease, placental 
abruption, stillbirth and preterm delivery, LBW infants, and preeclampsia (Allen, 2005; 
Lonn et al., 2006). Vitamin B12 also acts as a cofactor in the conversion of L-
methylmalonyl-CoA to succinyl CoA. Low levels of vitamin B12 will then result in a 
buildup of methylmalonic acid, which has detrimental consequences to fetal 
development. Children with genetic mutations who are deficient in the enzyme to 
perform this conversion are born with mental retardation and other developmental defects 
(Duggan et al., 2014). When serum vitamin B12 levels are inadequate, first DNA 
synthesis is decreased, followed by an increase in serum homocysteine and 
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methylmalonic acid concentrations, and finalizing in cell changes seen in megaloblastic 
anemia. Megaloblastic macrocytic anemia is characterized by large, immature red blood 
cells. Symptoms include fatigue, shortness of breath, pale skin, heart palpitations, 
insomnia, tingling of the extremities, loss of concentration and memory, disorientation, 
and dementia (S. S. Gropper et al., 2009).  
 Vitamin B12 and folate have a complex interaction with one another. The enzyme 
methionine synthase is dependent on vitamin B12 and functions in the methylation cycle, 
which also requires folate. A disruption of this cycle (due to either folate or vitamin B12 
deficiency) will result in reduced levels of myelin proteins, causing demyelination of 
peripheral nerves and the spinal column. Nerve demyelination can lead to neuropathy 
involving paralysis, ataxia, and even death if untreated. A lack of adequate vitamin B12 or 
folate for this cycle can also cause reduced DNA synthesis and megaloblastic anemia 
(FAO & WHO, 1998; Weir & Scott, 1999).  
When an individual has a deficiency in vitamin B12, but not folate, it will result in 
a pseudo-folate deficiency due to what is called the “methyl trap hypothesis”. The first 
reaction in the methylation cycle that requires folate is irreversible, and the only 
mechanism by which to convert this folate-containing intermediate product to the final 
product is through methionine synthase, the enzyme requiring vitamin B12. Without 
adequate vitamin B12, the body’s available folate will be “trapped” in the intermediate 
stage of this reaction, which results in symptoms of a folate deficiency (FAO & WHO, 
1998; Weir & Scott, 1999).   
 A study done in Malawi found that vitamin B12 deficiency affected 16-33% of 
pregnant women, depending on the cut-off value that was used (van den Broek & Letsky, 
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2000). Low vitamin B12 concentration was significantly correlated with megaloblastic cell 
changes in bone marrow aspirates (p <0.001), indicating that vitamin B12 deficiency is a 
cause of megaloblastic anemia in this population (van den Broek & Letsky, 2000).  
During pregnancy, it is estimated that 0.1-0.2 µg of vitamin B12 can be transferred 
to the fetus and accumulated in their liver during the second and third trimesters. 
However, infants born to mothers with inadequate vitamin B12 intake and status may 
present clinical signs of deficiency, such as neuropathy (FAO & WHO, 1998). Due to 
this trans-placental transfer of vitamin B12, there is an observed decrease in maternal 
serum levels close to term. At the end of pregnancy, it may be difficult to correctly assess 
vitamin B12  levels via serum (van den Broek & Letsky, 2000).  
 Inadequate maternal vitamin B12 concentrations can lead to adverse pregnancy 
and birth outcomes (Allen, 2005). A study from Nepal found that pregnant women who 
were vitamin B12 deficient had a two-fold increased risk of preeclampsia and preterm 
delivery (Bondevik et al., 2001). A study in Kenya found that pregnant women with 
vitamin B12 deficiencies were more likely to have growth restricted infants and stillbirth 
babies (Neumann et al., 2014). This study also found a negative relationship between 
maternal vitamin B12 status and newborn neurobehavioral scores. A limited supply of 
vitamin B12 from the mother to the fetus can lead to impaired fetal growth and brain 
development, which can translate to cognitive problems later in life (Neumann et al., 
2014). A systematic review and meta-analysis found that women with vitamin B12 
insufficiency during pregnancy had a 1.7 times increased risk of having a SGA or LBW 
infant (95% CI: 1.16, 2.50) (Sukumar et al., 2016). 
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Infants with vitamin B12 deficiencies are more likely to have anemia, muscle 
weakness, cognitive disorders, and psychomotor regression (Neumann et al., 2014). 
Infants who are exclusively breastfed from mothers with inadequate vitamin B12 intake 
are likely to develop a deficiency, because breast milk will be the infant’s only source of 
the vitamin. Elevated homocysteine levels have been linked to these adverse outcomes in 
fetal growth and development (Neumann et al., 2014).  
 A randomized controlled trial in India aimed to discover if maternal vitamin B12 
supplementation had an impact on infant vitamin B12 status and birth outcomes (Duggan 
et al., 2014). The study randomized 183 women to receive 50 µg vitamin B12 and 183 
women to receive a placebo. Women who took vitamin B12 supplements had higher 
serum vitamin B12 concentrations during the third trimester, as well as higher content in 
their breast milk. Infants born to mothers in the vitamin B12 group had higher serum 
concentrations of the vitamin, as well as lower concentrations of plasma homocysteine 
and methylmalonic acid. This study found no difference between the two groups in terms 
of birth weight or prevalence of IUGR, although the authors noted that the study was 
inadequately powered to detect a difference in these outcomes. This study indicated that 
supplementing pregnant women with vitamin B12 can elicit a response in the vitamin B12 
concentration of their infants, which can have positive effects on the infant’s growth 
(Duggan et al., 2014). 
 Low vitamin B12 status in a pregnant woman can have important consequences for 
both herself and her fetus. Studies have shown that maternal supplementation of vitamin 
B12 can improve the vitamin B12 status of infants, which can positively impact an infant’s 
development. A mother who has adequate vitamin B12 has a lower risk of anemia, 
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preeclampsia, and adverse birth outcomes, such as delivering a newborn who is LBW, 
IUGR, preterm, or stillbirth (Duggan et al., 2014). 
2.2.4 Folate/folic acid 
 Folate is the term used for the water soluble B-vitamin found in its reduced form 
in body tissue and naturally in foods (S. Gropper, Smith, & Groff, 2009). Food sources of 
folate include green vegetables, fruits, mushrooms, peanuts, legumes, lentils, and liver. 
The bioavailability of folate from foods can vary greatly, from 10-98%, based on genetic 
differences, intestinal pH, and various food inhibitors of folate absorption (S. S. Gropper 
et al., 2009; Sauberlich, 1985). 
 The RDA for folate for women who are pregnant or capable of becoming 
pregnant is set at 600 µg DFE, whereas the RDA for adults is set at 400 µg DFE. It is 
recommended that pregnant women (or women planning to become pregnant) take a 
supplement containing 400 µg of folic acid and consume folate-containing foods (Food 
and Nutrition Board, 1998; S. S. Gropper et al., 2009).  
 Absorption of folate is impaired by zinc deficiency, chronic alcohol use, and 
foods such as cabbage, oranges, lentils, and legumes; these will reduce digestion and 
absorption of folate from foods (S. Gropper et al., 2009). Folate functions in the 
cytoplasm and mitochondria as a coenzyme, making it essential for DNA synthesis, cell 
division and nucleotide synthesis. Folate is involved in the metabolism of the amino acids 
histidine, serine, glycine, and methionine. If there is inadequate folate in the body, 
homocysteine concentrations will increase, as discussed in section 2.2.3 (S. S. Gropper et 
al., 2009).  
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 Folate deficiency can result in megaloblastic macrocytic anemia, similar to a 
vitamin B12 deficiency. Initially, a folate deficiency will present with low plasma folate 
after approximately one month of low folate intake, followed by low red blood cell folate 
concentrations after 3-4 months (Hine, 1993). The symptoms of megaloblastic anemia 
occur after 4-5 months of deficient folate intake and are discussed in the previous section 
2.2.3. Red blood cells become enlarged (megaloblastic) because of abnormal DNA 
synthesis and the inability of blood cells to divide, combined with the continued 
formation of RNA. This results in an excess production of RNA and other cell 
components, such as hemoglobin, causing immature and large red blood cells (S. S. 
Gropper et al., 2009).  
 Pregnant women are at increased risk of developing a folate deficiency because 
fetal growth increases the demands for folate, especially in the second and third 
trimesters (McPartlin, Halligan, Scott, Darling, & Weir, 1993). Folate deficiencies during 
pregnancy are well known to cause fetal neural tube defects (NTDs). The effects of folate 
deficiency take place in early pregnancy, which is why it is crucial for all women who are 
capable of becoming pregnant to take folic acid supplements. The fetal neural plate closes 
to form the spinal cord and cranium between days 21 and 27 post-conception. If a woman 
has inadequate folate concentrations during this time, the spinal cord and/or cranium will 
not close properly, resulting in spina bifida and/or anencephaly, respectively (FAO & 
WHO, 1998). Maternal folate deficiency can also cause other congenital malformations, 
including orofacial clefts and cardiac defects, as well as pregnancy complications, such as 
preeclampsia, IUGR, bleeding and miscarriages (Black, 2001; Hovdenak & Haram, 
2012).  
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 Recent data on maternal folate deficiency in Malawi are lacking. A study from 
2000 analyzed causes of anemia in pregnant women in Malawi (van den Broek & Letsky, 
2000). Thirty-four percent of the anemic women in this study population were also found 
to have a folate deficiency. Folate deficiency may also be worsened by malarial infection 
(van den Broek & Letsky, 2000).  
 It is recommended that women take a 400 µg folic acid supplement pre-
conception and through the first trimester of pregnancy (Centers for Disease Control, 
1992; WHO, 2012a). However, recommendations for the second and third trimesters are 
not as clear. Women who took the recommended amount of folic acid during their first 
trimester were included in a study to determine whether there is a benefit to taking 400 
µg folic acid throughout the entire pregnancy (Mcnulty et al., 2013). Women in the 
placebo group had significantly lower serum and red blood cell folate levels and 
significantly higher homocysteine levels, compared to women who continued to take 
folic acid. Infants born to mothers in the folic acid group had significantly higher cord 
blood levels of folate. High homocysteine levels during pregnancy have been linked to 
preeclampsia, premature delivery, and lower birth weight babies, therefore it may be 
beneficial for women to continue to take folic acid throughout the entire pregnancy 
(Mcnulty et al., 2013; Vollset et al., 2000).  
 Fetal development and maternal health are both associated with adequate folate 
concentrations during pregnancy. Consequences of maternal folate deficiency include 
high risk of fetal NTD’s, high homocysteine levels and adverse pregnancy outcomes. It is 
imperative that women of reproductive age take folic acid supplements in order to 
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prevent these consequences, primarily congenital abnormalities of the fetus (FAO & 
WHO, 1998; Hovdenak & Haram, 2012).  
2.2.5 Iron 
 Iron is a mineral that has several essential functions in the human body, including 
being a carrier of oxygen to tissues via hemoglobin. The average person has between 2 
and 4 grams of iron in their body, which is dependent on gender, body weight, age and 
pregnancy. The only forms of iron that are in food and the body are the ferric (Fe3+) and 
ferrous (Fe2+) forms (FAO & WHO, 1998; S. S. Gropper et al., 2009).  
 There are two forms of iron in the diet, heme and non-heme (S. S. Gropper et al., 
2009). The primary difference between the two is that heme iron is derived from the 
hemoglobin and myoglobin in animal products, especially meat, poultry, and fish. Non-
heme iron is found in plant foods (such as grains, tofu, nuts, vegetables and fruits) and in 
small amounts in dairy products. The best sources of iron include liver, red meat, organ 
meats, clams, oysters, and beans. Iron is also fortified into some breads, pastas, cereals, 
and flours (S. S. Gropper et al., 2009).   
 There are several factors that can inhibit or enhance iron absorption. Compounds 
that bind with non-heme iron are known as chelates or ligands. A chelate/ligand complex 
with non-heme iron will either bind too strongly to it, resulting in excretion of iron, or it 
will bind loosely, enhancing absorption. The dietary factors that can either enhance or 
inhibit absorption are found in Table 2.4. Phytates are salts that store phosphates and 
minerals and are found in fruits, vegetables, grains and cereals, seeds, nuts, and roots. 
Zinc and iron negatively impact each other’s absorption by competing for the same 
transporters. Iron absorption is also linked to an individual’s body iron stores. People 
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with iron deficiencies may absorb up to 35%, whereas an individual with normal iron 
status will absorb only 10% (FAO & WHO, 1998; S. S. Gropper et al., 2009; Hallberg, 
Hulten, & Gramatkovski, 1997).  
Table 2.4. Dietary factors that can inhibit or enhance absorption of iron (FAO & 
WHO, 1998; S. S. Gropper et al., 2009).  
 INHIBITING FACTORS ENHANCING FACTORS 
Phytates (whole grains, bran, legumes, corn, 
soybeans, rice) 
 
Ascorbic acid/vitamin C (fruits and some 
vegetables) 
Polyphenols and tannins (tea and coffee) Sugars (fructose and sorbitol) 
Oxalic acid (spinach, chocolate, berries, tea) Meat, poultry, fish, and seafood  
Calcium, calcium-phosphate salts, zinc, 
nickel, manganese  
Fermented foods  
 
 Humans have unique methods for attempting to prevent iron deficiency and 
overload. Erythrocytes die after approximately 120 days, and the body will reutilize the 
iron from these spent red blood cells by bringing the iron back to other tissues or to 
erythrocyte precursors (FAO & WHO, 1998). This mechanism is also important to reduce 
the amounts of free iron circulating in the blood, because unbound iron can lead to free 
radicals, which are damaging to cells. Free iron is also readily used by bacteria for 
growth and multiplication, which can cause or worsen infections (S. S. Gropper et al., 
2009). Another method to maintain iron balance involves ferritin, the storage protein, 
which will create an iron reservoir in times of increased iron demands, such as during 
pregnancy. The intestines also play a role in maintaining iron balance by increasing 
absorption during times of low body iron stores and reducing absorption when iron levels 
are high (FAO & WHO, 1998).  
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 The RDA for iron for premenopausal women is 18 mg per day, whereas the RDA 
for men and postmenopausal women is 8 mg per day. During pregnancy, the RDA 
increases to 27 mg per day. While pregnant women do not lose menstrual blood, they still 
require a higher amount of iron because additional iron is needed for the fetus, placenta, 
increased plasma volume, and for a storage reservoir for blood loss during childbirth, as 
seen in Table 2.5 (Food and Nutrition Board, 2001). The World Health Organization 
recommends a dose of 30-60 mg per day during pregnancy, and that it should be 60 mg in 
areas where anemia is a severe public health problem (affecting >40% of the population) 
(WHO, 2012a).  
Table 2.5. Iron requirements and losses during a healthy pregnancy and delivery. 
Adapted from (FAO & WHO, 1998). 
Iron Needs for Pregnancy and Delivery Iron requirements or losses (mg) 
Fetus  300 
Placenta 50 
Maternal plasma expansion 450 
Basal iron losses  240 
Total Additional Iron Requirement 1040 
IRON BALANCE AFTER DELIVERY  
Contraction of maternal RBC mass +450 (back to mother) 
Maternal blood loss -250 
Net iron balance after delivery +200 
NET IRON REQUIREMENTS FOR 
PREGNANCY* 
840 (1040-200) 
        *If pregnancy begins with sufficient iron stores  
            Globally, iron is the most common nutrient deficiency in pregnant women 
(Ramakrishnan, 2002). A deficiency in iron can be with or without anemia, which doesn’t 
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occur until iron levels are severely depleted (S. S. Gropper et al., 2009). The criteria for 
anemia of pregnant women is usually defined as a hemoglobin concentration of <10.5 or 
11.0 g/dL (van den Broek & Letsky, 2000). As opposed to the megaloblastic macrocytic 
anemia seen with folate or vitamin B12 deficiencies, iron deficiency anemia presents with 
microcytic and hypochromic red blood cells (S. S. Gropper et al., 2009). While there are 
multiple potential causes of anemia, iron deficiency is the most common, accounting for 
approximately 50% of all anemia cases (Klemm, Sommerfelt, Boyo, & Barba, 2011; 
Sangaré, van Eijk, Ter Kuile, Walson, & Stergachis, 2014). During pregnancy, 
hemoglobin and hematocrit concentrations are known to decline throughout the first and 
second trimesters, followed by an increase in the third trimester (Scholl, 2005). Plasma 
ferritin concentrations can also be used to determine iron deficiency before anemia is 
present. Reported cut-off values for deficiency vary from 12.0-15.0 µg/L (FAO & WHO, 
1998; S. S. Gropper et al., 2009). However, ferritin is a positive acute phase protein, thus 
if inflammation or infection are present, ferritin levels will be falsely elevated (S. S. 
Gropper et al., 2009). A method to combat this problem is to also take measurement of an 
acute phase protein, such as C-reactive protein or α-1-acid glycoprotein (AGP) (Engle-
Stone, Nankap, Ndjebayi, Erhardt, & Brown, 2013).  
 Symptoms of iron deficiency include pale skin, reduced behavioral and cognitive 
abilities, fatigue, cold extremities, and short attention span (Scrimshaw, 1991). These 
symptoms are related to the reduced transport of oxygen (via hemoglobin) to tissues in 
the body (S. S. Gropper et al., 2009). 
 Anemia is a major cause of maternal and fetal morbidity and mortality, as well as 
adverse pregnancy outcomes (Scholl, 2005). Pregnant women require greater amounts of 
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iron to meet the needs of the placenta and fetus. Women of reproductive age in 
developing countries tend to have a diet that is inadequate to meet these increased iron 
needs. Women with higher parity, which is common in developing countries, have 
increased risk of iron deficiency (Scholl, 2005).  
The iron stores of a woman at the time of conception are thought to be a strong 
predictor of her iron status and anemia risk during pregnancy. It can be hard to replenish 
inadequate iron stores once pregnancy has begun (Allen, 2005). The placenta regulates 
how much iron is transferred from mother to fetus. When maternal iron levels are low, 
the number of receptors on the placenta will increase, in order to take up more iron for 
the fetus. The majority of iron transfer from mother to fetus occurs during the third 
trimester, typically after the 30th week (Allen, 2000).  
It has been estimated that for every 1.0 g/dL increase in hemoglobin 
concentrations in anemic pregnant women, there is a 20% reduction in risk of maternal 
mortality (Klemm et al., 2011). Maternal iron deficiency can result in increased risk of 
preterm delivery, neonatal and infant iron deficiency, LBW infants, stillbirths, and poor 
cognitive fetal development (Allen, 2005; Bhutta et al., 2012; Scholl, 2005). Iron 
deficiency anemia (IDA) is thought to contribute to preterm delivery through three 
potential mechanisms: hypoxia due to reduced oxygen transport, oxidative stress, and 
increased susceptibility to infections (Scholl, 2005). Oxidative stress is more likely to 
occur in mother-fetus pairs with iron deficiency because IDA leads to increased cortisol 
production, which can damage fetal red blood cells. Damaged erythrocytes can result in 
decreased fetal growth (Hovdenak & Haram, 2012). Infants born preterm are more likely 
to have perinatal complications and have stunted growth later on in life (Allen, 2000).  
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Children born to mothers who had inadequate iron stores during pregnancy are at 
increased risk of having lower cognitive, motor, and socio-emotional development skills 
(Prado & Dewey, 2014). Iron deficiency has an impact on neurodevelopment of the fetus 
due to a lack of hemoglobin, which transports oxygen to the brain (Prado & Dewey, 
2014). Maternal iron deficiency also leads to decreased iron transfer to the fetus, which 
can have an impact on the function of the developing brain (McArdle, Gambling, & 
Kennedy, 2014).   
Of 4,646 pregnant women attending a hospital in southern Malawi, 57% of them 
were found to be anemic, with deficiency in iron being the primary cause of the anemia. 
However, multiple micronutrient deficiencies were also common in this population. 
Sixteen percent of the anemic women were found to be severely anemic, with 
hemoglobin levels <7 g/dL (van den Broek & Letsky, 2000).   
Prenatal iron supplementation is a global public health measure in place to 
prevent maternal anemia. Maternal iron supplementation generally improves iron status 
within 3 months; however, women who begin pregnancy with iron deficiency may not be 
able to regain adequate iron status if iron is not taken from the start of pregnancy. 
Compliance with daily supplementation throughout the entire pregnancy can result in 
better iron stores for up to 2 months postpartum (Allen, 2000). It is important that 
maternal iron stores remain adequate after delivery because women in developing 
countries tend to have shorter intervals between pregnancies; thus, they will be more 
likely to enter a new pregnancy with better iron stores if iron supplements were taken 
throughout the previous pregnancy. Although maternal and cord blood ferritin tend to be 
closely related, maternal and cord blood hemoglobin are independent, unless the mother 
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is severely anemic. Infants who are born to anemic mothers are more likely to be anemic 
as well (Allen, 2000). In a Cochrane review, maternal iron supplementation was found to 
reduce anemia risk by 70%, reduce iron deficiency at term by 57%, reduce risk of LBW 
infants, and improve neonatal and infant iron stores (Pena-Rosas, De-Regil, Dowswell, & 
Viteri, 2012).   
While the evidence supporting prenatal iron supplementation is strong, there are 
also studies reporting the harmful effects of over-supplementation of iron.  In one study, 
women with ferritin levels above 41 ng/mL during pregnancy had increased risk of 
preterm delivery, possibly due to intrauterine infection (Goldenberg et al., 1996). There is 
concern that taking additional iron supplements in non-anemic women may result in 
symptoms of iron overload. Excessive maternal iron stores may impair blood flow to the 
placenta due to increased blood viscosity (Rush, 2000; Scholl, 2005). A study found that 
women with high hemoglobin in the first and second trimesters had higher risk of having 
SGA births, but not preterm births (Scanlon, Yip, Schieve, & Cogswell, 2000). A U-
shaped association has been reported between maternal hemoglobin levels and birth 
weight of infants (Mahomed, 2007). Both low (<8.0 g/dL) and very high (>12.0 g/dL) 
hemoglobin concentrations may lead to LBW infants (Scholl, 2005). Other issues 
associated with high maternal iron stores include increased risk of preeclampsia and 
gestational diabetes mellitus. Excess free iron in contact with oxygen can create harmful 
free radicals in the body, which damage cells and tissues. This oxidative damage and 
stress may contribute to increased risk of preterm delivery (Scholl, 2005).  
Another concern involving high iron stores involves the relationship between iron 
and malaria. Each year, 25 to 30 million women become pregnant in areas of Africa that 
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are malaria-endemic (Rogerson, Mwapasa, & Meshnick, 2007; Steketee, Nahlen, Parise, 
& Menendez, 2001). Malaria can cause severe anemia during pregnancy, resulting in 
10,000 maternal deaths per year worldwide (Guyatt & Snow, 2001). Malaria also 
contributes to 75,000-200,000 LBW babies born each year, due to a combination of 
IUGR and preterm deliveries (Guyatt & Snow, 2004; Rogerson et al., 2007). A placenta 
that is infected with malaria activates an immune response, which may be responsible for 
stimulating an early labor (Guyatt & Snow, 2004). The presence of free iron in the body 
may increase susceptibility to malarial infection by increasing growth of pathogens 
(Senga, Harper, Koshy, Kazembe, & Brabin, 2011). The malaria parasite requires iron for 
its survival, growth and proliferation (Sangaré et al., 2014). A case-control study in 
Malawi found that pregnant women with placental malaria had better iron stores than 
women without malaria. Iron deficiency may limit the availability of iron to the malaria 
parasite, thus reducing infection risk (Senga et al., 2011). Malaria can then cause anemia 
through removal of excessive numbers of red blood cells, immune destruction, and 
impaired red blood cell production (Ekvall, 2003; Ouma et al., 2007). Women in their 
first pregnancy tend to have higher malaria infection rates. This may be due to younger 
age, or the fact that multigravida women are more likely to be iron deficient due to 
compounding effects of iron requirements during pregnancy (Rogerson et al., 2007; 
Senga et al., 2011).   
A meta-analysis found that iron supplementation did not significantly increase 
risk of malaria (P. falciparum) infection during pregnancy or at delivery (Sangaré et al., 
2014). Women with low ferritin levels had a reduced risk of malaria; however, there was 
no association between malaria risk and other biomarkers of iron deficiency. The authors 
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conclude that iron supplementation does not increase malaria risk during pregnancy if the 
women are concurrently using malaria prevention strategies, such as insecticide-treated 
bug nets and prophylaxis medications. There currently is not enough evidence to support 
the notion that the risk of iron supplementation on malaria outweighs the benefits of 
reducing anemia. There have not yet been randomized controlled intervention trials that 
can prove a causal relationship between iron supplementation during pregnancy and 
increased risk of malaria (Sangaré et al., 2014).    
Iron deficiency may also be related to a phenomenon called pica. Pica is the 
craving and intentional consumption of non-food items. It has been found in nearly all 
cultures worldwide. There are different kinds of pica, including geophagy (consumption 
of earth), amylophagy (consumption of raw starches) and pagophagy (consumption of 
ice) (Danford, 1982; Young et al., 2010). Pica can contribute to micronutrient 
deficiencies because the components of non-food substances can bind to nutrients, thus 
limiting absorption. Geophagia can also lead to intestinal parasites, which can contribute 
to malabsorption. Pica is most commonly found in young children and pregnant women 
and is usually associated with iron deficiency. In a study of Tanzanian pregnant women, 
5.3% reported having geophagy during their pregnancy and 36.3% reported amylophagy 
(Young et al., 2010). Common substances consumed included uncooked rice, unripe 
mango, large amounts of ice, and different types of clay. Women who experienced any 
form of pica had significantly lower hemoglobin levels compared to women without pica. 
In this population, every 1 g/dL reduction in hemoglobin level correlated to a 31.5% 
increased likelihood of having pica. Women with later gestational age, low hemoglobin, 
and abdominal pain or nausea were more likely to have pica. While there is a strong 
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association between pica and iron deficiency, the reasons are still not fully understood 
(Young et al., 2010).  
Iron is the most prevalent nutrient deficiency seen in pregnant women, and the 
effects of prenatal iron supplementation are far-reaching. More research still needs to be 
done on the potentially deleterious effects of over-supplementing women who already 
have adequate iron stores. However, the high rates of iron deficiency in developing 
countries indicate that the benefits of iron supplementation (30-60 mg per day) are 
greater than the risks. Iron is a crucial nutrient for the proper growth and development of 
the fetus, as well as for the optimal health and survival of the mother.  
2.2.6 Zinc 
 Zinc is a trace mineral that is necessary in the human body for many cellular 
processes, including protein synthesis, energy metabolism, collagen formation, and 
genetic expression. Dietary sources of zinc include red meats, seafood, poultry, whole 
grains, legumes, vegetables, and dairy products. Plant sources of zinc have lower 
bioavailability than animal sources (FAO & WHO, 1998; S. S. Gropper et al., 2009).  
 Similar to iron, there are various ligands that can bind to zinc and influence 
absorption. Enhancers of zinc absorption include certain amino acids, citric acid, and 
products of protein digestion. Zinc absorption is regulated by zinc status; low levels of 
zinc will result in increased absorption. Inhibitors of zinc absorption are similar to 
inhibitors of iron absorption, and include phytates, oxalates, and polyphenols. Zinc binds 
to phytate or phytic acid with oxygen, creating a large, insoluble complex that is not well 
absorbed (S. S. Gropper et al., 2009). A high phytate diet is common in those who 
consume unrefined cereal grains with low intake of animal products (King, 2000). A 
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study in Malawi found that 36% of pregnant women had low plasma zinc levels. Women 
who consumed high levels of phytates combined with frequent pregnancies and high rates 
of malaria infection were more likely to have lower levels of zinc (Gibson & Huddle, 
1998). Polyphenols are found in tannins from tea, as well as some forms of fiber found in 
whole grains, fruits, and vegetables. Other nutrients, including iron and calcium, may 
interfere with the absorption of zinc. These minerals are divalent cations like zinc (Zn2+) 
and they compete for transporters and binding ligands in the intestine (Whittaker, 1998). 
Heme iron does not have the same effects on zinc absorption as non-heme iron does. The 
absorption of zinc is inhibited when the amount of non-heme iron consumed is greater 
than that of zinc by 20 mg. Studies on the interaction between calcium and zinc 
absorption vary based on type of calcium consumed (S. S. Gropper et al., 2009).  
 Zinc interacts with copper absorption in a negative way. High zinc intake results 
in increased production of thionein, a protein that is a binding ligand for zinc and 
becomes metallothionein when attached to a mineral. Thionein has a greater affinity for 
copper than it does for zinc, which traps copper in the enterocyte as part of 
metallothionein. This entrapment can result in copper deficiency if supplemental zinc is 
taken for too long or the tolerable upper intake level (UL [10 mg of elemental zinc per 
day]) is exceeded (Food and Nutrition Board, 2001; S. S. Gropper et al., 2009; Sandstead, 
1995).  
 Zinc functions in many different metalloenzymes through provision of structural 
integrity or participation in reactions. Zinc is estimated to be involved with 70 to 200 
enzymes, including those involved with liver and bone function, alcohol detoxification, 
respiration, protein digestion, nucleic acid synthesis, and antioxidant defense. Other 
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functions of zinc include skin integrity, cell growth and replication, bone formation, and 
host defense immunity. Zinc is an essential component of regulating transcription and 
gene expression. The involvement of zinc in so many essential activities makes it crucial 
for proper growth, development and functioning of the body (FAO & WHO, 1998; S. S. 
Gropper et al., 2009).  
 The RDA for zinc is set at 8 mg per day for women, which increases to 11 mg per 
day during pregnancy to account for increased needs for the fetus and placenta. Zinc 
status is most commonly evaluated with serum or plasma zinc, which can be affected by 
infection, stress, medication, and fasting status (S. S. Gropper et al., 2009). It has been 
estimated that 33% of the world does not consume sufficient amounts of zinc (Prado & 
Dewey, 2014). The mean zinc intake of Malawian women of reproductive age is 
approximately two-thirds of the RDA (Huffman, Baker, Shumann, & Zehner, 1998; 
Ramakrishnan, 2002). A study analyzing per capita food balance sheets and food 
composition tables estimated the risk of micronutrient deficiencies in many African 
countries. The dietary supply of zinc in Malawi was estimated to be 11.8 mg per capita 
per day, while the risk of zinc deficiency was estimated to be 33% (Fig. 2.6). The mean 
phytate to zinc ratio in Malawi was 37.7, which is higher than any other African country 
(Joy et al., 2014). 
 
 
 
 
 
 
 
43 
  
 
Figure 2.5. The dietary supply of zinc and the risk of zinc deficiency in African 
countries. Excerpted from (Joy et al., 2014). 
 Pregnant women and young children are at risk for zinc deficiency, due to the 
increased growth during these periods (FAO & WHO, 1998). Symptoms of zinc 
deficiency include growth retardation, skeletal abnormalities, poor wound healing, 
dermatitis, delayed sexual maturation in adolescents, reduced sense of taste, hair loss and 
impaired immunity (S. S. Gropper et al., 2009).   
Maternal zinc deficiency can cause altered DNA synthesis, chromosomal damage, 
oxidative stress and increased apoptosis in fetal cells, leading to abnormal embryo 
development (Uriu-Adams & Keen, 2010). These factors can lead to adverse birth 
outcomes, including IUGR, congenital abnormalities, LBW infants, preterm delivery, and 
fetal death (King, 2000). Later in life, infants and children with zinc deficiency may be 
affected by stunted growth, abnormal cognitive development, and reduced sense of taste 
(hypogeusia) (Akhtar, 2013; Kennedy et al., 2003). Adverse maternal outcomes include 
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pregnancy-induced hypertension, preeclampsia, hemorrhage, increased rates of 
infections, and prolonged labor (King, 2000).  
Animal studies have shown that maternal diets devoid of zinc can cause 
congenital anomalies and teratogenic effects (King, 2000). Zinc may be a nutrient, like 
folate, that is associated with neural tube defects (NTDs). A case-control study of 61 
newborns in Bangladesh found that cases with NTDs (n=29) and their mothers had 
significantly lower serum zinc concentrations compared to control newborns (n=32) and 
their mothers. There was a significant inverse correlation (point biserial correlation -
0.381, p <0.05) between maternal serum zinc concentration and incidence of NTDs in 
their infants (Figure 2.7). Women with higher parity were more likely to have a newborn 
with a NTD, although this was not significant. After adjustment for multiparity, newborn 
zinc status was still significantly correlated with incidence of NTDs, but maternal zinc 
status was not. In this small population, newborns with zinc deficiency were more likely 
to be affected by a NTD. Newborn and maternal zinc levels were highly and positively 
correlated (r=0.976, p<0.05) (Dey et al., 2010). 
 
Figure 2.6. Maternal serum zinc concentration and newborn NTD incidence 
(0=controls; 1=cases with NTDs). Excerpted from (Dey et al., 2010) 
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 Zinc in combination with other micronutrients may be beneficial to maternal and 
newborn health. A randomized controlled trial in Ghana aimed to determine if combined 
iron and zinc supplementation beginning before 16 weeks gestation (mean 13.7 weeks) 
would improve iron status in pregnant women more than iron alone. Women in the iron 
and zinc group who were deficient in hemoglobin (<11.0 g/dL) at baseline had a greater 
increase in hemoglobin (p=0.0001) and ferritin concentrations (p=0.013) than women in 
the iron-only group after an average of 18 weeks of supplementation (Saaka, 2012). In 
Indonesia, 2,173 pregnant women were randomized to receive zinc, vitamin A, zinc plus 
vitamin A, or a placebo starting at a mean of 17 weeks gestation until delivery 
(Prawirohartono, Nystrom, Nurdiati, Hakimi, & Lind, 2013). Supplementation with either 
zinc or vitamin A alone (not in combination) increased birth length by 0.3 cm and 0.2 cm, 
respectively, compared to placebo (p=0.04). Limitations in this study include low 
compliance (70%), lack of biochemical nutrient markers, unknown time of birth weight 
measurements, and possible low accuracy of birth length measurements (Prawirohartono 
et al., 2013).  
 Studies have shown that prenatal zinc supplementation, in addition to other 
nutrients, can improve maternal and newborn zinc status. A study in Peru randomized 
1,295 pregnant women to receive iron and folate supplements, with or without 15 mg 
zinc, beginning at 10-24 weeks gestation (L. E. Caulfield, Zavaleta, & Figueroa, 1999). 
Higher zinc concentrations were found in mothers at term and newborns of the zinc 
group, compared to those in the iron and folate group. In this study and others (Higashi, 
Tajiri, Matsukura, & Matsuda, 1988; Neggers et al., 1990; Swanson & King, 1987), zinc 
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concentrations decrease throughout pregnancy. However, the population in the study by 
Caulfield, et al (1999) experienced a greater decline in zinc concentrations, compared to 
the other studies reviewed (Figure 2.8). The authors indicate that zinc supplementation 
greater than 15 mg may be necessary to improve zinc concentrations throughout 
pregnancy. Results from this study indicate that the addition of zinc to prenatal 
supplements has a beneficial effect on maternal and neonatal zinc status; thus, zinc 
should be considered as a standard in prenatal nutrient supplementations (L. E. Caulfield 
et al., 1999).  
 
Figure 2.7. The decline of average serum zinc concentrations throughout gestation 
in previous literature, iron group, and iron-zinc group. Excerpted from (L. E. 
Caulfield et al., 1999). 
 
 Serum and plasma zinc concentrations can be affected by fasting status in non-
pregnant individuals. In pregnancy, fasting status has not been found to significantly 
affect zinc concentrations (Hotz, Peerson, & Brown, 2003). However, lower cut-off 
values for determining zinc deficiency based on trimester are proposed, due to the decline 
in serum zinc throughout pregnancy (Table 2.6).  
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Table 2.6 Proposed lower cut-offs for assessment of zinc deficiency during 
pregnancy 
 Lower cut-off value of serum zinc (ug/dL) 
First trimester 56 
Second and third trimester  50 
Adapted from (Hotz et al., 2003) 
Women in developing countries may be at higher risk for zinc deficiency because 
of diets low in zinc and animal products, and high in factors that inhibit zinc absorption, 
such as phytates commonly found in cereal- and grain-based diets. The addition of 
supplemental zinc during pregnancy should be considered to reduce the risks associated 
with inadequate zinc status (King, 2000).  
2.3 Nutrition, infections, and inflammation  
 The nutritional status of pregnant women can be greatly affected by the 
inflammatory process that occurs with infections, as well as the inflammation that occurs 
during pregnancy naturally. The concentrations of some micronutrients in the blood are 
altered by hemodilution during pregnancy, as well as by inflammation (Tomkins, 2003). 
This section addresses the nutrients that are affected by inflammation, including retinol, 
ferritin, zinc, and vitamin D, in addition to the aspects of the inflammatory response and 
common infections and diseases that affect Malawian women. 
2.3.1 The inflammatory response 
 The inflammatory response to an acute infection, also known as the acute phase 
response, results in metabolic changes characterized by increased concentrations of some 
plasma proteins (positive acute phase proteins [APPs]) and decreased concentrations of 
other plasma proteins (negative APPs). C-reactive protein (CRP) is a positive APP, while 
retinol binding protein (RBP), prealbumin, albumin, and transferrin are negative APPs. 
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Nutrients can also be classified as positive acute phase or negative acute phase reactants. 
Retinol, 25-hydroxyvitamin D, and plasma zinc concentrations are reduced during an 
acute phase response. Ferritin is a positive acute phase reactant, which increases during 
the inflammatory response (S. S. Gropper et al., 2009; Thurnham & Mccabe, 2012; 
Tomkins, 2003).  
 Inflammation is designed to be protective to the body and remove foreign 
invaders after a trauma or infection. Acute phase proteins protect the body by promoting 
wound healing and stimulating the immune system to respond to the injury (S. S. Gropper 
et al., 2009). However, chronic inflammation that persists for months or years due to 
long-term illnesses can be detrimental and will increase metabolic demands. The cascade 
of reactions that starts off the acute phase response typically involves macrophages, 
which release cytokines that trigger fibroblasts and endothelial cells to release more 
cytokines. When inflammatory cytokines are released, the hypothalamus responds by 
increasing body temperature and the liver responds by altering metabolism and 
stimulating production of the APPs (Thurnham & Mccabe, 2012).  
 There are many APPs with different functions and properties, but they all play a 
role in the restoration of homeostatic balance in the body after an injury, trauma or 
infection (Koj, 1985; Thurnham & Mccabe, 2012). CRP responds to stress and injury by 
triggering phagocytosis of white blood cells and stimulating other proteins that destroy 
pathogens and microorganisms with antibodies (S. S. Gropper et al., 2009). In response to 
inflammation, CRP will increase 20-1,000 fold in a timeframe of 24 to 48 hours and has a 
half-life of two days. The measurement of CRP is commonly used to assess inflammation 
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levels and to correct for nutrients that are affected by inflammation. A cut-off value for 
CRP of >5 mg/L is commonly used to define inflammation (Thurnham & Mccabe, 2012).  
 Retinol is known to decrease during the acute phase response, but the effect that 
inflammation has on retinol level depends largely on the individual’s overall nutritional 
status and the severity of the infection (Filteau & Tomkins, 1994; Thurnham & Mccabe, 
2012; Tomkins, 2003). Plasma retinol concentrations decrease quickly in response to 
inflammation, while CRP rises. If inflammation is not taken into account, then prevalence 
of vitamin A deficiency will be overestimated (Thurnham & Mccabe, 2012).  
 The inflammatory response reduces levels of circulating free iron and increases 
concentrations of binding and storage proteins, in order to reduce the amount of iron 
available to pathogens and microbes. Stress or injury will increase ferritin concentrations, 
even in individuals with iron deficiency. Plasma zinc is reduced during the acute phase 
response, which leads to decreased availability for microbial metabolism during an 
infection. Serum folate levels are also known to fall during an inflammatory response, 
while red blood cell folate is not affected (Tomkins, 2003). Many nutrients are affected 
by the inflammatory response; thus, it is crucial to measure concentrations of acute phase 
protein(s) to determine prevalence of true nutrient deficiencies.  
2.3.2 HIV/AIDS and pregnancy  
 Human immunodeficiency virus (HIV) is a retrovirus that targets immune cells of 
the host (CD4+ T-cells) by causing them to replicate HIV. The host cell dies after viral 
replication is complete. Immunodeficiency occurs once the numbers of CD4+ cells are 
almost depleted. Secondary, or opportunistic, infections occur when CD4+ cell levels are 
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low, because the body is not able to fight off infections. Yeast infections are common due 
to an excessive proliferation of normal bacteria (Montgomery, 2003).  
Transmission of HIV occurs through person-to-person exchange of infected body 
fluids (sexual contact with an infected person, contaminated needles or blood 
transfusions, or mother-to-child-transmission [MTCT]). HIV can progress to acquired 
immunodeficiency syndrome (AIDS) in some, but not all, cases (Montgomery, 2003; 
Nelms, Sucher, Lacey, & Roth, 2007). 
There is a complex interaction between HIV, nutrition, and immunity. HIV 
infection affects immune function, which has a bidirectional relationship with 
malnutrition and secondary infections (Figure 2.9). Weight loss is usually concurrent 
with events of opportunistic infections. All metabolic processes are affected by HIV, 
which can increase protein turnover and alter carbohydrate and lipid metabolism. 
Hyperlipidemia is common in those infected with HIV (Macallan, 1999a). Nutrient 
malabsorption is increased because the majority of the body’s T-cells reside in the gut 
(Nelms et al., 2007). 
 
Figure 2.8. The relationships between human immunodeficiency virus (HIV), 
immunity, and malnutrition. Excerpted from (Macallan, 1999a).  
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Individuals with HIV are living in a chronic inflammatory state, which differs 
intra-individually based on the severity of the infection (Nelms et al., 2007). The stressed 
tissues continually produce the stress hormone cortisol in response, which leads to 
catabolism of protein stores. The inflammatory process also affects nutrient metabolism 
and utilization (Fraker, 1994; Nelms et al., 2007). Protein metabolism becomes abnormal, 
as muscle protein stores are broken down to generate amino acids necessary to sustain the 
immune response (Scrimshaw & Sangiovanni, 1997).  
Wasting may occur, commonly in acute episodes of weight loss over a period of 
weeks to months (Macallan, 1999a). Wasting causes progressive loss of lean and fat body 
mass and is a strong predictor of mortality. Wasting has also been associated with higher 
viral load, lower CD4+ cell count, and faster disease progression (Villamor, Saathoff, 
Manji, et al., 2005).  
Individuals with HIV tend to have altered micronutrient concentrations, which are 
linked to HIV disease progression. Nutrient deficiencies can lead to a worsened immune 
response, oxidative damage and increased susceptibility to opportunistic infections 
(Nelms et al., 2007). Micronutrient deficiencies are common because of increased 
utilization and loss, and reduced food intake and nutrient absorption (Montgomery, 
2003). Important nutrients for proper immune system functioning include vitamins A, C, 
B6, D and E, minerals selenium, zinc, copper, iron, magnesium and manganese, as well as 
beta-carotene and essential fatty acids (Nelms et al., 2007). Immunodeficiency due to 
inadequate micronutrient concentration has been classified as nutritionally acquired 
immune deficiency (NAIDS) (Beisel, 1996). NAIDS may further reduce CD4+ cell 
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counts and increase susceptibility to infections, thus additionally progressing the HIV 
disease (Friis, 2006).  
According to the WHO, 35 million people were living with HIV and 2.1 million 
people were newly diagnosed with HIV in 2013. Sub-Saharan Africa is the most affected 
area, which accounts for close to 70% of the total new HIV infections globally (WHO, 
2014). Data from 2013 estimates that 500,000 women over age 15 in Malawi are living 
with HIV and/or AIDS (UNAIDS, 2012). A cross-sectional study of 3,825 pregnant 
Malawian women in their third trimester found that 30.2% were HIV-infected. Of these 
women, 94.3% did not know they were infected with HIV, despite almost all (99.57%) of 
the women reported receiving prior antenatal care (Gay et al., 2011).  
Both pregnancy and HIV infection increase caloric and nutritional needs for the 
mother. These needs may not be met because of reduced food intake, impaired nutrient 
absorption and increased nutrient losses (Friis, 2002; Montgomery, 2003).  
Infection with HIV may result in adverse pregnancy or birth outcomes. A 
systematic review found an increased risk of infant mortality in those born to HIV-
infected mothers (Brocklehurst & French, 1998). A study in pregnant Malawian women 
found that those with low serum vitamin A concentrations had increased MTCT of HIV 
(Semba et al., 1994). However, trials of vitamin A supplementation in HIV-infected 
pregnant women have produced mixed results. Maternal vitamin A supplementation in 
Malawi decreased risk of LBW infants; however, no significant effect was found for 
reduction in rates of preterm delivery or MTCT of HIV (Kumwenda et al., 2002). 
Supplementation of vitamin A in HIV-infected pregnant South African women found 
reduced rates of preterm delivery, but no effect on MTCT rates (Coutsoudis et al., 1999).  
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A study in Tanzania randomized 1,078 HIV-infected pregnant women to one of 
four treatment groups: vitamin A, multivitamin (B-complex, vitamin C and vitamin E), 
multivitamin with vitamin A added, or a placebo (Fawzi et al., 2004). Women in the 
multivitamin groups had significantly higher CD4+ cell counts during the median follow-
up period of 71 months, compared to women in the placebo group. Viral load was 
significantly reduced in women in the multivitamin group without vitamin A. Women 
taking multivitamins without vitamin A were less likely to die of AIDS-related causes or 
progress to stage 4 of the disease compared to women in the placebo group (RR 0.71, 
95% CI 0.51-0.98, p=0.04). Women in the multivitamin plus vitamin A group saw a non-
significant reduction in women dying of AIDS-related causes or progressing to stage 4 
(RR 0.80, 95% CI 0.58-1.10, p=0.17). Multivitamins (with and without vitamin A) 
reduced incidence of HIV-related complications, including thrush, oral ulcers, painful 
tongue or mouth, and rash. Multivitamins without vitamin A resulted in a significant 
reduction in nausea, vomiting, diarrhea, and difficulty swallowing. Vitamin A alone did 
not have significant effects on any clinical outcomes. Multivitamins may enhance 
immunity and decrease replication of HIV, thus reducing viral load, slowing progression 
of the disease and reducing risk of MTCT (Fawzi et al., 2004; Friis, 2006). Micronutrient 
supplementation to HIV-infected pregnant women may be an intervention that could 
reduce complications and adverse outcomes associated with HIV and AIDS (Friis, 2006).  
2.3.3 Inflammation and anemia of chronic disease  
 Individuals in a chronically inflamed state have altered iron metabolism, which 
can cause anemia of chronic inflammation (ACI), also known as anemia of chronic 
disease. ACI is typically milder than iron deficiency anemia and is characterized by 
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normochromic and normocytic cells, with low reticulocyte count (indicating reduced 
synthesis of red blood cells) (Thurnham & Mccabe, 2012; Weiss & Goodnough, 2005). 
ACI commonly occurs in developing countries due to high frequency of infections. 
Common diseases that lead to ACI include malaria, HIV, cancer, and autoimmune 
diseases. The inflammatory response inhibits iron absorption, thus iron supplementation 
may not have an effect on iron status in people with ACI. ACI affects the various iron 
biomarkers in different ways. Serum iron and ferritin are affected by inflammation within 
8 hours. Serum iron will decline by approximately 50%, while ferritin increases in 
parallel to the rise in CRP (Thurnham & Mccabe, 2012).  
ACI is characterized by abnormal iron homeostasis, uptake, and release (Weiss & 
Goodnough, 2005). In ACI, the immune response releases hepcidin, a peptide hormone 
that inhibits the release of iron stores, which then leads to decreased serum iron. Hepcidin 
is also responsible for limiting iron absorption in the small intestine. Long-term 
inflammation can result in altered hemoglobin and red blood cell production, as well as 
iron retention in storage sites, which can then lead to anemia (Petraro et al., 2013; 
Thurnham & Mccabe, 2012; Weiss & Goodnough, 2005).  
2.4 Multiple micronutrient supplementation interventions  
 It is common for women of reproductive age in developing countries to have 
coexisting micronutrient deficiencies. For this reason, it may be necessary to provide 
multiple micronutrient (MMN) supplements during pregnancy  (Bhutta & Das, 2014). 
Micronutrients play a crucial role in the growth, development, and immune system of the 
fetus, as well as preventing adverse pregnancy and birth outcomes. Women who have 
micronutrient deficiencies during pregnancy are more likely to have infants with 
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micronutrient deficiencies, thus creating an intergenerational cycle of malnutrition. Since 
many pregnant women in developing countries consume diets poor in essential nutrients, 
MMN supplements may be an appropriate method to combat micronutrient deficiencies 
in mothers and their infants (Haider & Bhutta, 2012, 2015).  
MMN supplements are generally cost-effective and deliver nutrients in a single 
delivery system. Micronutrients can be encapsulated into a pill or fortified into a 
supplementary food or beverage. Concerns of MMN supplementation include possible 
interactions between nutrients (e.g. iron and zinc) or potential overload from nutrients if 
consumed in excessive amounts (e.g. iron and vitamin A) (Haider & Bhutta, 2012). 
Another criticism is that some women may already have adequate nutrient levels, thus 
making MMN supplements unnecessary or even harmful (Gopalan, 2002; Shah & 
Ohlsson, 2009). Studies investigating the effectiveness of MMN supplements compared 
with iron and folic acid supplements alone have produced mixed results, especially in 
regards to maternal outcomes. Research has generally supported the hypothesis that 
MMN supplements result in some improved infant outcomes, such as birth weight and 
fetal growth, compared to iron and folic acid alone, although many of these studies are 
varied as well (Haider & Bhutta, 2012; Shah & Ohlsson, 2009).   
2.4.1 Maternal outcomes of multiple micronutrient supplementation  
 Maternal micronutrient deficiency may lead to many adverse outcomes, including 
anemia, labor complications, hypertension, hemorrhage, and death (Ramakrishnan et al., 
1999). It is hypothesized that replacing iron-folic acid supplements with MMN 
supplements may have a additional benefit in reducing anemia risk (Bhutta et al., 2012); 
however, not all studies support this hypothesis. A review of nutrition intervention trials 
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found that mothers who took iron, iron and folic acid, or vitamin A supplements had 
significantly reduced maternal anemia risk (Imdad & Bhutta, 2012b; Thorne-Lyman & 
Fawzi, 2012); however, supplements with additional micronutrients did not further 
decrease anemia risk (Bhutta et al., 2012). The review found that supplements including 
calcium reduced risk of preeclampsia, pregnancy-induced hypertension, severe morbidity 
and maternal mortality (Imdad & Bhutta, 2012a; Ramakrishnan, Imhoff-Kunsch, & 
Martorell, 2014).  
 A randomized controlled trial in Tanzania assessed the effectiveness of a 
beverage fortified with 11 micronutrients on ferritin, retinol, and hemoglobin 
concentrations in pregnant women between 12 and 34 weeks gestation (Makola, Ash, 
Tatala, Latham, & Ndossi, 2003). The intervention was eight weeks of supplementation 
with the fortified beverage or a placebo beverage, in addition to iron and folic acid 
supplementation. After the intervention period, the fortified group had a significantly 
lower proportion of anemic women compared to the placebo group (48.5% versus 37%, 
p=0.019), even though both groups received iron supplementation. Women in the 
fortified group were 51% less likely to have anemia post-intervention and had 
significantly higher ferritin and hemoglobin concentrations, compared to the women in 
the control group. Retinol levels were not significantly different between the groups after 
intervention. In this population, eight weeks of supplementation with a MMN-fortified 
beverage was sufficient to raise hemoglobin and ferritin levels and decrease anemia rates 
in pregnant women more than iron and folic acid alone (Makola et al., 2003).  
 A cluster trial in rural China assessed change in maternal hemoglobin 
concentration between three randomized groups: supplement with 15 MMNs 
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(UNIMMAP), iron and folic acid (IFA), or folic acid (FA) alone (the current antenatal 
standard of care in China) (Zeng et al., 2008). UNIMMAP is the international supplement 
prepared by the United Nations Children’s Fund, World Health Organization, and the 
United Nations University, which contains the RDA of 15 vitamins and minerals. There 
was a significant increase in hemoglobin concentrations from baseline to the third 
trimester in women in the MMN (+6.9 g/L; 95% CI, 4.1-9.6; p<0.001) and IFA (+5.0 
g/L, p=0.001) groups, compared to women in the FA group. Although over 40% of 
women in each group were still anemic in the third trimester, both MMN and IFA 
supplementation significantly increased hemoglobin concentrations (Zeng et al., 2008).  
 Not all studies reviewed found that MMN supplementation results in improved 
maternal iron status compared to IFA supplementation. In Bangladesh, a randomized 
controlled trial with a 2x3 factorial design aimed to determine whether timing of food 
supplementation in combination with micronutrient supplementation had an impact on 
maternal hemoglobin (Persson et al., 2012). The two food groups started either 
immediately after pregnancy diagnosis (“early invitation” group [average 9 weeks 
gestation]) or the “usual” group (average 20 weeks gestation). The food supplement 
contained roasted rice and pulse powders, molasses, and soybean oil, providing 608 kcal 
and 18 grams of protein. The three supplement groups were IFA (30 mg iron), IFA (60 
mg iron), or a MMN supplement (UNIMMAP). Hemoglobin concentrations were 
measured at 14 and 30 weeks gestation. The mean maternal hemoglobin at 30 weeks was 
11.5 g/dL and the prevalence of anemia was 32.9%. There were no significant differences 
in anemia rates or hemoglobin concentrations at 30 weeks between the micronutrient 
supplementation groups. All three micronutrient groups experienced a small decrease in 
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hemoglobin concentrations from 14 to 30 weeks gestation (Persson et al., 2012), which is 
consistent with the tendency of hemoglobin concentrations to decrease from first 
trimester to the third trimester (Scholl, 2005). The IFA group with 60 mg iron did not 
have additional benefits above 30 mg iron. In this study population with a low prevalence 
of iron deficiency at baseline, additional micronutrients or increased iron did not have an 
added effect on increasing maternal hemoglobin later in gestation (Persson et al., 2012). 
A study in rural China found that women who were taking prenatal MMN supplements 
did not have significantly different hemoglobin concentrations in the third trimester than 
women taking IFA supplements (p=0.34) (Liu et al., 2013). 
 There are other nutrient biomarkers that may be affected by supplementing with 
additional micronutrients as opposed to iron and folic acid alone. A trial in a low-income, 
multi-ethnic area of East London assessed the efficacy of a MMN supplement compared 
to FA alone in mothers under 13 weeks gestation at baseline (Brough, Rees, Crawford, 
Morton, & Dorman, 2010). Based on intention-to-treat analysis, women in the MMN 
group had significantly higher folate and hemoglobin concentrations at 26 and 34 weeks 
gestation, as well as vitamin D levels at 26 weeks, compared to women in the FA group. 
Although this study was affected by a high dropout rate, early MMN supplementation 
improved maternal nutrient status later in gestation (Brough et al., 2010).  
 Micronutrient supplementation may increase length of gestation, which can have 
beneficial effects for mother and fetus. Zimbabwean women who received a MMN 
supplement during pregnancy experienced an increase in gestational duration of 0.3 
weeks longer than women receiving iron and folic acid, although this did not reach 
significance (p=0.06) (Friis et al., 2004a). A longer gestation tends to be related to 
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increased birth size of infants (Friis et al., 2004a). However, a randomized controlled trial 
in rural China did not find a significant effect of MMN supplementation on gestational 
duration compared to IFA supplementation (0.05 weeks, CI -0.01-0.11, p=0.08) (Liu et 
al., 2013).  
 Among HIV-infected women, MMN supplementation improved several maternal 
outcomes in study in Tanzania by Fazwi, et al (1998). Women receiving a multivitamin 
supplement had significantly greater mean increase in CD4 cell count from baseline to 6 
weeks postpartum (55.0, 95% CI 12.51-97.49, p=0.01), compared to women receiving a 
placebo or vitamin A (in addition to the standard IFA). Multivitamins also proved 
beneficial to maternal anthropometry. Women who received MMN supplements saw a 
greater increase in weight from baseline to the third trimester, compared to women not 
receiving multivitamins (+304 g, 95% CI 17-590, p=0.04). Among these HIV-infected 
women, MMN supplements also raised hemoglobin concentrations significantly higher 
from baseline to 6 weeks postpartum (+0.7 g/dL, 95% CI 0.44-0.96, p<0.00001) 
compared to women receiving vitamin A or a placebo (Fawzi et al., 1998).   
Some research supports the hypothesis that maternal MMN supplements can 
reduce anemia further than IFA alone. Conflicting results of MMN supplementation on 
maternal outcomes indicate that more trials need to be conducted to determine the 
benefits of supplementing with multiple micronutrients during pregnancy.   
2.4.2. Infant outcomes of maternal multiple micronutrient supplementation  
 An estimated 75 million births occur annually in developing countries (Shah & 
Ohlsson, 2009), many of which result in inadequate growth or preterm delivery, which 
can lead to increased morbidity, mortality, stunted growth, and compromised cognitive 
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development (Friis et al., 2004a). Shah and Ohlsson (2009) estimate that 1.5 million 
infants (95% CI 0.75-2.25 million) born with low birth weight (<2500 grams) could be 
avoided if mothers in developing countries were given MMN supplements instead of iron 
and folic acid alone. Other infant outcomes that potentially could be improved from 
MMN supplementation include reduction in SGA infants, preterm births, neonatal and 
infant mortality, and stillbirths (Haider & Bhutta, 2012; A. H. Shankar et al., 2008).   
 The most widely studied infant outcomes of maternal MMN supplementation 
assess birth size and fetal growth, including birth weight, incidence of LBW, SGA and 
birth length. A 2015 Cochrane Review analyzed 17 trials (n=137,791) involving various 
interventions of maternal micronutrient supplementation. MMN supplements during 
pregnancy resulted in a 12% decrease in LBW infants (RR 0.88, 95% CI 0.85-0.91) and a 
10% decrease in SGA infants (RR 0.90, 95% CI 0.83-0.97) when compared to iron and 
folic acid supplements alone (Haider & Bhutta, 2015). Another meta-analysis (15 trials, 
n=62,244) found that maternal MMN supplements increased infant birth weight by 44 
grams (95% CI 28-60 g, p=0.003) (Kawai et al., 2011).  
Studies have shown a significant increase in birth weight ranging from 42 grams 
to 67 grams when compared to either IFA or folic acid alone, as seen in Table 2.6 (Fawzi 
et al., 2007; West et al., 2014; Zeng et al., 2008). A study in 1,106 Zimbabwean mother-
infant pairs produced contrasting results, in which maternal MMN supplementation 
resulted in non-significant increases in infant birth weight of 49 grams (95% CI; -6-104, 
p=0.08) (Friis et al., 2004a).  
Infants of women receiving MMN supplements in the study by West, et al. (2014) 
experienced a significant mean increase in birth length of 0.20 cm greater than infants of 
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women receiving IFA supplements during pregnancy. The studies by Zeng, et al. (2008) 
and Fawzi, et al. (2007) showed similar increases in birth length (0.22 cm and 0.20 cm, 
respectively); however, they did not reach significance due to smaller sample sizes.  
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Table 2.7. Infant outcomes from trials of maternal multiple micronutrient 
supplementation. (Fawzi et al., 2007; A. H. Shankar et al., 2008; West et al., 2014; 
Zeng et al., 2008) 
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 Preterm births result in smaller infants, which can lead to stunted growth later in 
life. Bangladeshi pregnant women receiving MMN supplements experienced a 15% 
reduction in preterm births compared to women receiving IFA supplements (RR 0.85, 
95% CI 0.80-0.91, p<0.001) (West et al., 2014). Women in the MMN group had longer 
gestational durations of 0.30 weeks (p<0.001), which corresponded to an increase in birth 
weight of 55 grams (West et al., 2014). However, a Cochrane review of 15 trials of 
maternal supplementation in developing countries found no significant differences in 
preterm birth rates between MMN and IFA supplements (RR 0.96, 95% CI 0.89-1.03) 
(Haider & Bhutta, 2015). Other studies reported non-significant reductions in preterm 
births by 14% when comparing MMN supplements to folic acid alone (Zeng et al., 2008) 
and 0.7% reduction when comparing MMN supplements to IFA supplements (Fawzi et 
al., 2007).  
 Stillbirths, fetal loss, and neonatal or infant mortality are common outcomes 
measured in maternal supplementation trials. MMN supplements resulted in a significant 
reduction in stillbirths of 11% (RR 0.89, 95% CI; 0.81-0.99, p=0.02) in one study (West 
et al., 2014), but non-significant reductions of 0.7% to 10% were found in trials from 
Fawzi, et al. (2007) and Shankar, et al. (2008), respectively. An interesting finding in the 
study by Zeng, et al. (2008) was a non-significant 39% increase in stillbirths from women 
in the MMN group compared to women receiving folic acid alone (RR 1.39, 95% CI; 
0.95-2.04). Pooled data from two Nepalese trials found that MMN supplementation 
during pregnancy increased the risk of perinatal mortality when compared to IFA 
supplementation (Christian et al., 2003; Osrin et al., 2005), which can possibly be 
explained by the increase in fetal size. Malnourished women delivering larger babies may 
 
 
64 
lead to difficult labors and cephalopelvic disproportions (Fawzi et al., 2007), as well as 
increased risk of birth asphyxia in infants who become large for gestational age (LGA) 
(Christian, Manandhar, Khatry, Costello, & West, 2005). Another hypothesis is that 
starting supplementation early in pregnancy allows mothers to carry frail fetuses that 
otherwise would have spontaneously aborted, but were carried for longer gestation due to 
improved maternal nutritional status, resulting in perinatal death instead (Christian et al., 
2005; Kawai et al., 2011).  
 Other studies have indicated that maternal MMN supplementation may have an 
impact on reducing perinatal or infant mortality. A study of 29,542 Indonesian women 
found an 18% reduced risk of early infant mortality (defined as death within 90 days after 
birth) in those taking MMN supplements (p=0.01) and a 30% reduced risk of post-
neonatal mortality (29-90 days after birth) (p=0.004), compared to infants of women 
taking IFA supplements (A. H. Shankar et al., 2008). Maternal MMN supplements also 
significantly reduced risk of fetal loss and neonatal mortality (defined as combined data 
of stillbirths, spontaneous abortions and neonatal death) by 11%, compared to women 
taking IFA supplements (A. H. Shankar et al., 2008). As seen in Table 2.6, other studies 
reported non-significant reductions in infant mortality of 1.2% (Fawzi et al., 2007) and 
5% (West et al., 2014) when comparing MMN to IFA supplements, and 29% when 
compared to folic acid alone (Zeng et al., 2008). 
 Adequate maternal micronutrient intake is crucial for fetal brain development, 
which has an impact on cognitive, emotional, motor, and social skills later in life. The 
Supplementation with Multi-Micronutrients Intervention Trial (SUMMIT) in Indonesia 
aimed to determine whether maternal MMN supplementation could impact the cognitive 
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and socio-emotional abilities of their children at 3.5 years (Prado, Alcock, Muadz, 
Ullman, & Shankar, 2012). Children of undernourished mothers (MUAC <23.5 cm) who 
received a supplement with 15 vitamins and minerals scored significantly higher in tests 
of motor development (0.35 SD, 95% CI; 0.01-0.69, p=0.044) and visual attention and 
spatial ability (0.35 SD, 95% CI; 0.08-0.63, p=0.011) compared to children of 
undernourished mothers who received IFA supplements. Children born to anemic 
mothers receiving MMN supplements saw similar advantages in visual attention and 
spatial ability scores compared to those in the IFA group. No differences were found 
between children born to well nourished, non-anemic mothers. Cognitive abilities of 
children at this age are better predictors of school and work achievements in later life 
than infant developmental scores. This study indicates that MMN supplements may 
protect against the negative developmental and cognitive effects of undernutrition or 
anemia during pregnancy (Prado et al., 2012). 
 There are several potential benefits of maternal MMN supplementation to both 
mother and infant. However, the research is not overwhelmingly in support of changing 
the antenatal standard of care from IFA to MMN supplements. Birth weight is generally 
increased in newborns born to mothers taking MMN supplements. Other outcomes, such 
as maternal anemia, infant mortality, and fetal loss have produced conflicting results in 
maternal supplementation trials. Further research should include large randomized 
controlled trials to determine if there is a rationale to support MMN supplements during 
pregnancy.  
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2.5 Supplementary and therapeutic foods  
 Ready-to-use supplementary foods (RUSF; also known as lipid-based nutrient 
supplements [LNS]) and ready-to-use therapeutic foods (RUTF) are increasingly being 
used in the treatment of acute malnutrition, especially in children and more recently, with 
pregnant and lactating women (Arimond et al., 2013). RUTFs are commonly provided to 
infants or young children with severe malnutrition and the RUTF will replace all foods 
other than breast milk. RUSFs, which are supplementary to the usual diet, are more 
typically used with children with moderate malnutrition and malnourished adults 
(Arimond et al., 2013). Most RUSF and RUTFs consist of powdered ingredients 
combined in a lipid emulsion, such as oil or peanut butter and are resistant to bacterial 
contamination. RUSF and RUTF are popular in developing countries because they don’t 
require cooking or further preparation (Manary, 2005). 
 Fetal growth may be enhanced by maternal supplementation with protein, energy 
and micronutrients (Bhutta et al., 2013), however, there is a lack of controlled trials 
evaluating the effect of fortified energy-protein supplementary food (Ashorn, Alho, 
Ashorn, Cheung, Dewey, Harjunmaa, et al., 2015; Kramer & Kakuma, 2010). A trial in 
Malawi assessed the impact of small-quantity lipid-based nutrient supplements (SQ-LNS) 
during pregnancy on birth outcomes (Ashorn, Alho, Ashorn, Cheung, Dewey, 
Harjunmaa, et al., 2015). Women under 20 weeks gestation were randomized to receive 
SQ-LNS, IFA, or MMN (containing 18 micronutrients) throughout the remainder of 
pregnancy (n=1,391). The women were generally well nourished (mean MUAC 26.5 cm; 
proportion of women with BMI <18.5 kg/m2: 4.6-5.9%). This study utilized small 
quantities of LNS because energy intakes were mostly adequate in this population, but 
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micronutrient intakes were low. SQ-LNS provided only 118 kcal/day but also contained 
micronutrients, protein, essential fatty acids, and additional minerals in a 20-g per day 
dose. LNS ingredients included soybean oil, peanut paste, dried skimmed milk, vitamin 
and mineral mix, and sugar. Data was available from 869 infants born to women in this 
study. Infants from the LNS group saw a 0.2 mm (p=0.006) and 0.1 mm (p=0.175) 
increase in birth MUAC compared to the IFA and MMN groups, respectively. Infants 
from the LNS group had increased birth weight by 52 g and 36 g compared to the IFA 
and MMN groups, respectively, although these results did not reach significance. No 
significant differences were found between groups for SGA, preterm birth, LBW, 
newborn stunting, or head circumference, nor for measurements of the children at 18 
months. Stillbirths were higher in the LNS group than the MMN group (p=0.006).  Also, 
infants in the IFA group gained length faster (from birth to 18 months) compared to those 
in the LNS group. The authors hypothesize that the slower postnatal growth in the LNS 
infants may be due to displacement of breast milk by LNS, which could slow growth. 
The authors conclude that SQ-LNS did not promote increased fetal growth and birth size 
in this study population, although the sample size was smaller than intended (Ashorn, 
Alho, Ashorn, Cheung, Dewey, Harjunmaa, et al., 2015).  
 A trial in Burkina Faso tested the effect of fortified food supplement (FFS) 
against MMN supplements in pregnant women (Huybregts et al., 2009). The FFS in this 
study contained peanut butter, soy flour, vegetable oil, sugar and multiple micronutrients, 
providing 372 kcal and 14.7 g protein. Pregnant women (n=1,296) were randomized to 
receive either FFS or a MMN supplement (UNIMMAP) throughout pregnancy, 
beginning at an average of 16 weeks gestation. The mean MUAC of women was 25.8 cm 
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(FFS) and 26.0 cm (MMN), with 13.3% (FFS) and 12.5% (MMN) classified by BMI as 
underweight at enrollment. Birth length was 4.6 mm greater in the FFS group (95% CI 
1.8-7.3, p=0.001) compared to the MMN group. Birth weight, stillbirths and neonatal 
mortality did not differ significantly between the two groups. Newborns of anemic 
mothers in the FFS group experienced a 143.8 g increase in birth weight which 
approached significance (95%CI; -5.8-293.4, p=0.059), compared to non-anemic mothers 
(Huybregts et al., 2009). An improvement in birth length can prevent stunting in early life 
(Schmidt et al., 2002). 
 A study in a semi-urban population of Ghanaian pregnant women (“iLiNS-DYAD 
study”) was conducted to assess the impact of a LNS on fetal growth and other outcomes, 
when compared to MMN and IFA supplements (Adu-Afarwuah et al., 2015). The trial 
randomized 1,320 women to receive IFA (60 mg Fe; 400 µg folic acid), MMN (20 mg Fe 
plus 100-200% the RDA for 18 micronutrients), or LNS (118 kcal; 20 mg Fe; same 
micronutrients as MMN plus 4 additional minerals: Ca, P, K, and Mg). This study used a 
lower dose of iron in the MMN and LNS treatments to test the theory that a 20 mg dose 
of iron is adequate during pregnancy and reduces gastrointestinal side effects, as well as 
because they intended to continue the treatment through lactation, which has a lower 
RDA for iron (9 mg/day). Infants of women in the LNS group had significantly greater 
mean birth weight (+85 g) compared to infants of women in the IFA group, while no 
differences were found between the LNS and MMN groups. In this population, parity 
significantly affected the outcomes. Primiparous women receiving LNS had infants with 
significantly greater birth weight, length and head circumference compared to 
primiparous women receiving IFA or MMN. These authors indicate that LNS has a more 
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beneficial effect on women who are nutritionally vulnerable, including those who are 
younger, anemic, primiparous, shorter, and of lower socioeconomic status. These 
demographics can also be a risk factor for fetal growth restriction, which can lead to poor 
infant birth outcomes. In the entire sample, LNS promoted an increase in birth weight. 
The macronutrients and essential fatty acids that were in the LNS treatment may promote 
fetal growth more than micronutrients alone (Adu-Afarwuah et al., 2015).  
 The iLiNS-DYAD study in Ghana also assessed maternal anemia and iron status 
(Adu-Afarwuah, Lartey, Okronipa, Ashorn, & Zeilani, 2016). The women in the IFA 
group (60 mg iron) had greater mean hemoglobin concentrations and lower prevalence of 
anemia at 36 weeks gestation, compared to the MMN and LNS groups, which only had 
20 mg of iron. However, overall rates of anemia (hemoglobin <100 g/L) were reduced in 
all groups by the end of pregnancy to 2.2-7.9%, and rates of iron deficiency were <20% 
across all groups. The authors conclude that 20 mg of supplemental iron per day may not 
be adequate during pregnancy, but that more research is needed to determine the ideal 
dosage; especially because dietary iron is likely low in this population that consumes a 
plant-based diet, high in phytates. Furthermore, high maternal hemoglobin and iron status 
has been linked to adverse birth outcomes, and the study published by Adu-Afarwuah et 
al. (2015) mentioned above did not find that those in the IFA group had increased infant 
birth size. Therefore, the authors speculate whether or not there is a rationale to increase 
iron supplementation above 20 mg per day, if there is in fact no impact on birth size 
(Adu-Afarwuah et al., 2016). 
 Corn-soy blend (CSB) is a common supplementary food provided to pregnant 
and/or lactating women in developing countries. In Cambodia, 547 pregnant women were 
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randomized to receive fortified CSB flour (CSB-Plus) containing IFA and other 
micronutrients with oil containing vitamins A and D, or IFA alone (Janmohamed et al., 
2016). The proportion of underweight women, as measured by BMI, was 37% in the 
CSB-Plus group and 33% in the control group. The CSB-Plus provided 760 kcal and 27 g 
protein per day and the oil provided an additional 90 kcal per day. Women in the CSB-
Plus group had significantly lower rates of anemia at week 36-38 gestation (34%), 
compared to 50% in the IFA group. There was a significantly lower rate of preterm birth 
in the CSB-Plus group (2.1%) compared to the IFA group (7.1%) (p=0.03). However, 
there were no significant differences between groups for birth weight, length, head 
circumference, or prevalence of LBW or SGA. An unexpected finding was no differences 
between groups for maternal weight gain, which was expected to increase in the CSB-
Plus group due to the high caloric content. The authors indicate that perhaps the women 
in the study shared the treatment food with other family members or that the CSB-Plus 
replaced her ordinary food, thus canceling out the effect of the additional calories. 
Women in the CSB-Plus group had significantly higher rates of fetal loss (10.2%) 
compared to 3.7% in the IFA group, which is concerning. Although the CSB-Plus did not 
have beneficial effects on maternal or infant growth, the benefits on maternal anemia and 
preterm birth are worth further research (Janmohamed et al., 2016).   
 Other populations have benefited from RUSF products. Non-pregnant, HIV-
infected adults in Malawi receiving a peanut-based RUSF experienced a greater increase 
in BMI and fat-free body mass compared to those receiving a corn-soy flour blend 
(Ndekha et al., 2009). In HIV-infected lactating women in Malawi, LNS providing 746 
kcal per day resulted in an increase in B-vitamins (riboflavin, niacin, pyridoxine and 
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vitamin B12) in breast milk compared to a control. Women receiving anti-retroviral 
therapy (ART) during lactation had decreased concentrations of vitamin B12, 
nicotinamide and pyridoxine in breast milk. In women taking LNS and ART together, the 
negative effects of ART were offset by the benefits of LNS increasing B-vitamins (Allen 
et al., 2015).  
Maternal malnutrition and inadequate weight gain during pregnancy increase the 
risk of preterm births, LBW, and IUGR newborns. Nutritional interventions that include 
calories, micronutrients, protein and fatty acids may be a method to increase birth weight, 
reduce rates of maternal malnutrition, and improve pregnancy and birth outcomes (Yang 
& Huffman, 2011). More research studies in varying populations of pregnant women, 
such as well nourished versus undernourished, are needed.  
2.6 Conclusions 
 Maternal nutrition is an important predictor of newborn health. Micronutrient 
deficiencies are common in developing countries and can contribute to increased 
malnutrition during pregnancy, which can have adverse effects for both the mother and 
fetus. Women of reproductive age in developing countries are especially vulnerable to 
malnutrition because of increased rates of infections (HIV, malaria), poverty, food 
shortages and frequent pregnancies. Micronutrient deficiencies are common in areas 
where food diversity is low. Increased nutrient demands during pregnancy often lead to 
inadequate energy, protein and micronutrient intake. Malnourished pregnant women are 
at increased risk of morbidity and mortality, and their offspring are more likely to be born 
preterm or with decreased birth size. Long-term consequences of maternal malnutrition 
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include stunted growth of the child, impaired immunity, and decreased cognitive, social, 
and educational abilities (Adair, 2014; R. Thomas et al., 2012).  
 Micronutrients are crucial for the proper growth and development of a fetus. 
Deficiencies are common in vitamins A, B12, D and folate, and minerals iron and zinc. 
Interventions such as multiple micronutrient supplements or RUSFs are potential 
methods to combat maternal malnutrition and improve birth outcomes. More research 
needs to be conducted, however, to determine if RUSFs are more beneficial to the mother 
and fetus than multiple micronutrient supplements or iron and folic acid supplements. 
Maternal malnutrition is a substantial issue that leads to increased morbidity and 
mortality of the mother and fetus, as well as adverse pregnancy and birth outcomes 
(Ahmed et al., 2012).    
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CHAPTER 3: MATERIALS AND METHODS 
3.1 Objective 
 The objective of this research was to assess micronutrient status and change in 
vitamin A, vitamin D, vitamin B12, folate, iron, zinc, albumin and C-reactive protein 
concentrations in a sample of moderately malnourished pregnant Malawian women 
before and after receiving one of three nutritional interventions and to determine if one of 
those interventions improves micronutrient status better than the others.  
3.2 Subjects  
 This was a sub-study (“MN sub-study”) of a larger randomized controlled trial 
(Mamachiponde) that measured the effectiveness of the Malawian standard of care 
treatment for moderate malnutrition during pregnancy against two other nutritional 
interventions.   
Pregnant women were recruited into the sub-study during enrollment into the 
Mamachiponde study at 15 antenatal clinics in southern Malawi between September 2014 
and May 2015. The study sites were in the health districts of Blantyre, Chikhwawa, 
Mulanje, and Zomba.  
Inclusion criteria for Mamachiponde included:  
• Pregnant women with MUAC ≥ 20.6 cm and ≤23.0 cm 
• Willingness to attend the antenatal clinic every two weeks during 
pregnancy  
• Willingness to remain in the area for delivery and until 3 months 
postpartum 
• Provision of written and verbal consent  
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• Consent to undergo HIV testing, if not done previously  
Exclusion criteria for Mamachiponde included: 
• Severe malnutrition (MUAC <20.6 cm) 
• Pregnancy complications, such as gestational diabetes, preeclampsia, or 
hypertension 
• Severe anemia (hemoglobin <7.0 g/dL) 
• Participation in any other nutrition study or supplemental feeding program 
Inclusion criteria for MN sub-study:  
• Same as listed above for Mamachiponde study 
• Fundal height <22 cm  
Exclusion criteria for MN sub-study: 
• Same as listed above for Mamachiponde study 
• Fundal height >22 cm 
The fundal height criterion was modified during the course of the MN sub-study. 
When the MN sub-study began, women with a fundal height measurement >26 cm at 
enrollment were excluded since they would likely deliver before the second blood draw. 
Fundal height is a proxy for gestational age. Five months after the MN sub-study began, 
it was determined that the exclusion criteria should be altered to exclude women with a 
fundal height >22 cm due to a high number of study participants delivering their child 
before the scheduled date of the second blood draw. At the start of both the 
Mamachiponde study and the MN sub-study, women below age 18 were excluded from 
the study. This criterion changed to include women 16 and 17 years of age two months 
after the micronutrient sub-study began due to the high rates of pregnant teenagers in the 
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area who could benefit from the study.  As a token of appreciation, the mother was 
provided with soap and plates after the first blood draw and a chitenje (cloth) after the 
second blood draw.  
This study is registered in ClinicalTrials.gov NCT02120599 and was approved by 
the Institutional Review Boards at Washington University (St. Louis), Cal Poly (San Luis 
Obispo), and College of Medicine at University of Malawi. 
3.3 Randomization and blinding  
 Subjects were randomized in blocks of 60 to receive one of the three nutritional 
treatments (RUSF, CSB-UNIMMAP, or CSB-IFA) using a random number generator, 
which assigned participants to a study group labeled A, B, or C. Pregnancy ID’s were 
placed individually in blank envelopes and each participant picked out one envelope 
containing her treatment assignment. The research team was blinded to treatment group 
for each participant; each mother was provided with a large opaque study bucket so that 
researchers could not see the visibly different treatment food that the mothers took home.. 
The study nurses and drivers were the only study personnel who were aware of which 
treatment group the participants were in. The study nurses needed to know treatment 
assignment in order to give each participant the correct instructions of how to prepare 
and/or take the foods and supplements. After the study participants completed all 
enrollment information and measurements in the clinic, she would go out to the study 
vehicle to collect her food The study driver would look up her study number to identify 
which treatment she would receive, and placed it into a colored opaque bucket so that 
neither research team members nor other study participants could see which treatment 
group the woman was on. Study participants were not blinded to which treatment group 
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they were in, because the RUSF is visually distinct from the CSB flour and the 
UNIMMAP supplement is visually distinct from the iron and folic acid supplements. 
Data entry and data analysis team members were blinded to group assignment.  
3.4 Study design 
 Mamachiponde is a researcher-blinded, randomized controlled trial designed to 
determine whether provision of a micronutrient-fortified ready-to-use supplementary 
food (RUSF) or a fortified corn soy blended flour (CSB+) plus a multiple micronutrient 
supplement provided to pregnant women with moderate malnutrition will result in 
improved recovery from malnutrition and improved maternal and infant outcomes, 
compared to women receiving the standard of care. The standard of care is fortified CSB 
flour plus daily iron and folic acid supplements. All treatment foods and supplements 
were provided for a 14-day supply.  
The original sample size was projected to be 300 women total (3 intervention 
groups, 100 women per group), to detect at least a 0.5 standard deviation unit difference 
between groups for all nutrients, with 0.05 level of significance and 80% power. The 
sample size was increased during the study to account for higher rates of dropouts than 
anticipated. A total of 343 women were enrolled in this study and had the first blood 
draw performed, with 335 of the women having analyses completed of their baseline 
nutrient levels. Eight women did not have their serum analyzed, due to reasons including 
hemolyzed samples, inadequate amount of blood drawn, and samples being lost.  A total 
of 229 women completed the study with both blood draws being performed.  
 The three intervention groups are described in detail below. Full nutrient profiles 
are provided in Appendix B.  
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1) RUSF: This treatment provided 900 kcal/day, 38 g protein/day, and 200% of 
the Recommended Dietary Allowance (RDA) for most micronutrients during pregnancy 
(except for vitamin A, vitamin B3, folic acid, iodine, magnesium, and calcium, which will 
remain near 100%). The energy content of RUSF was designed to provide 360-450 
calories required during the second and third trimesters of pregnancy, and an additional 
450-550 calories to support recovery from moderate malnutrition. Women randomized to 
this treatment arm did not receive any additional supplements since micronutrients were 
already in the formulated food.  
 2) CSB + UNIMMAP: This treatment included 5 kg every two weeks of a corn-
soy blended (CSB+) flour plus a standard antenatal micronutrient tablet (UNIMMAP) 
that contains 15 micronutrients, which together provided a fairly similar amount of 
energy, protein, and micronutrients as the RUSF treatment.  
 3) CSB-IFA: This is the control group, which is the Malawian standard of care 
treatment for moderate and severe malnutrition during pregnancy. This treatment 
included 5 kg CSB every two weeks plus daily iron (60 mg) and folic acid (400 mcg) 
supplements.  
 Enrolled women visited the clinic every 2 weeks for measurements, health checks 
and received their two-week supply of treatment food. Women who achieved a MUAC 
>23.1 cm were considered ‘graduated’. Women whose MUAC remained >23.1 cm for 
two consecutive visits no longer received food treatment, however, she still received iron 
and folic acid supplements. After graduation, women came to clinic every month to 
ensure no relapse into malnutrition had occurred.  If relapse (MUAC <23.1) occurred, 
mothers went back onto their assigned treatment food/supplements. Women who 
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graduated and/or relapsed were still included in the analysis. Blood draws were taken at 
two time points, enrollment into the study and ten weeks later (at visit five), as described 
in detail in Section 3.5.  
3.5 Data collection 
 Women eligible and willing to consent in the primary study and sub-study had 
anthropometrics measured by a study team member. Anthropometrics included height, 
weight, MUAC, triceps skin fold (TSF), and blood pressure (BP Omron Intellisense 
BP760). Weight was measured in kilograms using a Detecto Slimpro scale (Webb City, 
MO). Height was measured in centimeters using a Seca stadiometer (Birmingham, United 
Kingdom). MUAC was measured twice with a TALC measuring tape (Herts, UK) and if 
the measurements were >1 mm different from each other, a third measurement was made 
and the two closest measurements were recorded; TSF was measured twice using Lange 
skinfold calipers (Beta Technology, Santa Cruz, CA) and similarly to MUAC, if the 
measurement differed by >1 mm, an additional measurement was taken and the two 
closest measurements were recorded. Hemoglobin was tested using Hemocue Hb 201+ 
(Angelholm, Sweden). Fundal height was measured by Malawian nurses and recorded to 
the nearest 0.5 cm by a standard measuring tape. Trained Malawian staff interviewed 
subjects and recorded information regarding demographics, clinical symptoms, household 
food security and food consumption frequency.  
 If the subject was determined to be eligible for the sub-study, she was invited to 
participate in the micronutrient sub-study. A study nurse reviewed the sub-study 
information in Chichewa, the primary language in Malawi, and if she consented to 
participate, the subject either signed her name (if able to write) or placed her thumb into 
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an inkpad and signed with a thumbprint. The “Mamaponde Micronutrient Sub-study 
Form” (see Appendix C) was filled out by a study team member. It included her 
Mamachiponde study ID number, barcode ID number for specimen tubes, fundal height, 
hemoglobin, time of blood draw, and fasting status. If she was not fasting, it was 
recorded how long ago she ate (in hours).  
3.6 Sample collection 
 Blood samples were taken at two separate occasions from each eligible and 
willing subject. The first blood draw took place when the subject enrolled into the 
Mamachiponde study and the second blood draw took place 10 weeks later. Venous 
blood samples were drawn in the morning with 21 gauge x 1” blood collection needles 
(Jelco; Smiths Medical) using Universal Precautions into serum separator tubes (“Tiger 
Top” BD Vacutainer tubes; tube size of 16x100 mm; draw volume capacity of 7.5 mL) 
for vitamins B12, A, D, folate and proteins albumin and C-reactive protein (CRP), and 
into Trace Element heparin tubes for the mineral zinc (dark blue/royal blue BD 
Vacutainer; tube size of 13x100 mm; draw volume capacity of 6.0 mL). The amount of 
blood that was drawn from each subject was approximately 9-10 mL total (3-4 mL into 
the Trace Element Vacutainer and 6 mL into the Serum Separator Tubes). This amount of 
whole blood allowed for 4-5 mL of serum to be separated and used for analysis.  
The procedures can be found in Appendix D.  
After a study nurse drew the blood, tubes were labeled with a barcode number 
corresponding to the subject’s study ID number, covered with foil to protect from light, 
and packed in a small cooler box with ice packs for transport. The tubes were centrifuged 
at 3500 rpm for 10 minutes at <25° C (Eppendorf Centrifuge 5804R) and the serum was 
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pipetted off into separate storage tubes (Rainin Classic Air Displacement Pipette PR-100; 
Mettler Toledo; Oakland, CA) at the College of Medicine in Blantyre, Malawi.  The time 
of centrifugation was recorded to ensure that the time between blood draw and 
centrifugation was less than 4 hours. Two mL of serum were pipetted into two separate 
amber-colored storage tubes (to block out light) for analysis of vitamins B12, A, D, folate, 
ferritin, and proteins albumin and CRP, and 1 mL of serum was pipetted into a clear 
storage tube for zinc analysis. These tubes were stored at -80° C in freezers at the College 
of Medicine (Thermo-Scientific -80°C Revco Elite Plus Freezer). The samples were 
shipped back to the United States periodically in nitrogen gas tanks for analysis at Central 
Coast Pathology (CCP) laboratory in San Luis Obispo, CA. One amber storage tube was 
used to analyze ferritin, vitamin B12, folate, albumin, and CRP at CCP laboratory. The 
second amber storage tube was sent to Physician’s Automated Laboratory (PAL) in 
Bakersfield, CA for vitamins A and D analysis. The clear storage tube was sent to 
Clinical Pathology Lab (CPL) in Texas for zinc analysis.  
 The minimum serum requirements are as follows:  
• 0.5 mL serum for vitamin B12, folate, ferritin, and retinol  
• 0.3 mL serum for vitamin D  
• 0.2 mL serum for albumin  
• 0.3 mL for CRP)  
• 0.5 mL serum for zinc 
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3.7 Nutrient assay methods   
Table 3.1 Assays used for analysis of nutrients and proteins 
Nutrient/protein Assay method- CCP1 Assay method-PAL2 
Retinol Nephelometry Chemiluminescence 
25-hydroxyvitamin D N/A Chemiluminescence 
(Liason XL Diasorin) 
Ferritin Electrochemiluminescence 
Immunoassay (ECLIA) 
Chemiluminescence 
(Beckman Coulter DXI) 
Zinc Quantitative Inductively Coupled 
Plasma-Mass Spectrometry 
Plasma-Mass Spectrometry 
Folate ECLIA N/A 
Vitamin B12 ECLIA Chemiluminescence 
(Beckman Coulter DXI) 
Albumin Bromcresol Green (BCG) BCG (Beckman Coulter 
DXI) 
C-reactive protein Immunoturbidimetric Immunoturbidimetric 
(Beckman Coulter 5800) 
1Central Coast Pathology; 2Physician’s Automated Laboratory  
Table 3.2 Normal deficiency and marginal status cut-off values for pregnancy and 
deficiency values in inflammatory state 
Nutrient Units Severely 
deficient 
Deficiency Deficiency 
with 
inflammation 
Marginal cut-
off values 
Folate1 ng/mL  <3.0 -- 3.0-5.91 
Vitamin B122 pg/mL  <203.0 -- -- 
Vitamin D3 ng/mL <12.0 12-20 -- 20-30 
Ferritin ng/mL  <15.0 <19.04 -- 
Retinol umol/L  <0.70 <0.604 <1.05 
Albumin g/dL  <3.4 -- -- 
Zinc ug/dL  1st trimester <575 
2nd/3rd trimester: 
<50 
-- -- 
CRP mg/L  Elevated >5.0 -- -- 
1Cut-off values determined from (WHO, 2012c) 
2Cut-off value determined from (WHO, 2008) 
3Vitamin D cut-off values determined using ARUP Laboratory Reference Ranges 
4Inflammation cut-off values determined from (Thurnham & Mccabe, 2012) 
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5Zinc deficiency cut-off values for pregnancy determined from (Abbassi-Ghanavati, 
Greer, & Cunninghahm, 2009; Hotz et al., 2003)  
 
Inflammation cut-off values were used to determine prevalence of deficiency (%) 
when using chi-square testing for categorical variables. CRP was used to control for the 
acute phase response when using ANOVA models for continuous response variables. 
During pregnancy, different zinc cut-off values were used for each trimester to control for 
the inflammatory process (Table 3.2) (Abbassi-Ghanavati et al., 2009).  
3.8 Statistical analysis methods  
Baseline characteristics and differences between mothers were tested for significance 
using the chi-squared test for categorical variables and the Student’s t-test for continuous 
variables. For longitudinal measures, the groups were compared using repeated measures 
mixed model analysis of variance (MANOVA) to analyze mean change in nutrients from 
week 0 to week 10, controlling for the inflammatory response with CRP. The mixed 
model analysis also tested for any interactions between treatment group and time. Percent 
deficiency rates were compared using chi-square testing, while controlling for CRP. 
Nutrient concentrations at week 10 were analyzed by analysis of variance (ANOVA) and 
Tukey’s HSD test to determine if any treatment groups were different from one another. 
Covariates included in this model were nutrient concentration at week 0, baseline CRP, 
CRP at week 10, parity, HIV status, and maternal baseline MUAC.  
Normality was assessed by analyzing histograms of residuals and goodness-of-fit 
tests. To achieve normality, vitamin B12and ferritin were transformed logarithmically and 
albumin achieved normality using square root transformation. The p-values were 
obtained using the transformed data while the means were displayed from the raw data. 
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Outliers were removed from vitamin B12 (n=2), ferritin (n=2), and zinc (n=1) to achieve a 
normal distribution.  
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CHAPTER 4: RESULTS 
4.1 Enrollment characteristics  
 A total of 343 women were enrolled into this study. Some samples from both 
blood draws were not included due to physical loss, hemolysis of blood, or inadequate 
amount of serum to analyze (Figure 4.1). The primary reason of subjects not completing 
the study was due to delivery before the second blood draw date (n=62). Other reasons 
included refusal (n=7), miscarriage (n=1), infant death (n=1), and loss to follow up (n=7).    
 
Figure 4.1 Flow chart of enrollment into the study 
 
343	women	enrolled	and	
randomly	assigned	
119	randomly	
assigned	to	RUSF			
109	randomly	assigned	to	
CSB-UNIMMAP	
115	randomly	
assigned	to	CSB-IFA	
	112	ﬁrst	blood	draw	
analysis	completed	
80	included	in	ﬁnal	
analysis	
	109	ﬁrst	blood	draw	
analysis	completed	
74	included	in	ﬁnal	
analysis	
	114	ﬁrst	blood	draw	
analysis	completed	
77	included	in	ﬁnal	
analysis		
3	samples	not	included	due	
to	hemolysis,	inadequate	
amount,	or	lost	samples	
5	samples	not	included	due	
to	hemolysis,	inadequate	
amount,	or	lost	samples	
22	delivered	before	
second	blood	draw	
3	lost	to	follow	up		
1	miscarriage	
1	refused		
5	unknown			
20	delivered	before	
second	blood	draw	
2	lost	to	follow	up		
3	refused		
10	unknown		
	
20	delivered	before	
second	blood	draw	
2	lost	to	follow	up		
3	refused	
1	infant	death		
11	unknown		
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4.2 Baseline characteristics  
 The age range of participants was 16 to 38 years and the median age was 19 
years. Educational level ranged from no schooling (n=27) to tertiary school (n=3), with 
the most common educational level as four to six years (n=135). The number of other 
adults in the household ranged from one to eight. The RUSF group had significantly 
more adults in the household at baseline than CSB-UNIMMAP or CSB-IFA (p=0.029) 
(Table 4.1). Twenty-one percent of participants experienced one or more illness within 
the two months before enrollment, including diarrhea (6%), pneumonia (3%), and malaria 
(15%). All groups had similar proportions of women reporting malarial and diarrheal 
illness, however, pneumonia prevalence was significantly different between groups, with 
the CSB-IFA group having the most women with pneumonia in the last two months 
(Table 4.1).  
 The average weeks of gestation at baseline differed significantly by treatment 
group. CSB-UNIMMAP and CSB-IFA had greater gestational ages at enrollment (19.64 
and 19.57 weeks, respectively), compared to the RUSF group (18.42 weeks) (p=0.04) 
(Table 4.1). Parity ranged from 0 to 9 previous pregnancies, with a mean of 0.9 previous 
pregnancies. Fifty-four percent of women were primiparous and 46% were multiparous. 
The majority of the participants were already taking supplements at study enrollment 
(folic acid and/or iron), which is consistent with Malawian antenatal care guidelines, 
which would be stopped once she started participating in this study. Mean baseline height 
(154.1 cm), weight (45.8 kg), MUAC (22.2 cm), and BMI (19.4 kg/m2) did not differ 
significantly by treatment group. The proportion of HIV-positive women at enrollment 
was greater in the CSB-IFA group (15.6%), compared to CSB-UNIMMAP (9.2%) and 
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RUSF (8.7%), although this was not significant. Although the overall average of women 
with HIV was 11.2% (n= 38), only 18 women reported taking anti-retroviral therapy 
(ARV) (Table 4.1). HIV status was significantly related to number of previous 
pregnancies. Women with lower parity were more likely to be HIV-positive (p=0.001). 
Primiparous women were 4.1 times more likely to be HIV-positive, compared to 
multiparous women (95% CI for OR: 1.4, 12.1, p=0.008). Age at enrollment approached 
a significant relationship with HIV status. Older women were slightly more likely to be 
HIV-positive; the mean age of HIV-positive women was 23.2 years and the mean age of 
HIV-negative women was 20.3 (p<0.001). When age was used as a categorical variable, 
21% of HIV-infected women were 16-17 years, 37% were 18-21 years, 16% were 22-29 
years, and 26% were 30-40 years (p=<0.0001). 
Table 4.1 Baseline characteristics of the participants at enrollment, by treatment 
group 
Baseline characteristic  RUSF  
(n=119) 
CSB-
UNIMMAP  
(n=109) 
CSB-IFA 
(n=115) 
P-value1 
Age at enrollment 
      16-17 y (%) 
      18-21 y 
      22-29 y 
      30-40 y 
20.2±4.22 
25.6 
44.4 
23.1 
6.8 
20.7±0.9 
13.6 
59.1 
23.6 
3.6 
21.0±4.8 
19.0 
53.4 
18.1 
9.5 
0.38 
0.106 
Educational level 
       None (%) 
       1-3 y 
       4-6 y 
       7-8 y 
       Secondary   
       Tertiary 
 
6.7 
15.1 
37.0 
26.9 
13.4 
0.8 
 
11.0 
17.4 
36.7 
22.9 
11.0 
0.9 
 
6.1 
19.1 
45.2 
13.9 
14.8 
0.9 
 
0.48 
Number of children in household 0.7±1.2 0.8±1.1 0.9±0.2 0.46 
Number of adults in household 2.4±1.1 2.2±0.6 2.2±0.7 0.03* 
Illness in the last 2 months (%) 19.3 21.1 22.6 0.18 
Diarrhea in the last 2 months (%) 6.0 6.4 4.3 0.77 
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Pneumonia in the last 2 months 
(%) 
0.0 3.6 5.2 0.01* 
Malaria in the last 2 months (%) 16.2 13.6 15.5 0.85 
Uses a bed net (%)  76.5 73.4 69.6 0.49 
Currently uses tobacco (%) 0 1.8 1.7 0.34 
Weeks gestation at enrollment 18.4±4.4 19.6±4.0 19.6±3.8 0.04* 
Number of previous pregnancies 0.9±1.6 1.0±1.3 1.0±1.3 0.86 
Number of live births 0.7±1.3 0.8±1.3 0.9±1.2 0.34 
Number of miscarriages 0.1±0.3 0.04±0.2 0.08±0.3 0.44 
Number of stillborn pregnancies 0.08±0.34 0.09±0.3 0.02±0.1 0.10 
Currently taking medicine  
       Amoxicillin (%) 
       ARV3 
      Malarial treatment 
      Paracetamol 
      Other  
24.4 
0 
4.2 
9.2 
12.6 
5.9 
22.0 
0.9 
2.8 
8.3 
12.8 
4.2 
30.4 
0.9 
9.2 
7.8 
13.0 
7.0 
0.34 
 
 
Currently taking supplements 
       Folic acid (%) 
       Iron (%) 
72.3 
2.5 
69.7 
70.6 
0.9 
68.8 
67.8 
3.5 
64.4 
0.76 
 
Roof material of home  
       Metal sheets (%) 
       Thatch 
       Other 
 
21.0 
78.2 
0.8 
 
20.2 
79.8 
0 
 
15.6 
84.3 
0  
 
0.49 
Food insecure household (%)  28.6  36.7 30.4  0.40 
HIV status (% positive)  8.7 9.2 15.6 0.18 
Baseline height (cm) 154.3±5.3 153.9±5.4 154.1±5.4 0.91 
Baseline MUAC (cm) 22.2±0.6 22.2±0.6 22.2±0.6 0.83 
Baseline weight (kg) 45.9±3.8 45.8±3.8 45.7±3.4 0.93 
Baseline BMI (kg/m2) 19.3±1.4 19.3±1.3 19.5±3.0 0.740 
Baseline underweight (%)4 28.7 25.0 28.3 0.795 
1P-values were obtained by ANOVA for continuous variables or chi-squared test for 
proportions 
2Mean ± SD (for all such values unless noted otherwise)  
3ARV: anti-retroviral therapy  
4Underweight determined by BMI <18.5 kg/m2 
*Indicates a significant p-value (<0.05) 
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4.3 Laboratory results  
 Baseline laboratory results indicate moderate to high levels of deficiency in 
multiple nutrients (Table 4.2). No significant differences were found between treatment 
groups in deficiency rates or baseline mean concentrations. The majority of participants 
were deficient in hemoglobin at baseline (67.5-75.2%); however, lower proportions were 
deficient in ferritin (22.3-23.9%). Unadjusted ferritin concentrations at baseline were 
greater in the RUSF group (61.8 ng/mL), compared to CSB-UNIMMAP (51.7 ng/mL) 
and CSB-IFA (45.1 ng/mL), although this did not reach significance (p=0.09).  
Nutrients of concern with high rates of deficiency included ferritin (22.9%), and 
zinc (35.4%), as well as marginal vitamin D (31.9%), retinol (32.4%) and folate (22.4%) 
concentrations. Low serum albumin was found in 42.7% of participants and 50.7% had 
elevated C-reactive protein (CRP) (Table 4.2). These deficiency rates were adjusted for 
inflammation (via CRP) for ferritin, retinol and albumin and adjusted for the effect of 
trimester for zinc and CRP (Table 4.2). Vitamin D was classified into multiple categories. 
None were severely deficient (<12 ng/mL) at baseline, 3.2% were deficient (<20 ng/mL), 
31.9% had marginal status (20-30 ng/mL), and 64.8% were sufficient in vitamin D. 
Table 4.2. Unadjusted serum nutrient/protein means and adjusted proportions of 
deficiency at baseline 
Nutrient/protein  CSB-IFA 
(n=112) 
CSB-
UNIMMAP 
(n=109) 
RUSF 
(n=114) 
P-
value1 
Capillary hemoglobin (g/dL) 
% deficient3 
10.0±1.52 
71.6 
9.9±1.5 
75.2 
10.3±1.6 
67.5 
0.27 
0.44 
Serum folate (ng/mL) 
   % marginal4 
9.2±4.3 
27.7 
10.1±4.9 
20.2 
9.9±4.6  
19.3 
0.25 
0.25 
Serum vitamin B12 (pg/mL) 
   % deficient5  
309.2± 148.7 
17.9 
308.3±143.0 
22.0 
313.7±145.2 
23.7 
0.96 
0.55 
Serum vitamin D (ng/mL) 
   % deficient6 
   % marginal 
33.2±7.7 
1.8 
32.1 
34.1±7.5 
0.9 
32.1 
32.5±7.7 
7.0 
31.6 
0.28 
0.10 
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Serum retinol (µmol/L) 
   % deficient7 
   % marginal8 
1.1±0.4 
4.5 
34.5 
1.1±0.5 
8.4 
37.0 
1.1±0.4 
6.1 
26.1 
0.89 
0.50 
0.18 
Serum ferritin (ng/mL) 
   % deficient9 
45.1±42.0 
22.3 
51.7±59.4 
22.9 
61.8±67.7 
23.7 
0.09 
0.97 
Serum zinc (µg/dL) 
   % deficient10 
55.2±9.8 
38.2 
57.1±9.9 
29.0 
54.7±9.1 
38.8 
0.15 
0.24 
Serum albumin (g/dL)  
   % deficient11 
3.4±0.5 
45.5 
3.4±0.5 
45.9 
3.5±0.5 
36.8 
0.49 
0.30 
Serum C-reactive protein 
(mg/L) 
   % elevated12 
9.3±10.5 
50.0 
12.5±23.2 
49.5 
12.0±16.5 
52.6 
0.36 
0.88 
1P-values were obtained by chi-squared testing for categorical variables 
2Unadjusted means ± SD for all such values  
3Cutoff for hemoglobin deficiency <11.0 g/dL 
4Cut off for folate marginal status <5.9 ng/mL 
5Cutoff for vitamin B12deficiency <203 pg/mL  
6Cutoff for vitamin D deficiency <20 ng/mL, marginal status 20-30 ng/mL 
7Cutoff for retinol marginal status controlling for inflammation using <0.93 µmol/L 
8Cutoff for retinol deficiency controlling for inflammation <0.60 µmol/L  
9Cutoff for ferritin deficiency controlling for inflammation using <19 ng/mL 
10Cutoff for zinc deficiency in 1st trimester: <57 µg/dL; 2nd or 3rd trimester: <50 µg/dL 
11Cutoff for albumin deficiency <3.4 ng/mL 
12Cutoff for CRP elevated status >0.5 mg/dL 
 
 Adjusted baseline means of nutrients and proteins are described in Table 4.3. No 
significant differences were found between treatment groups.  
 
Table 4.3 Baseline adjusted mean (SE) concentrations by treatment group1 
 CSB-IFA 
(n=112) 
CSB-
UNIMMAP 
(n=109) 
RUSF (n=114) P-value2  
Folate (ng/mL) 9.64 (0.5) 9.59 (0.57) 9.64 (0.55) 0.212 
Vitamin B12 (pg/ml)3 312.2 (16.8) 313.5 (18.3) 314.8 (17.8) 0.991 
Vitamin D (ng/mL) 34.8 (0.86) 36.1 (0.94) 34.7 (0.91) 0.317 
Retinol (µmol/L) 1.04 (0.04) 1.08 (0.04) 1.04 (0.04) 0.663 
Ferritin (ng/mL) 41.9 (5.7) 41.6 (6.2) 50.8 (6.0) 0.302 
Zinc (µg/dL) 53.2 (1.0) 54.6 (1.2) 53.1 (1.1) 0.449 
Albumin (g/dL) 3.4 (0.05) 3.4 (0.06) 3.5 (0.06) 0.586 
CRP (mg/L)3 12.3 (2.0) 16.2 (2.1) 15.5 (2.1) 0.231 
1Covariates adjusted for include CRP concentration, fasting status, baseline MUAC, HIV 
status, parity, and gestational age  
2P-value attained by ANOVA   
3CRP adjusted for baseline MUAC, HIV status, parity, and gestational age   
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Analysis of nutrient concentration differences by treatment group was done in two 
ways, as described in Section 3.7. Table 4.4 shows adjusted mean concentrations at week 
10, while controlling for covariates including baseline concentration, CRP at baseline and 
week 10, parity, HIV status and baseline MUAC. 
Table 4.4 Adjusted least square mean concentrations (SE) at week 10 by treatment 
group1  
 CSB-IFA 
(n=80) 
CSB-UNIMMAP 
(n=74) 
RUSF (n=77) P-value2  
Folate (ng/mL) 13.2 (0.78) 11.7 (0.84) 11.3 (0.84) 0.080 
Vitamin B12 
(pg/ml)3,4 
255.4 (11.3) 281.5 (12.3) 310.4 (12.3) <0.001 
Vitamin D (ng/mL)5 35.5 (1.0) 35.6 (1.1) 39.9 (1.1) <0.0013 
Retinol (µmol/L) 1.06 (0.04) 1.09 (0.04) 1.10 (0.04) 0.726 
Ferritin (ng/mL)4 27.4 (3.2) 29.8 (3.5) 26.5 (3.5) 0.680 
Zinc (µg/dL) 53.3 (1.4) 54.6 (1.5) 56.0 (1.5) 0.257 
Albumin (g/dL) 3.3 (0.05) 3.3 (0.05) 3.2 (0.06) 0.326 
CRP (mg/L)6 9.7 (3.4) 13.1 (3.7) 11.3 (3.7) 0.698 
Hemoglobin (g/dL) 10.9 (0.2) 10.9 (0.2) 10.8 (0.2) 0.859 
1Adjusted for week 0 concentration, week 0 CRP, week 10 CRP, fasting status, 
gestational age, parity, baseline MUAC 
2P-value attained by ANOVA  
3Interaction between time and treatment added into model  
4Logarithmic transformation utilized for the p-values for vitamin B12and ferritin  
5Vitamin D concentration also controlling for season of blood draw (rainy versus dry) 
6CRP controlling for CRP at week 0, HIV status, parity, MUAC at enrollment   
 Vitamins B12and D concentrations at week 10 were significantly different 
between treatment groups (Table 4.4). The subjects in the RUSF group had the greatest 
vitamin B12and D concentrations at week 10, compared to CSB-UNIMMAP and CSB-
IFA. The other nutrients and proteins did not have significant differences between 
treatment groups at week 10.  
 Adjusted mean change in concentration from week 0 to week 10 was analyzed 
using repeated measures MANOVA, controlling for the acute phase response via CRP at 
both time points (Table 4.5). Vitamin B12 was the only nutrient to maintain significance 
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for both the effect of treatment and the effect of treatment over time. Mean change in 
vitamin D concentrations was not significantly different by treatment group; however, the 
effect of time and the interaction of time and treatment were significant for vitamin D 
(p<0.001). Ferritin also did not reach significance for differences in mean change by 
treatment, but the effect of time and the interaction of time and treatment were again 
significant (p=0.047). Almost all nutrients, except retinol, zinc, and CRP, had significant 
effects from the treatment over time.   
Table 4.5 Mean change in adjusted concentrations from week 0 to week 10, by 
treatment group1 
 CSB-IFA 
(n=80) 
CSB-
UNIMMAP 
(n=74) 
RUSF 
(n=77) 
Treatment 
effect P 
Time 
effect P 
Time* 
Treatment 
effect P 
Folate 
(ng/mL) 
4.0 1.7 2.2 0.365 <0.001 0.062 
Vitamin B12 
(pg/ml)2 
-52.9 -36.1 -17.1 0.007 <0.001 0.002 
Vitamin D 
(ng/mL) 
1.7 3.2 6.0 0.315 <0.001 <0.001 
Retinol 
(µmol/L) 
-0.06 -0.02 -0.01 0.955 0.182 0.604 
Ferritin 
(ng/mL)2 
-18.0 -17.8 -23.1 0.812 <0.001 0.047 
Zinc  
(µg/dL) 
-2.7 -2.1 1.4 0.394 0.472 0.072 
Albumin 
(g/dL) 
-0.19 -0.12 -0.25 0.961 <0.001 0.404 
CRP (mg/L) 1.8 1.2 1.9 0.157 0.372 0.984 
Hemoglobin 
(g/dL) 
0.82 0.77 0.56 0.616 <0.001 0.588 
1Least square means and p-values obtained from repeated measures MANOVA, 
controlling for CRP at both time points  
2Logarithmic transformations used for vitamin B12 and ferritin 
 
 Change in percent deficient or of marginal status from week 0 to week 10 was 
analyzed, shown in Table 4.6. Inflammation cut-off values were used to determine 
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deficiency and to control for the acute phase response with ferritin and retinol. 
Inflammation was controlled for with zinc and albumin. Trimester of pregnancy at each 
blood draw was also used to correct for differences in zinc deficiency.  
Table 4.6 Percentage of deficiency or elevation by treatment at week 0 and week 10 
 CSB-IFA CSB-UNIMMAP RUSF P1 
 Week 0 Week 10 Week 0 Week 10 Week 0  Week 10  
Folate2  27.7 6.3 20.2 18.9 19.3 13.0 0.053 
Vitamin B123 17.9 42.5 22.0 25.7 23.7 19.5 0.005 
Vitamin D4  
  marginal 
  deficient 
 
32.1 
1.8 
 
23.8 
0.0 
 
32.1 
0.9 
 
23.0 
1.4 
 
31.6 
7.0 
 
20.3 
2.5 
 
0.693 
Retinol 
marginal5 
deficient6 
 
34.6 
4.6 
 
25.0 
7.5 
 
37.0 
8.4 
 
32.4 
8.1 
 
26.1 
6.1 
 
33.8 
5.2 
 
0.430 
0.747 
Ferritin7 22.3 43.8 22.9 35.6 23.7 48.1 0.293 
Zinc8 38.2 33.8 28.9 39.2 38.8 31.6 0.739 
Albumin9 45.5 67.5 45.9 71.6 36.9 71.4 0.741 
CRP10 50.0 41.3 49.5 48.7 52.6 33.8 0.177 
Hemoglobin11 71.6 44.2 75.2 43.0 67.5 48.5 0.705 
1Proportions of deficiency and p-value determined using chi-square testing for categorical 
variables; p-value indicating differences between treatment groups at week 10; p-values 
controlling for inflammation for ferritin, retinol, albumin, zinc  
2Cut off for marginal folate status <5.9 ng/mL  
3Cutoff for B12 deficiency <203 pg/mL   
4Cutoff for vitamin D deficiency <20 ng/mL, marginal status 20-30 ng/mL  
5Cutoff for marginal retinol status controlling for inflammation using <0.93 umol/L 
6Cutoff for retinol deficiency controlling for inflammation <0.60 umol/L  
7 Cutoff for ferritin deficiency controlling for inflammation using <19 ng/mL 
8Cutoff for zinc deficiency in 1st trimester: <57 ug/dL; 2nd or 3rd trimester: <50 ug/dL 
9Cutoff for albumin deficiency <3.4 g/dL 
10Cutoff for CRP elevated status >5 mg/L 
12Cutoff for hemoglobin deficiency (anemia) <11.0 g/dL 
 The most significant differences were found between treatment groups for percent 
deficient in vitamin B12 at week 10 (Table 4.6). All treatments saw a decrease in mean 
vitamin B12 concentration and an increase in percentage deficient, however, the RUSF 
group had the lowest proportion of women deficient in vitamin B12 at week 10 (19.5%), 
compared to 42.5% in the CSB-IFA group and 25.7% in the CSB-UNIMMAP group. At 
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week 10, all groups had similar percentage with marginal vitamin D status, although the 
RUSF group experienced the greatest decrease in percentage points deficient from week 
0 to week 10 (-11.3%), compared to -8.3% in the CSB-IFA group and -9.1% in the CSB-
UNIMMAP group. The percentage of women deficient in vitamin D at week 10 was 
small and similar between groups. The proportion of women with marginal folate status 
at week 10 was the least in the CSB-IFA group (6.3%), compared to 18.9% in the CSB-
UNIMMAP group and 13.0% in the RUSF group, which almost reached significance 
(p=0.056). 
 A two-way comparison using the Tukey analysis is shown in Table 4.7. Adjusted 
vitamin B12 concentrations were significantly different between the RUSF and CSB-IFA 
groups (p<0.001) and between CSB-IFA and CSB-UNIMMAP (p=0.05). The RUSF 
group had the highest adjusted vitamin B12 concentrations at week 10. Adjusted vitamin 
D concentrations were significantly different between the RUSF and CSB-IFA groups 
(p<0.001) and between RUSF and CSB-UNIMMAP (p=0.019). No other nutrients or 
proteins were significantly different from each other in this analysis.  
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Table 4.7 Adjusted means (least square) by treatment and two-way Tukey 
comparison of treatment effect between groups  
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4.4 Folate  
 Folate concentrations had the greatest improvement in the CSB-IFA group (Table 
4.5), followed by RUSF, then CSB-UNIMMAP (Figure 4.2). At baseline, CSB-IFA had 
the highest proportion of marginal folate status (27.7%), compared to 20.2% in CSB-
UNIMMAP, and 19.3% in the RUSF group (p=0.25). Differences between treatment 
groups in percentage with marginal folate status at week 10 approached significance, 
with RUSF decreasing to 6.3%, and CSB-UNIMMAP and RUSF groups decreasing to 
18.9% and 13.0%, respectively (p=0.053, Table 4.5).  
  
Figure 4.2 Change in folate means from week 0 to week 10 by treatment group.  
  
Folate concentrations at baseline were similar by treatment group, but had 
significant differences based on gestational age at enrollment. Women who were further 
along in their pregnancy at enrollment had a lower mean folate concentration at baseline 
(p=0.006). Folate concentrations at week 10 were not significantly affected by any other 
covariates, including CRP, parity, gestational age at enrollment, or HIV status. 
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4.5 Vitamin B12 
 Vitamin B12 decreased from week 0 to week 10 in all treatment groups, as is 
expected during pregnancy (van den Broek & Letsky, 2000). The RUSF group 
experienced the smallest decrease throughout treatment (-17.1 pg/mL), compared to -36.1 
pg/mL in the CSB-UNIMMAP group and -52.9 pg/mL in the CSB-IFA group (p=0.007) 
(Figure 4.3, Table 4.5). The effect of time and the effect of the interaction of time and 
treatment were also significant. CSB-IFA experienced the greatest increase in percentage 
of vitamin B12 deficiency (from 17.9% to 42.5%), while CSB-UNIMMAP experienced a 
smaller increase (22.0% to 25.7%). The RUSF group saw a significant decrease in 
percent deficient (23.7% to 19.5%)(Table 4.6).  
 
Figure 4.3 Change in adjusted mean vitamin B12 concentrations (pg/mL) by 
treatment group  
 
 Vitamin B12 concentrations at week 0 and week 10 were highly correlated 
(r2=0.56, p<0.001)(Figure 4.4). The inflammatory response (CRP) was not significantly 
correlated to vitamin B12 concentrations at either time point (p=0.624 at baseline and 
p=0.646 at week 10).   
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Figure 4.4 Correlation of week 0 to week 10 concentrations of vitamin B12 (pg/mL) 
(p<0.001, r2=0.56).  
Two-way comparison indicated that vitamin B12 concentrations for RUSF were 
significantly different from CSB-IFA, and CSB-UNIMMAP concentrations were 
significantly different that CSB-IFA (Table 4.7). RUSF had a greater mean increase of 
53.95 pg/mL compared to CSB-IFA (95% CI 22.15, 85.75, p<0.001). CSB-UNIMMAP 
had a greater mean increase of 30.98 pg/mL than CSB-IFA (95% CI 0.58, 62.5, p=0.05). 
Vitamin B12 concentrations were not significantly affected by any other covariates, 
including CRP, parity, gestational age at enrollment, baseline MUAC, and HIV status.  
4.6 Vitamin D 
 Vitamin D concentrations were significantly greater in the RUSF group at week 
10 (39.9 ng/mL), compared to the CSB-UNIMMAP (35.6 ng/mL) and CSB-IFA groups 
(35.5 ng/mL)(p<0.001). Although rates of deficiency and marginal status were similar at 
week 10 (Table 4.6), the change in mean concentrations differed significantly (Figure 
4.5).  
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Figure 4.5 Mean increase in vitamin D concentrations from week 0 to week 10, by 
treatment group  
 
 There was a significant interaction found between time points and treatment for 
vitamin D (Table 4.5, p<0.001). This interaction was added into the ANOVA model 
analyzing differences between mean concentrations at week 10 (Table 4.4). Differences 
between the concentrations with and without the interaction added in the model are 
shown in Table 4.7. Both methods maintain a high level of significance.  
Table 4.8 Difference in adjusted mean vitamin D concentrations (ng/mL) with and 
without the interaction of time*treatment added into the model  
 Least square mean (SE) 
 CSB-IFA CSB-UNIMMAP RUSF P 
Vitamin D (ng/mL) 
No interaction 
35.1 (2.4) 36.5 (2.4) 39.3 (0.1) <0.001 
Vitamin D (ng/mL) 
Interaction 
35.4 (0.9) 36.6 (1.0) 39.5 (1.0) 0.0003 
 
 Vitamin D concentrations and clinic site were significantly related. When grouped 
into districts, significance was lost. Women from the clinic site Ngabu (Chikhwawa 
district) had significantly higher vitamin D concentrations at week 10 (when controlling 
for baseline concentration and all other covariates previously mentioned) than women 
from Matiya (Zomba district), Kambenje (Mulanje district), and Makwapala (Zomba 
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district)(Table 4.8). The left column displays clinic site in decreasing order of serum 
vitamin D concentrations.  
Table 4.9 Comparison of vitamin D concentrations (ng/mL) at week 10 by clinic site 
and clinic district  
Clinic site1 Vitamin 
D2 
P Clinic district  Combined vitamin 
D in district2 
P 
Ngabu 
(Chikhwawa) 
40.39 0.006 Chikhwawa 38.32 0.149 
Matiya    
(Zomba) 
33.43  Zomba 36.64  
Kambenje 
(Mulanje) 
32.71  Mulanje 34.68  
Makwapala 
(Zomba)  
30.95  Blantyre 35.92  
1Eleven other clinic sites excluded from data table (non-significant) 
2Least square mean from ANOVA, controlling for baseline vitamin D, treatment group, 
parity, weeks gestation, and baseline MUAC 
 
 Maternal MUAC at baseline was significantly correlated with vitamin D 
concentration at week 10, when controlling for baseline vitamin D, treatment group, HIV 
status, parity and gestational age (p=0.011). Women with a greater vitamin D 
concentration had lower baseline MUAC’s (Figure 4.6).  
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Figure 4.6 Correlation of baseline maternal MUAC and vitamin D concentration at 
week 10 (p=0.011).  
 
At baseline, vitamin D concentrations were significantly affected by gestational 
age and HIV status. Women who were 0.24 weeks further along in the pregnancy had a 1 
ng/mL increase in vitamin D concentrations (p=0.02). Interestingly, women who were 
HIV-positive had a higher baseline vitamin D concentration (37.8 ng/mL), when 
controlling for CRP and clinic site, compared to HIV-negative women (32.8 
ng/mL)(p<0.001). Vitamin D concentrations were significantly related to season (rainy 
season December-April and dry season May-November) for the second blood draw. 
Women who got their second blood drawn during the rainy season had significantly 
greater vitamin D concentrations, when controlling for other covariates (39.7 ng/mL), 
compared to 34.4 ng/mL in women who got their second blood drawn in the dry season 
(p<0.001).  At baseline, seasonality did not affect vitamin D concentrations. Vitamin D 
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concentrations at week 10 were not significantly related to any other covariates, including 
CRP, parity, gestational age at enrollment, or HIV status.  
4.7 Retinol  
 Retinol did not differ significantly by treatment group with any form of analysis. 
Mean adjusted concentrations at week 10 were almost identical, at 1.06, 1.09, and 1.10 
µmol/L for CSB-IFA, CSB-UNIMMAP, and RUSF, respectively (p=0.726). All 
treatment groups saw a small and similar decrease in mean concentration from week 0 to 
week 10 (-0.06, -0.02, and -0.01 µmol/L for CSB-IFA, CSB-UNIMMAP, and RUSF, 
respectively [p=0.955]). Changes in percent deficient and percent with marginal status 
differed non-significantly by treatment group (Figure 4.7).  
 
Figure 4.7 Percent of deficient, marginal, and sufficient retinol status by treatment 
group from week 0 to week 10.  
 
 Baseline retinol concentrations were related to HIV status. HIV-positive women 
had a significantly lower baseline retinol mean (0.96 µmol/L), compared to HIV-negative 
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women (1.13 µmol/L), when controlling for CRP concentration (p=0.007). Retinol at 
week 10 was not significantly related to HIV status. From week 0 to week 10, HIV-
positive women saw an improvement in mean retinol from 0.96 umol/L to 1.05 umol/L, 
while HIV-negative women had constant retinol concentrations (1.13 umol/L at both time 
points).  
The RUSF group experienced an increase in percentage with marginal retinol 
status (26.1 to 33.8%), but a decrease in percentage with deficient status (6.1 to 5.2%, 
non-significant)(Table 4.9). RUSF was the only group to show a decrease in percentage 
deficient from week 0 to week 10. However, RUSF was also the only group to experience 
a decrease in percentage with sufficient retinol status. None of these shifts in proportions 
were significant.  
Table 4.10 Proportions of sufficient, marginal, and deficient retinol status by 
treatment group, from week 0 to week 10, controlling for inflammation. 
 CSB-IFA CSB-UNIMMAP RUSF 
Retinol  Week 0 Week 10 Week 0  Week 10 Week 0  Week 10 
Sufficient (%)1 60.8 67.5 54.6 59.5 67.8 61.0 
Marginal (%)2 34.6 25.0 37.0 32.4 26.1 33.8 
Deficient (%)3 4.6 7.5 8.4 8.1 6.1 5.2 
1Cutoff for sufficient retinol status >0.94 µmol/L 
2Cutoff for marginal retinol status controlling for inflammation using <0.93 µmol/L 
3Cutoff for retinol deficiency controlling for inflammation <0.60 µmol/L  
 Retinol concentrations at baseline were significantly and negatively correlated 
with CRP concentrations (Figure 4.8)(r=0.13; p<0.0001). Retinol concentrations are 
expected to decrease during an inflammatory response, which is indicated in this 
population as well. At week 10, retinol concentrations and CRP concentrations were also 
correlated significantly, although not as strongly as with the baseline concentrations 
(r=0.08, p<0.0001). 
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Figure 4.8 Correlation of baseline retinol (µmol/L) and baseline CRP (mg/L) 
(p<0.0001). 
 
4.8 Ferritin 
 Ferritin concentrations at baseline did not differ significantly by treatment group. 
Adjusted ferritin concentrations at week 10 were similar between groups: 27.4, 29.8, and 
26.5 ng/mL for CSB-IFA, CSB-UNIMMAP, and RUSF, respectively (p=0.245)(Table 
4.4). Ferritin concentrations decreased throughout treatment for all treatment groups 
(Table 4.5). The RUSF group had the greatest decrease from week 0 to week 10 (-23.1 
ng/mL), compared to -17.8 ng/mL in the CSB-UNIMMAP group and -18.0 ng/mL in the 
CSB-IFA group (p=0.812). Significant interactions between time and treatment were 
observed for the analysis of change in ferritin concentrations (Table 4.5).  
 Percentages of women deficient in ferritin at baseline were similar among 
treatment groups (22.3-23.7%). At week 10, the percentage had increased for all groups, 
with RUSF having the greatest amount of deficiency (48.1%), compared to 35.6% in the 
CSB-UNIMMAP group and 43.8% in the CSB-IFA group. These changes in percent 
deficient were not significant between treatment groups (Table 4.6).  
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 Baseline ferritin concentrations were significantly related to CRP concentrations, 
parity, and HIV status. Women with a higher CRP had significantly higher ferritin 
concentrations (p<0.0001). Women with higher parity had significantly lower mean 
ferritin concentrations  (p=0.005)(Figure 4.9). In analysis using parity as a categorical 
variable, the effect remained significant. Primiparous women had significantly higher 
baseline ferritin concentrations (mean 64.4 ng/mL), compared to multiparous women 
(mean 39.0 ng/mL)(p<0.0001). HIV-positive women had a significantly lower baseline 
mean ferritin (34.98 ng/mL), compared to HIV-negative women (54.76 ng/mL)(p=0.031). 
 
Figure 4.9 Correlation of parity and baseline ferritin concentrations 
(ng/mL)(p<0.0001) 
 Ferritin was significantly and positively correlated to CRP, at both baseline and 
week 10. Figure 4.10 depicts the correlation between ferritin and CRP at week 10 
(r2=0.44, p<0.0001). Ferritin concentrations are expected to increase with the 
inflammatory response.  
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Figure 4.10 Correlation of week 10 ferritin (ng/mL) and week 10 CRP 
(mg/L)(p<0.0001). 
 
4.9 Zinc 
 Zinc concentrations did not differ significantly by treatment group. All treatment 
groups experienced high rates of deficiency at baseline (38.2%, 29.0%, and 38.8% 
deficient in the CSB-IFA, CSB-UNIMMAP, and RUSF groups, respectively)(Table 4.2). 
Zinc concentrations decreased from week 0 to week 10 in the CSB-IFA (-2.7 µg/dL) and 
CSB-UNIMMAP (-2.1 µg/dL) groups, but not in the RUSF group, which experienced an 
increase of 1.4 µg/dL (Table 4.5, Figure 4.11). The effect of treatment was not significant 
(p=0.394), although the interaction between time and treatment approached significance 
(p=0.072).  
 Baseline zinc concentrations were significantly correlated to gestational age at 
enrollment. Women who had a higher gestational age had significantly lower zinc 
concentrations at baseline (p=0.0002). Fasting status impacted zinc concentrations at 
baseline. Women who were in a fasted state had significantly higher baseline zinc 
concentrations (56.9 µg/dL), compared to 50.7 µg/dL in women who were not fasted at 
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the time of blood draw (p<0.001). Zinc concentrations at baseline and week 10 were not 
significantly affected by other covariates, including CRP, HIV status, parity, or baseline 
MUAC. Rates of zinc deficiency increased 10.3% in the CSB-UNIMMAP group, while 
the RUSF and CSB-IFA groups saw a decrease in deficiency rates of 7.2% and 4.4%, 
respectively (p=0.604).  
 
Figure 4.11 Adjusted serum zinc concentrations at baseline and week 10 by 
treatment group 
 
 Zinc concentrations were significantly related to hemoglobin concentrations, 
when controlling for CRP and gestational age. Higher hemoglobin concentrations at 
baseline and week 10 were correlated with higher zinc concentrations at baseline and 
week 10 (p=0.015 and p=0.009, respectively). A 1.23-g/dL increase in hemoglobin 
concentration correlated to 1 ug/dL increase in zinc concentration at week 10. Ferritin 
and zinc were also related. Those with greater ferritin concentrations were more likely to 
have greater zinc concentrations at baseline (p=0.0014); this association did not remain 
significant at week 10.  
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4.10 Albumin  
 Albumin concentrations did not differ significantly by treatment group. 
Concentrations decreased from week 0 to week 10 by 0.19, 0.12, and 0.25 g/dL in the 
CSB-IFA, CSB-UNIMMAP, and RUSF groups, respectively. The effect of treatment was 
not significant (p=0.961), although the effect of time was significant (p<0.001, Table 
4.5). At week 10, all groups had high rates of hypoalbuminemia: 67.5%, 71.6%, and 
71.4% in the CSB-IFA, CSB-UNIMMAP, and RUSF groups, respectively (p=0.818). 
Baseline means were close to the cutoff value for hypoalbuminemia of 3.4 g/dL, thus the 
small decrease that each group experienced correlated to a large increase in percent 
deficient.   
 Albumin at baseline was significantly and negatively correlated to CRP 
concentration (p=0.001). Women with lower albumin concentrations at baseline were 
more likely to have higher CRP concentrations. Albumin is a negative acute phase 
responder and is expected to decrease during an inflammatory response.  Albumin at 
week 10 was not related to CRP at week 10 (p=0.243).  
4.11 C-reactive protein 
 Mean C-reactive protein (CRP) concentrations were elevated at week 0 and week 
10. All treatment groups saw a small and non-significant increase in CRP concentrations. 
However, the percentage of women with elevated CRP status decreased from week 0 to 
week 10 by 8.7%, 0.8%, and 18.8% in the CSB-IFA, CSB-UNIMMAP, and RUSF 
groups, respectively (p=0.177). As discussed in previous sections, CRP was significantly 
correlated with retinol, ferritin, and albumin concentrations. CRP at week 10 was 
significantly correlated with CRP at baseline.  
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CRP was related to HIV status, when controlling for parity and recent illness. At 
baseline, HIV-infected women had a mean CRP of 17.6 mg/L, compared to 10.7 mg/L in 
HIV-uninfected women (p=0.025). However, the amount of HIV-positive women in this 
population was small (n=38). CRP was also related to self-reported infection with malaria 
within the last two months. Women who answered “yes” to having malaria within the 
previous two months had a significantly greater mean CRP (19.6 mg/L) compared to 
women who did not have malaria (8.65 mg/L) (p<0.0001). Reported pneumonia and 
diarrhea were not related to CRP.  
  CRP was not affected by clinic site or district, parity, education level, age, or 
weeks of gestation at enrollment.  
4.12 Hemoglobin  
 Mean adjusted hemoglobin concentrations at baseline were 9.8, 9.8, and 10.2 g/dL 
for the CSB-IFA, CSB-UNIMMAP, and RUSF groups, respectively (p=0.135). Overall, 
71% of women were anemic, based on hemoglobin concentrations <11 g/dL.   
Hemoglobin at baseline was significantly related to baseline ferritin levels. Interestingly, 
baseline hemoglobin and ferritin were negatively correlated. Women with higher 
hemoglobin were more likely to have a lower ferritin at baseline (p<0.001)(Figure 4.12). 
Women with a lower gestational age were more likely to have a greater baseline 
hemoglobin concentration (p=0.03). Baseline hemoglobin was slightly higher in women 
with greater MUAC, although this did not reach significance (p=0.055). Parity was 
related to baseline hemoglobin; women who were primiparous had lower hemoglobin 
concentrations (mean 9.7 g/dL) compared to multiparous women (10.1 g/dL) (p=0.03). 
Baseline hemoglobin was significantly related to clinic district. Women in the Zomba 
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district had the highest baseline hemoglobin concentrations (10.5 g/dL), compared to 
Mulanje (10.0 g/dL), Chikhwawa (9.6 g/dL), and Blantyre (9.6 g/dL)(p<0.001). This 
effect did not remain significant at week 10 hemoglobin concentrations (p=0.051).  
 
Figure 4.12 Correlation of baseline hemoglobin (g/dL) to baseline ferritin (ng/mL) 
 
 Hemoglobin at week 10 increased for all groups to 10.9, 10.8, and 10.8 g/dL for 
CSB-IFA, CSB-UNIMMAP, and RUSF groups, respectively (p=0.819). Week 10 
hemoglobin was negatively and non-significantly related to ferritin at week 10, although 
it approached significance (p=0.051). Women who were HIV-positive had non-
significantly lower mean hemoglobin concentrations at week 10 (10.5 g/dL) compared to 
HIV-negative women (11.1 g/L)(p=0.09).  
 Hemoglobin was related to albumin concentrations at baseline. Women with a 
greater hemoglobin concentrations of 1 g/dL were related to an increase in albumin 
concentrations of 0.59 g/dL at baseline (p=0.0004), when controlling for gestational age, 
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parity, ferritin and CRP concentrations.  The trend still remained at week 10, but not was 
significant (p=0.08).  
4.13 Birth outcomes  
 Birth measurements of weight, length, MUAC, and head circumference were not 
significantly different between treatment groups (Table 4.10). Three-month 
measurements of weight, length, and head circumference were not significantly different. 
Measurements from twin births were removed (n=1). Overall prevalence of low birth 
weight (<2500 g) was 35.1%, with no significant differences between treatment groups. 
Table 4.11 Unadjusted mean±SD (n) of birth and 3-month measurements by 
treatment group 
 CSB-IFA  CSB-UNIMMAP  RUSF  P1 
Birth weight2  2.67±0.38 (94) 2.65±0.36 (91) 2.63±0.49 (91) 0.825 
3 month weight  5.42±0.81 (93) 5.67±0.74 (92) 5.52±0.65 (89) 0.067 
Birth length3  46.97±2.18 (94) 46.76±1.93 (88) 46.51±2.42 (90) 0.356 
3 month length  58.3±2.89 (91) 58.3±2.29 (93) 58.1±2.49 (88) 0.767 
Birth MUAC4  9.33±0.09 (94) 9.38±0.09 (90) 9.33±0.09 (90) 0.927 
3-month MUAC  12.9±1.12 (93) 13.3±1.0 (93) 13.0±0.92 (88) 0.017* 
Birth HC5 34.14±1.54 (94) 34.05±1.36 (91) 33.94±1.75 (91) 0.678 
3 month HC 40.2±1.8 (92) 40.4±1.4 (92) 40.5±1.7 (89) 0.529 
3 month Hgb6 9.5±1.4 (93) 9.5±1.7 (89) 9.6±1.3 (85) 0.879 
1P-value obtained by Student’s t-test  
2Weight (kg) 
3Length (cm) 
4MUAC: mid-upper arm circumference (cm) 
5HC: head circumference (cm) 
6 Hgb: Hemoglobin (g/dL) 
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 Infant MUAC at 3 months was significantly related to treatment group, with 
infants of mothers from the CSB-UNIMMAP having the greatest 3-month MUAC. 
However, the significance was lost when birth MUAC and maternal MUAC were 
controlled for (p=0.087).  
 Maternal MUAC was not significantly related to birth weight, length, MUAC, or 
head circumference. There was a significant relationship between 3-month infant weight 
and baseline maternal weight (p<0.001), when accounting for infant birth weight. 
Some correlations were found between maternal nutrient concentrations and 
infant measurements. Baseline maternal ferritin concentrations (when controlling for 
CRP) were significantly and negatively related to infant birth weight (p=0.036). When 
parity was added into the model, significance lost (p=0.17). However, 3-month infant 
weight was positively and significantly related to baseline maternal ferritin (p=0.017) and 
had similar loss of significance when parity was added into the analysis (p=0.13).   
Folate concentration at week 10 approached a significant relationship with birth 
length, when controlling for parity and CRP at week 10 (p=0.07). The trend did not 
remain for 3-month infant length.  
Interestingly, birth length was significantly and negatively related to retinol 
concentration at week 10, when controlling for CRP at both time points and parity. When 
retinol concentrations at week 10 were decreased, mean infant birth length was increased 
(p=0.045). This trend did not remain significant for 3-month infant length. No other 
nutrients were significantly related to birth weight or birth length at either time point. 
 Infant 3-month hemoglobin was significantly and positively associated with 
maternal baseline hemoglobin concentration (p=0.0497). Significance was lost when 
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maternal week 10 hemoglobin was added as a covariate. Ferritin at either time point was 
not significantly related to infant 3-month hemoglobin.  
 Infant birth weight, length, and head circumference were not significantly 
associated with CRP concentration at baseline or week 10. Analysis was done using CRP 
both as a continuous variable and as a categorical variable (elevated versus non-elevated). 
Infant birth MUAC approached significance when CRP was used as a categorical 
variable. Women with an elevated CRP at week 10 were more likely to have an infant 
with a lower birth MUAC (p=0.056). Forty-seven percent of women who had elevated 
CRP at week 10 had infants with LBW (p=0.11).  
Interestingly, HIV-infected women were significantly more likely to have an 
infant with greater birth weight (mean 2.86 kg) compared to HIV-uninfected women 
(mean 2.68 kg), when adjusting for CRP, treatment group, and parity (p=0.049). This did 
not remain significant with 3-month infant weights. 
 Infant birth MUAC was slightly negatively correlated to baseline maternal 
vitamin D, however, the significance was lost when controlling for CRP (p=0.09). There 
was a trend of a lower baseline vitamin D concentration correlating with a higher infant 
birth MUAC. Infant MUAC was not significantly related to any other nutrient measures 
at baseline or week 10. Infant head circumference at birth was not significantly related to 
any baseline or week 10 nutrient concentrations in the mother.   
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CHAPTER 5: DISCUSSION 
 In this randomized, researcher-blinded controlled clinical trial, we found that 
treatment with the macro- and micronutrient fortified RUSF for 10 weeks improved 
serum vitamins B12 and D status in moderately malnourished pregnant women more than 
treatment with a fortified corn-soy blended flour plus a prenatal multiple micronutrient 
supplement (CSB-UNIMMAP) or a fortified corn-soy blended flour with iron and folic 
acid supplementation (CSB-IFA). Serum folate concentrations had the greatest 
improvement after treatment with CSB-IFA. Changes in serum ferritin, retinol, zinc and 
albumin concentrations were not significantly different between treatment groups. 
Despite provision with 200% the RDA (or greater) for most micronutrients, inflammation 
and deficiency rates for all nutrients measured except vitamin B12 and folate remained 
high and were changed little by any intervention.  
 This population experienced overall high rates of deficiency at baseline in zinc 
(35.4%), ferritin (22.9%), vitamin B12 (21.2%), hemoglobin (71.3%), and albumin 
(42.7%). Marginal proportions of vitamin D (31.9%), retinol (32.4%) and folate (22.4%) 
were also prevalent. Primiparous women had significantly higher baseline ferritin 
concentrations. An acute phase response was present in more than half of the women 
(50.7%), as measured by a CRP concentration >5 mg/L. At week 10, the most significant 
differences between groups were found for serum vitamins B12 and D, with women in the 
RUSF group experiencing the greatest improvement in these nutrients.    
5.1 Folate  
 The CSB-IFA group experienced the greatest increase in folate concentrations, 
followed by RUSF, then CSB-UNIMMAP. Differences between the treatment groups at 
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week 10 and change in percent with marginal status from week 0 to week 10 approached 
significance, with CSB-IFA experiencing the greatest improvements in both. None of the 
women were deficient in folate at baseline therefore marginal status was assessed instead 
(<5.9 ng/mL). While approximately 70% of women reported taking supplements at 
baseline, only 2% reported taking folic acid supplements (the rest iron).  
The overall mean serum concentration at baseline was 9.7 ng/mL. In contrast, a 
study in anemic southern Malawian pregnant women found that the mean serum folate 
concentration was 7.8 ng/mL, which is markedly lower than the folate concentrations in 
this study (van den Broek & Letsky, 2000). Using cut-off values of both 4.1 ng/mL and 
3.4 ng/mL for deficiency, van den Broek & Letsky found that 34% and 21% of the 
women had a folate deficiency, respectively. The more stringent criteria were used to 
account for hemodilution during pregnancy. There are several reasons for this better 
folate status in the present study. The women in the van den Broek study may have had a 
larger proportion with folate deficiency because they were all anemic, which increases 
the likelihood of deficiency in more than one nutrient (van den Broek & Letsky, 2000). 
However, 71% of women in the present study were anemic at baseline. Second, folate 
status may be worsened by malarial infection (van den Broek & Letsky, 2000). At 
baseline in the present study, 15.2% of women reported having malaria within the two 
previous months, and at the time of enrollment, 8% of women were taking malarial 
treatment. In the van den Broek study, 8% of women had malaria parasites in their blood 
(van den Broek & Letsky, 2000). 
Women who had a greater gestational age at baseline had lower folate 
concentrations, which is consistent with hemodilution throughout pregnancy. Greater 
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maternal folate concentrations at week 10 were related to a nearly significant trend of 
greater infant birth length (p=0.052).  
 Although the proportion of those with marginal folate status decreased in all 
treatment groups, the largest decrease was in the CSB-IFA group. It is possible that the 
CSB-IFA group experienced the greatest benefit from supplementation because the 
amount of folic acid present in the CSB-IFA and CSB-UNIMMAP treatments (659 ug) 
were higher than the amount in RUSF (574 ug) (Appendix B).   
Supplementation with folic acid during pregnancy is universally recommended, in 
order to reduce the risk of neural tube defects and congenital abnormalities (FAO & 
WHO, 1998). However, coverage of supplements at antenatal care clinics (ANC) may not 
be reaching all pregnant women in the areas. In this study, only 2% of women reported 
taking folic acid supplements at baseline, indicating that the clinics may not have 
adequate supplies to consistently give out to pregnant women.  
In this population, neither the RUSF nor CSB-UNIMMAP treatments improved 
folate status more than the CSB-IFA group. However, folate concentrations were 
relatively high to begin with and no subject had deficient status during this study.   
5.2 Vitamin B12 
 Vitamin B12 deficiency was found in 21.2% of women at baseline. This is similar 
to the previously mentioned study in Malawi (van den Broek & Letsky, 2000), which 
found that 16-33% of anemic pregnant women had a deficiency in vitamin B12 
(depending on the cut-off value that was used). A systematic review and meta-analysis by 
Sukumar, et al (2016) found that the average vitamin B12 insufficiency from 57 studies 
worldwide was at 21%, 19%, and 29% in the first, second and third trimesters, 
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respectively, which is in a consistent range with the population in the present study 
(Sukumar et al., 2016). The RUSF group was the only treatment to have a significant 
decrease in percentage deficient from week 0 to week 10, whereas CSB-UNIMMAP and 
CSB-IFA both increased their percentage of women deficient throughout the study. 
  Vitamin B12 concentrations were significantly different between treatment groups 
at week 10, with women in the RUSF group having the greatest improvements. Vitamin 
B12 concentrations are known to decrease throughout pregnancy due to a trans-placental 
transfer of the vitamin close to term (van den Broek & Letsky, 2000).There was a 
decrease in vitamin B12 from week 0 to week 10 in all treatment groups; however, the 
RUSF group experienced the smallest decrease and CSB-IFA experienced the greatest 
decrease.  
 The fact that at week 10, 42.5% of the women in the CSB-IFA group were 
classified as vitamin B12 deficient is important (compared to 19.5% in the RUSF group). 
A Nepalese study of pregnant women found that those who were vitamin B12 deficient 
had a two-fold increased likelihood of preeclampsia and preterm delivery (Bondevik et 
al., 2001). Maternal vitamin B12 deficiency is also linked to poor fetal growth and brain 
development (Neumann et al., 2014). The meta-analysis by Sukumar, et al (2016) found 
that the odds ratio of women with insufficient vitamin B12 status having a low birth 
weight (LBW) or small for gestational age (SGA) infant was 1.70 (95% CI: 1.16, 2.50) 
(Sukumar et al., 2016). Although this sub-study did not assess adverse pregnancy and 
birth outcomes, birth measurements were available for majority of the subjects’ infants 
and were not significantly related to maternal vitamin B12 concentration. It is possible that 
the inconsistency of results from this study compared to others is due to the small sample 
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size (n=276) producing inadequate power to detect a difference in birth measurements. A 
similarly powered study randomized 366 women in India to receive vitamin B12, iron and 
folate, or just iron and folate during pregnancy. Vitamin B12 concentrations were 
significantly greater in both mother and infant in the vitamin B12 group, however, infant 
birth weight was not significantly different between groups (Duggan et al., 2014).  
The association of insufficient vitamin B12 status and pregnancy complications, 
including preeclampsia and preterm birth, are typically mediated by the elevated 
homocysteine concentration that accumulates when vitamin B12 is low (Sukumar et al., 
2016). The present study did not measure serum homocysteine concentrations, so this 
factor is unknown.  
 The prevalence of low vitamin B12 concentrations at baseline may be related to 
low dietary intake of vitamin B12, which is only found in animal products. It is likely that 
these women have infrequent access to animal proteins, contributing to low vitamin B12 
status. Commonly consumed foods per day in Malawi include nsima (maize porridge), 
beans, rice, and some fruits and vegetables. A study done in HIV-positive pregnant 
women in Malawi analyzed dietary patterns, wealth and anthropometrics, and found that 
women with greater wealth were more likely to consume an animal-based diet, compared 
to lower wealth women consuming mostly plant-based or grain-based diets (Ramlal et al., 
2015). While that study did not analyze serum or dietary vitamin B12 concentrations, it is 
likely that women consuming the plant- or grain-based diets typical of Malawian women 
in the present study were consuming low levels of dietary vitamin B12. Another study in 
Malawian women found that the median intake of protein from animal sources was 5.6 
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grams per day (out of a median of 46.9 grams total protein per day)(Gibson & Huddle, 
1998).  
 Although maternal vitamin B12 concentrations did not produce significant effects 
on infant birth measurements, it is possible that vitamin B12 supplementation may have 
long-term effects on the child. One study found that children of mothers who had the 
lowest vitamin B12 concentrations at 28 weeks gestation had lower attention and memory 
test score performance compared to children of mothers with the highest vitamin B12 
concentrations (Bhate, Deshpande, Bhat, Joshi, & Ladkat, 2009). Another study found 
that higher vitamin B12 and lower homocysteine concentrations in children were related to 
higher mental development scores at age 12-18 months (Strand et al., 2013). Vitamin B12 
is a crucial nutrient for pregnancy, fetal, birth, and child outcomes in later life. Results 
from this study and others indicate that the addition of vitamin B12 to standard antenatal 
supplementation practices may be warranted.  
5.3 Vitamin D 
 The RUSF group experienced significant increases in vitamin D concentrations, 
compared to CSB-UNIMMAP and CSB-IFA. Only three percent of women in this 
population were severely vitamin D deficient, however, marginal status affected 
approximately one-third of women at baseline. The RUSF group saw the greatest 
increase in serum vitamin D concentration, compared with a lesser increase in the CSB-
UNIMMAP and CSB-IFA groups. Vitamin D content of the treatment foods was slightly 
different, with RUSF containing 30 µg, CSB-UNIMMAP containing 30.9 µg, and CSB-
IFA containing 25.4 µg vitamin D.  
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Although all treatment groups contained approximately double the RDA for 
vitamin D during pregnancy, the RUSF group contained 2.26 g of alpha-linolenic acid 
(omega-3 fatty acid) and 13.96 g of linoleic acid (omega-6 fatty acid). Vitamin D is a fat-
soluble nutrient; therefore absorption of vitamin D from the treatment food may have 
been better facilitated by the RUSF. Intake of fat from other dietary sources is not likely 
to be high, due to majority of Malawian diets being higher in grains and other 
carbohydrates. The study by Ramlal et al. (2015) found that average fat intake in 
Malawian women consuming a grain-based diet was 19.9 g/day (Ramlal et al., 2015). 
 There is some discrepancy in the literature regarding cut-off values to use for 
vitamin D deficiency and insufficiency, which can lead to challenges in assessing 
similarities and differences between studies. The present study utilized the more lenient 
cut-off value of <20 ng/mL classified as deficient and 20-30 ng/mL classified as marginal 
status.  
 Serum vitamin D concentration in this study was significantly related to clinic 
location. The participants were sampled from 15 antenatal clinics, which were grouped 
into 4 districts.  The clinic site that had significantly higher week 10 vitamin D 
concentrations was Ngabu (Chikhwawa district), which is a rural area in a valley which 
experiences higher temperatures and less shade than the other districts. Women from 
Ngabu experienced almost a 10 ng/mL increase in vitamin D concentrations at week 10 
compared to women from the Makwapala clinic in Zomba district, which is in the 
highlands. The other clinic districts of Mulanje and Blantyre are in the mountains and 
urban settings, respectively. The differences in vitamin D concentrations from women of 
differing geographic areas in Malawi are interesting, and could be due to time spent in the 
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sun and amount of clothing worn. Women in the Chikhwawa district generally are 
walking or working during the day for long periods of time and wear less protective 
clothing compared to women in the more urban areas of Blantyre. Dietary vitamin D was 
likely not different between the clinic sites, as Malawian food does not typically contain 
much vitamin D. Important sources of vitamin D are fatty fish, eggs, animal products, 
and fortified foods.  
 Two relationships were unexpected and interesting. First, there was a negative 
correlation between maternal baseline MUAC and week 10 vitamin D concentrations, 
meaning that women with a lower MUAC at baseline had higher vitamin D levels at 
week 10, regardless of treatment group. There was no correlation between baseline 
MUAC and baseline vitamin D concentrations. This could indicate that women who were 
less nourished at baseline were able to benefit more from supplementation than better-
nourished women, thus producing a greater increase in vitamin D concentrations in those 
women. Second, HIV-positive women had significantly higher baseline vitamin D 
concentrations compared to HIV-negative women, which was not affected by CRP 
concentration. It is possible that women with HIV have differences in diet or exposure to 
sun compared to women without HIV. However, the reasons for these findings are 
unknown and warrant further research.  
 Inadequate maternal vitamin D during pregnancy has been linked to adverse birth 
outcomes, including LBW (Thorne-Lyman & Fawzi, 2013), premature (Bodnar et al., 
2013) and SGA infants (Aghajafari et al., 2013). Low maternal vitamin D stores are 
related to impaired infant growth measurements in other studies. A trial by Kalra et al. 
(2012) found that women receiving vitamin D during pregnancy had infants with 
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significantly higher birth weights, lengths, and head circumference compared to women 
not receiving vitamin D treatment (Kalra et al., 2012). Again, the present study did not 
have adequate power to determine if birth measurements had significant differences 
between treatment groups.   
 The differences in vitamin D concentrations at week 10 between treatment groups 
are important when considering the effect that adequate maternal vitamin D stores can 
have on the health of both mother and infant. While the relationship between maternal 
MUAC and vitamin D concentration deserves further research, these results suggest that 
treatment with the RUSF containing omega-3 and omega-6 fatty acids may improve 
vitamin D status better than treatments with similar vitamin D content but containing 
little fat.  
5.4 Retinol  
 Retinol status was not significantly changed by any treatment. Approximately 
11% of the study population was deficient in retinol at baseline (<0.70 µmol/L), while 
approximately 50% of the population had marginal retinol status (<1.05 µmol/L). These 
results are similar to an analysis done by WHO with data from 1995-2005, which 
estimated that 13.7% of pregnant Malawian women had a deficiency in vitamin A (<0.70 
µmol/L) (WHO, 2009). At week 10 in the present study, retinol concentrations were very 
similar between treatment groups and the change in percent deficient or marginal was 
small. The vitamin A content in the treatment foods was similar, although the CSB-
UNIMMAP treatment contained the highest amount (3210 ug), compared to 2628 ug in 
the RUSF treatment and 2410 ug in the CSB-IFA treatment.  
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 A study assessed the effect of prenatal supplementation with LNS, MMN or IFA 
on breast milk retinol (Klevor et al., 2016). Results were similar to the present study, in 
that there were no significant differences in retinol between treatment groups. Although 
the assessment method was different than the present study (breast milk versus serum 
retinol), the results were consistent in that a lipid-based supplement did not have any 
additional benefit above a MMN supplement. These authors conclude that dietary vitamin 
A intake may have been sufficient in this population of Ghanaian women (Klevor et al., 
2016). Common vitamin A or beta-carotene containing foods include leafy green 
vegetables, red or orange vegetables, sweet potatoes, and red palm oil. Mangoes are also 
a good source of vitamin A, which are commonly consumed in Malawi.  
 A study by Kumwenda et al. (2002) in 697 Malawian HIV-infected pregnant 
women found contrasting results to the present study. These women were randomized to 
receive either 10,000 IU (3000 ug) vitamin A plus iron and folic acid daily during 
pregnancy, or just iron and folic acid. Women in the vitamin A group had significantly 
higher plasma vitamin A concentrations at 38 weeks gestation and higher breast milk 
retinol compared to women receiving only iron and folic acid (Kumwenda et al., 2002). 
It’s possible that the present study did not see a significant improvement in retinol status 
because the mean retinol concentration at baseline was already sufficient (1.16, 1.19 and 
1.19 for CSB-IFA, CSB-UNIMMAP, and RUSF, respectively). The percentage of 
retinol-deficient women in the CSB-IFA group did increase by 2.9% from week 0 to 
week 10, while the percentage of retinol-deficient women in the RUSF group decreased 
by 0.9% (non-significantly). This could indicate that the most deficient women were able 
to see a benefit from the lipid-containing RUSF. 
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 Another interesting result was that retinol at week 10 was negatively correlated to 
infant birth length (p=0.027). When controlling for CRP concentration, HIV status and 
parity, significance was reduced but still maintained (p=0.04). It is unclear why a higher 
maternal retinol would correlate to a reduced infant birth length. In contrast, the study in 
Malawi by Kumwenda et al. (2002) found that infants of mothers who were 
supplemented with vitamin A during pregnancy had a significantly greater length at 6 
weeks compared to infants of mothers receiving iron and folic acid (p=0.03), although 
this significance was lost when infants were measured at 14 weeks and 6 months 
(Kumwenda et al., 2002).  
 Retinol concentrations at baseline and week 10 were highly negatively correlated 
with CRP concentration, as is expected with the inflammatory response (Thurnham & 
Mccabe, 2012). HIV status was also related to baseline retinol concentration. Women 
who were HIV-positive were more likely to have lower retinol status, compared to HIV-
negative women, even when controlling for CRP concentration. The relationship was not 
significant for week 10 concentrations because HIV-positive women saw a greater 
improvement in retinol concentrations than HIV-negative women. Although non-
significant, the improvement of mean retinol concentrations in HIV-positive women from 
0.96 µmol/L to 1.05 µmol/L is clinically relevant, as that changes the overall 
classification of HIV-positive women in this study from marginal status to sufficient 
status. It is possible that HIV-positive women experienced the greatest benefit from 
vitamin A supplementation due to their compromised immune systems. Vitamin A is 
highly involved in immune function. People with vitamin A deficiency are more likely to 
develop infections, and infections can in turn increase the risk of vitamin A deficiency 
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(Christian et al., 1998). HIV-infected women with vitamin A deficiency are more likely 
to have a LBW infant and have increased risk of mother-to-child transmission (MTCT) of 
HIV (Semba et al., 1995). In the present study, MTCT was not measured and birth weight 
was not affected by retinol status. However, there was a relationship between birth 
weight and HIV status in that HIV-positive women were more likely to have infants with 
greater birth weight compared to HIV-negative women, which is inconsistent with the 
literature. However, when maternal retinol concentration was added as a covariate into 
the model, significance was lost, indicating that retinol concentration may play a role in 
infant birth weight.   
 Supplementation with a lipid-containing RUSF did not improve retinol 
concentrations in pregnant women more than supplementation with a multiple 
micronutrient tablet or iron and folic acid, all containing similar amounts of vitamin A. 
Infants of mothers with higher retinol concentrations were more likely to have a reduced 
birth length, although more trials with a larger sample size would be required to confirm 
these results.  
5.5 Ferritin  
 Serum ferritin concentrations decreased from week 0 to week 10 in all treatment 
groups, although none of the differences were significant between groups. Approximately 
one-quarter of this population was ferritin deficient at baseline, which increased to 
43.8%, 35.6%, and 48.1% in the CSB-IFA, CSB-UNIMMAP, and RUSF groups, 
respectively. The amount of iron in the CSB-IFA treatment (79.2 mg) was almost double 
the content of the CSB-UNIMMAP and RUSF treatments (45.3 mg and 45 mg, 
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respectively). Despite the high amount of iron present in all treatment groups, ferritin 
concentrations were not improved.  
 The decrease in ferritin concentrations in this population has also been noted in 
the literature. Serum ferritin tends to decrease between weeks 12 and 25 of gestation due 
to expansion of maternal red blood cell mass, thus making assessment of deficiency 
difficult (Allen, 2000; Kaestel, Aaby, Ritz, & Friis, 2015). Most of the iron transfer to the 
fetus occurs after week 30 of pregnancy, further reducing maternal iron stores (Allen, 
2000).  
 In this population, women with a higher CRP had significantly higher ferritin 
concentrations, as is expected with the inflammatory response (Kaestel et al., 2015). A 
cross-sectional study of pregnant women in Guinea-Bissau found that one-third of the 
subjects had low ferritin concentrations, which were significantly associated with stage of 
pregnancy. Women above 29 weeks gestation had up to 59% lower ferritin 
concentrations compared to women under 16 weeks gestation (Kaestel et al., 2015). In 
the present study, gestational age was not related to ferritin concentration.   
Parity was significantly associated with ferritin. Primiparous women had 
significantly higher ferritin concentrations at baseline compared to women with higher 
parity. More pregnancies are likely to result in the mother becoming nutritionally 
depleted, especially if the pregnancies are closely spaced together (Kaestel et al., 2015). 
A contrasting study in Zimbabwean pregnant women found that higher parity (gravida 
>3) women had 1.21 times higher ferritin concentrations compared to primiparous 
women. This study also found that ferritin concentrations were lower in women with 
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gestational age of 32-35 weeks, compared to women of 22-25 weeks gestation (Friis et 
al., 2001).   
 Since CRP is a marker for an inflammatory response, it is logical that a woman 
with an infection would have higher CRP concentrations, thus higher ferritin 
concentrations. In the population studied by Friis et al., women with malarial parasitemia 
had a 2.25 times higher serum ferritin concentration compared to women without malaria 
(Friis et al., 2001). The relationship between high iron stores in the body and increased 
susceptibility to malaria has been studied. A study in Malawian women found that those 
with malaria had better iron stores than those without malarial infection (Senga et al., 
2011). In the present study, ferritin and hemoglobin concentrations at baseline and week 
10 were not significantly related to malarial infection within the previous two months, 
when controlling for CRP concentrations, HIV status and parity.  
 HIV-infected women in this population had significantly lower ferritin 
concentrations at baseline compared to HIV-uninfected women. Friis et al. found similar 
results, in that women with HIV infection had 0.93 times lower serum ferritin 
concentrations compared to women not infected with HIV (95% CI: 0.86, 0.99) (Friis et 
al., 2001). 
 An interesting finding in the present study was that hemoglobin and ferritin 
concentrations were significantly and inversely correlated, at both baseline and week 10, 
even after adjusting for CRP concentration and HIV status. The incongruity between 
ferritin and hemoglobin concentrations may be due to the serum analysis of ferritin 
versus capillary analysis of hemoglobin. The study by Friis et al. (2001) found conflicting 
results; low serum ferritin was a significant predictor of low hemoglobin in the 
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Zimbabwean pregnant women (Friis et al., 2001). However, the study by Kaestel et al. 
(2015) found that pregnant women in Guinea-Bisseau with high serum ferritin 
concentrations (>150 ug/L) were significantly more likely to have lower hemoglobin 
concentrations after adjustment for the acute phase response. The authors indicate that 
this implies the acute phase response was not fully controlled for, which could be true for 
the present study as well (Kaestel et al., 2015). 
 Serum ferritin tends to normalize later than CRP does, thus has been suggested to 
use a “late” acute phase protein, such as alpha-1-acid glycoprotein (AGP) in addition to 
CRP, the “early” acute phase protein (Kaestel et al., 2015).   The fact that infections and 
inflammation are so strongly related to ferritin may indicate that a second acute phase 
protein should be assessed in future research to gain a full picture of the inflammatory 
response. It is likely that the inverse correlation between ferritin and hemoglobin is 
partially due to inadequate adjustment of the inflammatory response.  
 Another interesting finding was that maternal baseline ferritin concentrations 
were significantly and negatively correlated to infant birth weight and length. A review 
by Allen (2000) states that a negative relationship between serum ferritin and birth 
weight is likely due to the presence of infection (Allen, 2000), however, in the present 
study, the significance remained even after controlling for CRP. This could be another 
indication that a second acute phase protein should be measured in studies of 
micronutrient assessment during pregnancy.  
5.6 Zinc 
 Zinc deficiency at baseline in this population was high, at 38.2%, 29.0%, and 
38.8% in the CSB-IFA, CSB-UNIMMAP, and RUSF groups, respectively. Zinc 
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concentrations decreased from baseline to week 10 in the CSB-IFA and CSB-UNIMMAP 
groups, however, zinc concentrations increased from week 0 to week 10 in the RUSF 
group, although this was not significant. The RUSF and CSB-UNIMMAP treatment 
foods had similar amounts of zinc, while the CSB-IFA treatment had less than half of that 
amount, but is still greater than the RDA for zinc during pregnancy.  
 Other research has found that maternal serum zinc concentrations decline during 
pregnancy (L. E. Caulfield et al., 1999). Although it was not significant, it is interesting 
that the mean zinc concentration of the RUSF group increased throughout the study, 
while the other groups experienced the traditional declines. Caulfield et al. (1999) found 
that Peruvian pregnant women supplemented with iron, folic acid and zinc had 
significantly higher serum zinc concentrations compared to women supplemented with 
iron and folic acid alone (L. E. Caulfield et al., 1999). However, this is different from the 
present study because our control group (CSB-IFA) still received 11 mg of zinc in their 
supplemental food.  
 In this population, gestational age was significantly associated with baseline zinc 
concentration. As is consistent with the literature, women who were further along in their 
pregnancy had significantly lower baseline zinc concentrations. Zinc status at either time 
point was not significantly related to parity, which differs from other studies. A study in 
rural Malawian pregnant women found that primiparous women had significantly higher 
hair zinc concentrations (but not plasma zinc) compared to multiparous women. Hair zinc 
is used to assess chronic zinc status over time (Gibson & Huddle, 1998). 
 Zinc concentrations were significantly and positively related to both ferritin and 
hemoglobin concentrations at baseline, and significantly related to hemoglobin at week 
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10. The association between zinc and iron status has been reported in the literature; 
however, research has shown that zinc and iron tend to be negatively correlated. Iron and 
zinc compete for binding sites in the body, thus supplementation with both may affect its 
efficacy on serum status of zinc or iron markers (Nguyen et al., 2012). A study in non-
pregnant Guatemalan women found that there were no differences in iron or zinc status 
after supplementation for 12 weeks with IFA, with or without zinc (Nguyen et al., 2012). 
Similarly, a study in pregnant Peruvian women did not find any differences in serum 
ferritin or hemoglobin concentrations after supplementing with IFA with or without zinc 
(Zavaleta, Caulfield, & Garcia, 2000). In contrast, Ghanaian pregnant iron-deficient 
women receiving a combination of IFA and zinc had improved hemoglobin and ferritin 
concentrations compared to IFA supplements alone (Saaka, 2012).  
 Dietary zinc intake in Malawian women has been reported as inadequate (Gibson 
& Huddle, 1998). Cereals and grains are staples in Malawian diet, which are both low in 
zinc and high in phytates, which are known to inhibit zinc absorption. Phytates are also 
found in corn, which is the basis of the CSB supplementary food. Readily available zinc 
is found in animal products, which are not often consumed in low-income or rural 
Malawians. A study of dietary intake in rural Malawian pregnant women found that the 
median intake of zinc was 9.0 mg per day, of which only 20.6% was available (as 
estimated by a ratio of phytate to zinc). The women in that study who had higher dietary 
phytate-zinc ratios had significantly lower hair zinc concentrations (Gibson & Huddle, 
1998). A higher phytate diet is likely to result in low zinc concentrations, which could be 
a factor in the present study relating to the high rates of zinc deficiency.  
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 Studies have generally found that the addition of zinc to a prenatal supplement 
(usually containing iron and folic acid, with or without additional micronutrients) does 
not have an effect on birth outcomes or measurements.  The study with Peruvian pregnant 
women mentioned above also analyzed birth outcomes after supplementing with IFA, 
with or without zinc (L. Caulfield, Zavaleta, Figueroa, & Leon, 1999). Data from 957 
infants found no differences in birth weight, head circumference, MUAC, or incidence of 
low birth weight or preterm birth (L. Caulfield et al., 1999). In Nepal, pregnant women 
receiving iron, folic acid and zinc supplements did not have infants with greater birth 
weight, length or head circumferences compared to infants of women receiving one of 
four other treatments (folic acid, folic acid and iron, multiple micronutrients, or vitamin 
A alone) (Christian et al., 2003). The present study did not have a control group without 
zinc; therefore it is unknown whether prenatal supplementation with zinc has an effect on 
maternal zinc concentrations over iron and folic acid alone. The present study was also 
inadequately powered to detect differences in infant birth measurements.  
 Due to the fact that there were no significant differences between maternal serum 
zinc concentrations at week 10, there may not be a need for double the RDA of zinc 
during prenatal supplementation. At week 10, approximately one-third of women were 
still zinc deficient, which suggests that there are other factors contributing to zinc 
deficiency in addition to inadequate intake and low bioavailability due to anti-nutrients 
like phytate.  
5.7 Hemoglobin 
Change in capillary hemoglobin concentrations did not differ significantly by 
treatment group. Seventy-one percent of the women were anemic at baseline with 
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hemoglobin concentrations <11 g/dL, which was improved to 45% at week 10. 
Hemoglobin was slightly improved from week 0 to week 10 in all groups, but not 
significantly. The overall mean improved from 10.07 g/dL at week 0 to 11.12 g/dL at 
week 10.   
Women with higher parity had greater baseline hemoglobin concentrations. In 
contrast, it has been reported previously that women with higher parity are more likely to 
have lower iron markers, due to nutritional depletion and iron loss during multiple 
pregnancies (Scholl, 2005). A potential reason for the present results could be that 
women who had previous pregnancies were taking iron supplements and built up their 
iron stores. Women with lower gestational age had greater hemoglobin concentrations, 
which could be because they had not yet transferred as much of their iron stores to the 
fetus compared to women who were further along in their pregnancies.  
Hemoglobin and albumin were significantly correlated. Of anemic women at 
baseline, 48.2% also had low serum albumin, while 28.4% of non-anemic women were 
low. This could be due to the low dietary intake of animal products, which are good 
sources of both iron and protein. A study in North Indian pregnant women found that 
those who were anemic and primiparous had significantly lower albumin concentrations 
compared to non-anemic, multiparous women (H. Shankar et al., 2015). 
Clinic site was also related to hemoglobin. Women living in the Zomba district 
had significantly higher baseline hemoglobin concentrations, compared to women in the 
Mulanje, Chikhwawa, and Blantyre districts. The difference in hemoglobin 
concentrations may be due to diet variation or perhaps differences in infections or 
parasites that can be related to anemia.    
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 In the present study, treatment group had no effect on hemoglobin concentrations. 
In contrast, a study by Adu-Afarwuah et al. (2016) randomized Ghanaian women to 
receive iron and folic acid (60 mg Fe), MMN (20 mg Fe), or LNS (20 mg Fe). At week 
36 of gestation, the IFA group had significantly greater hemoglobin concentrations and 
lower prevalence of anemia when compared to the MMN or LNS groups (Adu-Afarwuah 
et al., 2016). These results would be expected in the present study because of the greater 
amount of iron in the CSB-IFA treatment food compared to CSB-UNIMMAP and RUSF; 
however, no differences were found.  
The lack of differences in anemia rates between treatment groups in the present 
study could be partially due to anemia having multiple causes. If iron deficiency were the 
only cause of anemia, then it would be logical that the majority of women receiving iron 
supplementation would recover from anemia. However, all women in this study received 
almost double or triple the RDA for iron; thus, it is likely that there are other factors 
contributing to anemia in this population, such as protein-energy malnutrition, malaria, 
parasites and other infections.  
5.8 Albumin 
 Prevalence of hypoalbuminemia was high in this population and concentrations 
decreased in all groups from week 0 to week 10. Overall hypoalbuminemia rates were 
42.7% at baseline and 70.1% at week 10. Because the mean albumin concentrations at 
baseline were close to the deficiency cut-off value of 3.4 g/dL, the slight decrease that 
each group experienced resulted in a much larger proportion of deficiency at week 10.  
 Albumin is a negative acute phase protein, thus it is expected to decrease in the 
presence of inflammation (Tomkins, 2003). This was true for baseline measures, in which 
 
 
133 
albumin and CRP were negatively correlated. However, the significance of this 
association was lost when measuring week 10 concentrations, and did not differ by 
treatment groups. HIV-positive and HIV-negative women had similar albumin 
concentrations. This differs from a study that found lactating women in South Africa who 
were HIV-infected had lower serum albumin concentrations compared to HIV-uninfected 
women after controlling for the acute phase response (Papathakis, Rollins, Chantry, 
Bennish, & Brown, 2007). This study also found that serum albumin increased in all 
women from 6 weeks to 24 weeks postpartum (Papathakis et al., 2007). Thus, it is 
possible that women in the present study experienced decreases in albumin 
concentrations due to inadequate protein intake as well as pregnancy itself being an 
inflammatory process.  
5.9 C-reactive protein  
 C-reactive protein (CRP) concentrations were highly elevated in this population 
with over half of the women experiencing elevated CRP at baseline. The mean CRP 
concentrations increased from baseline to week 10 in all groups, although the percentage 
of women with elevated status decreased, likely due to the large standard deviation in 
concentrations.  
 In this population, malarial infection and HIV infection were significantly related 
to CRP concentration, as is expected with the inflammatory response. Women who had 
HIV or malaria had significantly greater CRP concentrations than women not infected 
with either disease. In the study by Papathakis et al. (2007), HIV-infected lactating 
women had higher CRP concentrations compared to HIV-uninfected women, although 
the differences were not significant (Papathakis et al., 2007). A study in Ghanian 
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pregnant women found that mean CRP concentrations were 5.8-7.9 mg/L (Adu-Afarwuah 
et al., 2016), which is markedly lower than overall baseline CRP mean of 11.3 mg/L in 
the present study.   
 Treatment group had no significant effect on CRP concentrations in this study. 
The study by Adu-Afarwuah et al. (2016) described previously found similar results. All 
groups (IFA, MMN, and LNS) in that study saw a small decrease in mean CRP 
concentrations after receiving one of the three interventions during pregnancy; however, 
none of the treatment groups improved inflammatory status better than another (measured 
by both CRP and AGP) (Adu-Afarwuah et al., 2016). A study in Nepal randomized 
women to receive IFA or MMN supplementation during pregnancy and collected blood 
samples at baseline (12-20 weeks gestation) and at week 32 of gestation (Hindle et al., 
2006). In the Nepalese population, mean CRP at week 36 of gestation was 1.33 mg/L, 
which is much lower than the CRP found in the present study. CRP concentrations did 
not differ significantly between the MMN and IFA groups, which is consistent with the 
present study (Hindle et al., 2006).  
 In the present study, there was a trend of higher maternal CRP at week 10 and 
lower infant birth MUAC (p=0.056). No other birth measurements were significantly 
related to maternal CRP status. The study by Hindle et al. (2006) found that women with 
higher inflammatory markers were more likely to have infants with preterm birth 
(elevated CRP and AGP) and low birth weight (elevated AGP) (Hindle et al., 2006). 
Although the present study did not measure preterm birth, rates of low birth weight were 
not affected by CRP concentrations. Hindle et al. suggest that the relationship between 
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elevated CRP and preterm birth may be related to the relationship between preterm birth 
and reproductive tract infections (Hindle et al., 2006).   
 Overall, CRP concentrations in this population were highly elevated, even in the 
absence of HIV infection or self-reported malaria, pneumonia, or diarrhea within the 
previous two months. The disparity between infection rates and elevated CRP indicate 
that there may be other underlying causes of an inflammatory state. The methods of 
determining illness data for this study were not medical diagnoses but were self-reported; 
therefore it is possible that women did not correctly recall their recent illnesses. Also, 
there could be other illnesses not asked on the baseline questionnaire that could be 
contributing to elevated CRP. For example, parasitic infections may be a factor affecting 
this population. Lastly, CRP may be elevated more in this population due to the 
inflammatory state of pregnancy itself and the fact that this study only included 
moderately malnourished women. Women who are more adequately nourished are better 
able to fight off infections and illnesses (Lartey, 2008).  
5.10 Birth and infant measurements 
 Some trends between maternal nutrient concentrations and infant measurements 
were found. At baseline, a lower maternal ferritin correlated to a higher infant birth 
weight. At three months, a lower maternal baseline ferritin then correlated to a lower 
infant weight. There has been concern about over-supplementation in women who are 
iron sufficient. A study in African-American pregnant women found that those in the 
highest quartile of plasma ferritin concentrations at week 26 of gestation had 2.7 times 
increased risk of preterm birth, 3.9 times increased risk of very low birth weight (<1500 
g) and 2.0 times increased risk of LBW (<2500 g) infants, compared to women with 
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ferritin concentrations in the lowest quartiles (Goldenberg et al., 1996). However, the 
researchers did not account for the acute phase response, which could affect both ferritin 
concentrations and adverse birth outcomes, thus it is difficult to generalize these findings. 
However, other research has found that high maternal iron status during pregnancy may 
lead to decreased fetal growth. High hemoglobin (>12.0 g/dL) has been linked to LBW 
infants, as well as low hemoglobin (<8.0 g/dL) (Scholl, 2005). In the United States, 
hemoglobin concentrations of >14.4 g/dL during the first and second trimesters have 
been associated with SGA infants (Scanlon et al., 2000). Changes in hemoglobin 
concentration during pregnancy typically occur due to changes in plasma volume and 
hemodilution (Steer, 2000). However, if the plasma volume does not expand enough, 
fetal growth may be restricted, leading to SGA or LBW infants, who are then more likely 
to be born preterm. The mechanism by which inadequate plasma volume expansion leads 
to restricted fetal growth may be related to changes in blood viscosity that reduces blood 
flow to and from the placenta (Steer, 2000). 
In the present study, mean hemoglobin at baseline (typically in the first or second 
trimester) was 10.1 g/dL, with a range of 7.0-15.1 g/dL. Decreases in hemoglobin 
concentrations are expected throughout pregnancy; however, the present study saw the 
opposite. At week 10, the mean hemoglobin concentration increased by 1.0 g/dL. 
Maternal baseline and infant 3-month hemoglobin concentrations were significantly and 
positively correlated. The mean infant hemoglobin was 9.5 g/dL (range 2.5-14.4 g/dL), 
which was not significantly different by treatment group.  
 Another interesting finding is that HIV-infected women were more likely to have 
infants with greater birth weights (2.86 kg), compared to HIV-uninfected women (2.68 
 
 
137 
kg), when controlling for the effect of treatment. A study in Zimbabwe that randomized 
pregnant women to receive MMN or IFA supplements found no significant differences in 
infant birth weight between HIV-infected or HIV-uninfected women (Friis et al., 2004a). 
However, HIV-infected women receiving MMN supplements had a trend towards infants 
with greater birth weights (3017 g) compared to HIV-infected women receiving IFA 
supplements (2916 g) (95% CI -3, 205; p=0.057). These authors had expected HIV-
infected women to have infants with greater birth weights because they predicted MMN 
supplements would produce a larger effect and benefit to these women due to the 
increased nutrient requirements that occur with HIV (Friis et al., 2004a). Although there 
were no significant differences in infant size by treatment group for HIV-infected women 
in the present study, the reasoning provided by Friis et al. (2004a) is logical; HIV-
infected women receiving nutritional interventions may respond more positively than 
women without disease.  
5.11 Strengths and limitations  
 A major strength of this study was the fact that it was randomized. Assessment of 
serum nutrient status at two time points during the pregnancy was a strength that enabled 
us to evaluate change in nutrient status. The fact that the primary study (Mamachiponde) 
gathered so much baseline data and anthropometric measurements at each visit allowed 
this sub-study to utilize much more information.  
Limitations include the inability to double-blind the study. Researchers were 
blinded; however, due to the nature of the interventions and their visible differences, it 
was impossible to blind the subjects. However, that did not likely affect the outcomes of 
the study. Loss to follow-up was high in this study (n=112, 33%), with the majority of the 
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women lost because they delivered their infant before the second blood draw (n=62). Due 
to the high rates of delivery before the second blood draw, the inclusion and exclusion 
criteria for this sub-study were altered partway through the study to require a lower 
gestational age, which could be considered a limitation. Another criterion that was altered 
after initiation of the primary study was the age criteria, which was lowered from 18 to 
16 years. This should not have had an effect on outcomes. However, a factor that could 
affect outcomes is that compliance with the interventions was unknown for all subjects. 
It’s also possible that the treatment foods were shared with other family members, even 
though the women were advised not to. However, due to the randomized nature of the 
study, the effect between groups should be similar.  
There were some methodological drawbacks in this study. Due to women having 
to walk far distances and wait long periods of time for their antenatal visits, it seemed 
unethical and unfeasible to advise women to fast before their blood draws. Sixty-six 
percent of women were in a fasted state for the first blood draw, however, only 37 
percent were fasted at the second blood draw. Fasting status did have an impact on some 
nutrients (zinc, folate, retinol), but this variable was accounted for in all analyses. Due to 
the long distance between some clinic sites and the laboratory, the range of time from 
blood draw to centrifuge was two to five hours. This could potentially have had an impact 
on nutrient assessment and outcome. Another limitation would be that only one marker of 
inflammation (CRP) was measured. It would be ideal to have two measures (i.e. CRP and 
AGP) to be able to assess both early and late stages of inflammation. 
If there were unlimited resources, it would have been interesting to assess a full 
nutrient panel. Some micronutrients were present in the RUSF treatment food, but not in 
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the CSB-IFA and/or CSB-UNIMMAP treatment, including copper, magnesium, and 
selenium. It would have been interesting to measure the serum status of those minerals. 
Also, even though the CSB-IFA group was considered the control group, the treatment 
food still contained calories, macronutrients, and micronutrients other than iron and folic 
acid, which could make some of the results difficult to interpret. However, because all of 
the women in the study were moderately malnourished, it would be unethical to have a 
true control group with no treatment. On a related note, because all the women were 
moderately malnourished, the results of this study may be not able to be generalized to 
the adequately nourished population of pregnant women. Finally, this sub-study did not 
have adequate power to detect differences in infant outcomes. However, the primary 
study (Mamachiponde) does have adequate power and will be assessing infant outcomes.  
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CHAPTER 6: CONCLUSIONS 
 Multiple micronutrient (MMN) supplements or fortified food-based supplements 
may be an effective way to improve maternal nutrition, which in turn has the ability to 
improve infant and child health.  Since micronutrient deficiencies can lead to adverse 
pregnancy and birth outcomes, it is imperative to figure out the ideal method to support 
maternal health, especially in developing countries like Malawi. This study adds evidence 
to the growing body of research.  
 It was hypothesized that supplementation with a micro- and macronutrient 
fortified supplementary food (RUSF) would improve the serum nutrient status of 
pregnant women more than supplementation with a fortified corn-soy blended flour 
combined with either iron and folic acid (CSB-IFA) or a multiple micronutrient 
supplement (CSB-UNIMMAP). However, the only nutrients that saw significant 
differences between treatment groups were vitamins B12 and D, with RUSF providing the 
greatest improvement. For vitamin D status, there may have been a greater improvement 
in those receiving RUSF treatment because of the fatty acid content in that intervention, 
which could increase absorption of vitamin D. Vitamin D is a crucial nutrient for proper 
immune functioning of both mother and fetus and deficiency is associated with impaired 
fetal growth. Maternal deficiencies in vitamin B12 during pregnancy have been associated 
with adverse birth outcomes, including restricted fetal growth, stillbirth, or preterm birth, 
and increased risk of anemia and preeclampsia in the mother.   
 The high rates of deficient or marginal status in all nutrients and proteins are 
concerning and are similar to other studies of pregnant women in Malawi or other 
developing countries. The fact that supplementation with 200% the RDA of most 
 
 
141 
micronutrients still did not improve nutrient status of all women indicates that other 
factors are altering the women’s nutritional state, potentially including infections, 
inflammation, malabsorption, genetic differences, or nutrient interactions. It needs to be 
considered that iron and zinc have a competing relationship, and that high iron status has 
been linked to increased rates of infection, specifically malaria. Given that RUSF 
produced improved vitamin D and B12 status, it suggests that using a fortified 
supplementary food to improve the nutritional status of moderately malnourished 
pregnant women may be indicated. However, not all nutrients were significantly 
improved by the RUSF treatment, and folate concentrations were improved the most in 
the CSB-IFA group.  
These results indicate that further research is needed. Micronutrients have a 
complex relationship, especially during pregnancy and in developing countries; thus, 
many additional and larger randomized controlled trials should be performed to lead 
international health policies in the right direction. Hopefully, future research can identify 
the best proportions of micro- and macronutrients to help pregnant women recover from 
malnutrition or nutrient deficiencies and improve pregnancy, birth, and infant outcomes. 
In conclusion, antenatal treatment of moderate malnutrition with a peanut-based, macro- 
and micronutrient fortified supplementary food improved vitamins B12 and D 
concentrations more than treatment with fortified corn-soy blended flour plus iron and 
folic acid or a multiple micronutrient supplement. Ferritin, folate, retinol, zinc and 
albumin concentrations were not significantly different when comparing treatments.  
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APPENDICES 
APPENDIX A: RECOMMENDED DIETARY ALLOWANCES (RDA) OR 
ADEQUATE INTAKES (AI) FOR PREGNANCY1 
Vitamins <18 years 19-30 years 31-50 years 
Thiamin (mg) 1.4 1.4  1.4 
Riboflavin (mg) 1.4  1.4  1.4 
Niacin (mg) 18 18 18 
Biotin (AI, mg) 30 30 30 
Pantothenic acid (AI, mg) 6 6 6 
Vitamin B6 (mg) 1.9 1.9 1.9 
Folate (µg) 600 600 600 
Vitamin B12 (µg) 2.6 2.6 2.6 
Choline (AI, mg) 450 450 450 
Vitamin C (mg) 80 85 85 
Vitamin A (µg) 750 770 770 
Vitamin D (AI, µg)2 15 15 15 
Vitamin E (mg) 15 15 15 
Vitamin K (AI, µg) 75 90 90 
Minerals    
Sodium (AI, mg) 1500 1500 1500 
Chloride (AI, mg) 2300 2300 2300 
Potassium (AI, mg) 4700 4700 4700 
Calcium (AI, mg) 1300 1000 1000 
Phosphorus (mg) 1250 700 700 
Magnesium (mg) 400 350 360 
Iron (mg) 27 27 27 
Zinc (mg) 12 11 11 
Iodine (µg) 220 220 220 
Selenium (µg) 60 60 60 
Copper (µg) 1000 1000 1000 
Manganese (AI, mg) 2.0 2.0 2.0 
Fluoride (AI, mg) 3 3 3 
Chromium (AI, µg) 29 30 30 
Molybdenum (µg) 50 50 50 
1(S. S. Gropper et al., 2009) 
2(National Institutes of Health, 2014) 
 
 
172 
 
Tolerable Upper Intake Levels (UL) for Pregnancy1 
Vitamins <18 years 19-50 years 
Niacin (mg) 30 35 
Vitamin B6 (mg) 80 100 
Folate (µg) 800 1000 
Choline (AI, mg) 3000 3500 
Vitamin C (mg) 1800 2000 
Vitamin A (µg) 2800 3000 
Vitamin D (AI, µg)2 100 100 
Vitamin E (mg) 800 1000 
Minerals   
Sodium (AI, mg) 2300 2300 
Chloride (AI, mg) 3600 3600 
Calcium (AI, mg) 2500 2500 
Phosphorus (mg) 3500 3500 
Magnesium (mg) 350 350 
Iron (mg) 45 45 
Zinc (mg) 34 40 
Iodine (µg) 900 1100 
Selenium (µg) 400 400 
Copper (µg) 8000 10,000 
Manganese (AI, mg) 9 11 
Fluoride (AI, mg) 10 10 
Molybdenum (µg) 1700 2000 
Boron (mg) 17 20 
Nickel (mg) 1.0 1.0 
1(S. S. Gropper et al., 2009) 
2(National Institutes of Health, 2014) 
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APPENDIX B: NUTRIENT COMPARISON BY TREATMENT GROUP 
Nutrient RUSF 
Amount (%RDA) 
CSB+UNIMMAP1 
Amount (%RDA) 
CSB-IFA2  
Amount (%RDA) 
Energy (kcal) 920 893 893 
Protein (g) 36 33 33 
α-linolenic acid (g) 2.26 (161) 0 0 
Linoleic acid (g) 13.96 (107) 0 0 
Vitamin A (µg) 2628 (341) 3210 (417) 2410 (312) 
Vitamin B1 
(Thiamin; mg) 
3.2 (228) 1.7 (121.5) 0.3 (20) 
Vitamin B2 
(Riboflavin; mg) 
3.8 (270) 4.7 (355) 3.29 (235) 
Niacin (B3; mg) 35 (194) 36.8 (204) 18.8 (104) 
Vitamin B6 (mg) 4.0 (210) 5.9 (198) 4.0 (210) 
Vitamin B12 (µg) 5.5 (262) 7.3 (253) 4.7 (181) 
Folic acid (µg) 574 (143) 659 (165) 659 (163) 
Vitamin C (mg) 170 (200) 281 (331) 211 (249) 
Vitamin D (µg) 30 (200) 20.9 (206) 25.4 (169) 
Vitamin E (mg) 39.2 (261) 29.5 (197) 19.5 (130) 
Vitamin K (µg) 192 (213) 70.5 (78) 70.5 (78) 
Iodine (µg) 300 (136.4) 244 (170) 94 (43) 
Copper (µg) 2400 (240) 2000 (200) 0  
Iron (mg) 45 (170) 45.3 (180.7) 79.2 (292) 
Zinc (mg) 24.6 (223) 26.8 (243) 11.8 (107) 
Magnesium (mg) 327 (93) 0 0 
Calcium (mg) 1830 (183) 851 (85) 851 (85) 
Selenium (µg) 123 (205) 65 (108) 0 
1 Estimates a daily portion of 235 g CSB+ per day plus UNIMMAP supplement 
2Estimates a daily portion of 235 g CSB per day plus iron (60 mg) and folic acid (400 µg) 
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APPENDIX C: MICRONUTRIENT SUB-STUDY FORM 
 
  
Version 4 
 
 MAMAPONDE  Micronutrient Blood Draw Sub-Study 
  
 
 
 
 
 
 
WEEKS GESTATION AT ENROLLMENT (enrollment criteria ≤ 26 weeks): ______________ 
 
WEEKS GESTATION AT 2ND VISIT: ____________________________ 
 
 
ID Number: 
     
Place: 
   
DATE OF FIRST BLOOD DRAW: 
 
_________________________________ 
(dd/mm/yy) 
DATE OF SECOND BLOOD DRAW: 
 
_________________________________ 
(dd/mm/yy) 
PLACE BARCODE 1ST BLOOD DRAW PLACE BARCODE 2ND BLOOD DRAW 
  
Write number here:  Write number here: 
FIRST BLOOD DRAW (Enrollment) 
 
1. Hemoglobin (must be >7.0 g/dL): ___________________ 
 
2. Did you eat this morning?  Yes     No      
If yes, how long ago did you eat? _____________________________________ 
 
 
3. Record time of blood draw: _____________ 
 
4. Record time of centrifuge: ________________      Record time of freeze: ______________ 
SECOND BLOOD DRAW (Visit 6) 
1. Did you eat this morning?  Yes     No      
If yes, how long ago did you eat? _____________________________________ 
 
2. Record time of blood draw: _____________ 
 
3. Record time of centrifuge: ________________  Record time of freeze: ______________ 
NOTES:  
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APPENDIX D: MICRONUTRIENT SUB-STUDY PROCEDURES 
------------------------------------------------------------------------------------------------------  *BLUE	tube	FIRST	à 	Half	full	à 	Invert	8-10x	
*TIGER	TOP	tube	SECOND	à 	All	the	way	full	à 	Invert	5x	
AT	CLINIC:		
1. Nurse	will	get	informed	consent	from	the	woman.	
2. Nurse	will	make	sure	the	woman	is	26	weeks	gestation	or	lower.	We	want	to	make	sure	she	doesn’t	deliver	before	the	second	blood	draw.		
3. Make	sure	hemoglobin	has	been	done	and	that	it	is	above	7.0	g/dL.		
4. Nurse	will	ask	questions	on	blood	draw	form	(about	food).		
5. Nurse	will	wash	hands	and	put	on	new	gloves.		
6. Volunteer	will	prepare	cup	of	Sobo	and	4	cookies.		
7. Volunteer	will	tear	off	the	next	7	identical	barcodes	from	the	roll	of	barcodes.	Make	sure	they	all	have	the	same	number.		*NOTE*:	We	have	2	rolls	of	barcodes.	One	roll	has	numbers	starting	with	“10001”.	These	are	for	the	first	blood	draw.	The	second	roll	has	numbers	starting	with	“20001”.	These	are	for	the	second	blood	draw.	The	end	numbers	should	be	the	same	for	each	woman.		
o Example:	The	first	woman	will	have	“10001”	for	her	first	blood	draw	and	“20001”	for	her	second	blood	draw.		
8. Volunteer	will	place	one	barcode	label	on	the	woman’s	paper	form.		
9. Do	not	put	the	other	barcodes	on	the	tubes	until	after	the	blood	draw	is	completed	and	acceptable.			
10. Identify	a	vein	to	be	used	for	blood	draw.		*NOTE:	Veins	will	be	more	prominent	if	she	forms	a	fist	with	her	hand	
11. Volunteer	will	get	out	one	tiger	top	tube,	one	dark	blue	tube,	one	safety	holder,	a	needle,	cotton,	and	tape.		
12. Volunteer	will	record	time	of	blood	draw	on	the	paper	form.		
13. Select	a	21	gauge	needle	(green	cap)	if	the	woman	has	normal	sized	veins.	
14. Select	a	22	gauge	needle	(black	cap)	if	the	woman	has	small	sized	veins.		*NOTE:	21	gauge	is	bigger	than	22	gauge.	Try	to	use	the	21	gauge	needle	if	possible	because	there	is	usually	better	blood	flow.		
15. Nurse	will	clean	the	arm	around	the	vein	site	with	cotton	and	mineral	spirits.	Let	it	dry	before	taking	blood.		
16. Tie	a	tourniquet	around	woman’s	arm	above	a	few	inches	above	her	elbow.		
17. Unscrew	the	clear	top	from	the	needle.		
18. Insert	grey	rubber	end	pointed	down	into	the	orange	part	of	the	safety	holder	and	screw	in	place	tightly.	
19. Gently	place	the	dark	blue	tube	onto	grey	rubber	side	of	needle,	but	do	not	puncture	it	yet!	Make	sure	the	label	is	facing	down	so	you	can	see	the	insides	of	the	tube.		
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20. Pull	off	green	(or	black)	cap	from	needle,	carefully.		
21. 	Hold	the	arm	and	place	your	thumb	below	the	blood	draw	site.	
22. Insert	the	needle	into	the	vein	with	the	orange	safety	cap	facing	up	towards	you	AND	with	the	“bevel”	facing	up.	The	bevel	is	the	larger	opening	of	the	needle.	You	can	spin	the	orange	safety	cap	around	until	both	are	in	the	upright	position.		
23. After	puncturing	the	skin,	make	sure	you	have	a	steady	grip	with	one	hand.	With	the	other	hand,	push	the	dark	blue	tube	up	all	the	way	so	the	needle	punctures	it	until	blood	starts	flowing	in.		*NOTE:	ALWAYS	fill	up	the	dark	blue	tube	FIRST,	because	the	tiger	top	tube	has	special	ingredients	in	it	that	will	contaminate	the	dark	blue	tube.		
24. Fill	up	the	dark	blue	tube	only	half	way	(about	3	mL).		
25. Remove	it	from	the	safety	holder	and	place	it	upright	in	the	rack.	
26. NEVER	remove	the	rubber	top	of	tube	because	the	vacuum	pressure	will	be	released.		
27. Pierce	the	tiger	top	tube	into	the	safety	holder	side	and	fill	it	all	the	way	until	you	get	to	the	top	line	on	the	tube.		
28. Remove	the	tiger	top	tube	and	place	it	upright	in	a	rack.	
29. Take	off	tourniquet.		
30. Remove	the	needle	from	the	arm	and	apply	firm	pressure	with	a	cotton	ball	to	the	puncture	site	with	one	hand.		
31. With	the	other	hand,	carefully	push	the	safety	holder	onto	the	needle	using	a	table	or	hard	surface,	until	you	hear	it	click.		
32. Put	the	entire	needle	and	holder	into	a	biohazard/sharps	container.	
33. Place	a	piece	of	tape	over	the	cotton	ball	on	the	arm.		
34. Place	one	barcode	label	on	the	tiger	top	tube	and	one	label	on	the	dark	blue	tube.	Make	sure	that	the	numbers	on	the	tubes	match	the	number	on	her	paper	form.		
35. Place	the	remaining	barcodes	into	a	Ziplock	bag	in	the	cooler	to	be	taken	to	the	lab.		
36. Invert	the	dark	blue	tube	8	to	10	times.		
37. Cover	the	dark	blue	tube	with	foil	and	place	it	into	the	small	cooler	with	ice	packs.	
38. Invert	the	tiger	top	tube	up	and	down	5	times.		
39. Let	the	tiger	top	tube	sit	out	for	up	to	30	minutes	to	allow	the	blood	to	clot.	After	30	minutes,	cover	the	tiger	top	tube	with	foil	and	place	it	into	the	cooler	with	ice	packs	for	transport	to	the	laboratory	at	the	College	of	Medicine.		
40. Write	gift	(plates&Soap	for	first	blood	draw	or	chitenje	for	
second	blood	draw)	on	woman’s	passbook!		
41. Write	“BLOOD”	at	Visit	6	on	Clinic	Card		
	
	
AT	THE	LAB:	
1. Put	on	safety	equipment.		
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2. Record	time	of	centrifuge.		
3. Centrifuge	tubes	at	3500	rpm	for	10	minutes,	keeping	temperature	below	25	degrees	C.		
4. If	there	are	an	odd	number	of	tubes	for	any	reason,	fill	up	a	tiger	top	tube	or	dark	blue	tube	with	water	to	create	a	balance	tube	to	go	across	in	the	centrifuge.		
5. Take	out	the	remaining	barcodes	from	the	cooler.		
6. While	it’s	centrifuging,	hand	write	the	Study	ID	number	and	the	barcode	label	number	on	a	separate	sheet	of	paper.	This	will	be	transferred	to	an	Excel	file	later.		 	
7. Only	do	one	woman’s	blood	at	a	time	(one	tiger	top	tube	and	one	dark	blue	tube)	to	avoid	mix-ups.	
8. Find	the	barcode	labels	that	match	the	labels	on	the	tiger	top	and	dark	blue	tube	that	you	are	about	to	use.		
9. Put	one	label	on	a	clear	transport	tube,	one	label	on	an	amber	tube,	and	one	label	on	another	amber	tube.		
10. With	a	Sharpie,	write	“1”	on	one	amber	tube	and	“2”	on	the	other	amber	tube.	Write	it	above	the	barcode	label	below	the	cap.	“Amber	1”	will	be	the	tube	to	be	analyzed	at	Central	Coast	Pathology.	“Amber	2”	will	be	the	tube	to	be	sent	to	Bakersfield	lab.			
11. In	a	rack,	place	the	tubes	in	the	following	order	from	left	to	right:	Tiger	top	tube,	dark	blue	tube,	amber	1,	amber	2,	clear	tube.			
12. Place	a	pipette	tip	on	the	pipette.	
13. From	the	tiger	top	tube,	pipette	2	mL	of	serum	into	Amber	1	and	2	mL	of	serum	into	Amber	2.		
14. Discard	the	pipette	tip	into	the	biohazard	container.		
15. Place	a	new	pipette	tip	on	the	pipette.		
16. From	the	dark	blue	tube,	about	2-3	mL	of	serum	will	be	transferred	into	a	trace	mineral	free	transport	tube.	
17. Scan	with	the	barcode	scanner	to	ensure	each	woman	has	5	tubes	(1	tiger	top,	1	dark	blue,	2	amber,	1	clear	transport	tube)	matched	with	the	barcode	label	on	her	paper	form.		
18. Store	the	amber	tubes	and	clear	tubes	in	racks	in	-70	degree	Celsius	freezer	at	the	College	of	Medicine	until	they	are	transported	back	to	Central	Coast	Pathology	for	analysis.		
19. Dispose	of	the	SST	and	dark	blue	tubes	properly	into	a	biohazard	container.		
 
 
 
 
 
  
 
 
178 
APPENDIX E: MAMAPONDE MICRONUTRIENT BLOOD DRAW INFORMED 
CONSENT  
Informed Consent: Vitamin and Mineral Study 
 
Assessment of micronutrient status in pregnant Malawian women before and after 
treatment for moderate malnutrition: a randomized controlled trial 
 
You are invited to participate in a research study conducted by Cambria Glosz, Dr. Peggy 
Papathakis, Dr. Manary and colleagues. 
 
The study is looking at levels of vitamins and minerals in your body. Our study is trying to help 
you recover from malnutrition.  
 
1. The purpose of this study is to see if the levels of vitamins and minerals in your body change 
with the food supplement, and which one of the three supplements helps pregnant women the best 
in terms of vitamins and minerals.  
 
2. You will have your blood drawn to assess your vitamin and mineral levels two times: The first 
time will be today when you enroll in the study, and once more about 10-12 weeks later after you 
have recovered from malnutrition or before delivery if you have not yet recovered. Each time, we 
will draw approximately 8-10 mL or about 2 teaspoons of blood from your arm. It is possible that 
you might have some pain or bruising at the site where the blood was drawn. To minimize these 
risks, a trained Malawian study nurse will be drawing your blood, using Universal Precautions. 
 
3. You will receive plates and soap the first time you have your blood drawn and you will receive 
a chitenje the second time you have your blood drawn.  There is no cost to you to participate.   
 
4. If you agree you volunteer to participate, you may withdraw consent and discontinue your 
participation at any time without penalty.  You may also choose not to participate in specific 
procedures or answer specific questions if you would prefer not to.  
 
5. All reasonable measures to protect the confidentiality of your medical records and your identity 
will be taken. There is a possibility that your medical record, including identifying information, 
may be inspected and photocopied by government or University officials or members of the 
Human Studies Committee. 
 
6. If you have any questions or concerns regarding this study, if any problems arise, or there any 
feelings of pressure to participate, you may call the Principal Investigator Cambria Glosz at (858) 
722-8231, Dr. Peggy Papathakis at (805) 756-7205, or Dr. Mark Manary at Queen Elizabeth 
Central Hospital in Blantyre, Malawi at 0999-921-656. If you have questions or concerns 
regarding the manner in which the study is conducted, you may contact Dr. Steve Davis, Chair of 
the Cal Poly Human Subjects Committee, at (805) 756-2754, sdavis@calpoly.edu, or Dr. Dean 
Wendt, Interim Dean of Research, at (805) 756-1508, dwendt@calpoly.edu.You may also ask 
questions or state concerns regarding your rights as a research subject to Dr. Kalanda, the 
COMREC chair at the University of Malawi, College of Medicine at 099 946 0737 locally if you 
have any questions or concerns about this study. 
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7. You will be informed of any significant new findings developed during the course of 
participation in this research that may have a bearing on your willingness to continue in the study.  
This vitamin and mineral study is not intended to diagnose or treat any medical problems not 
specifically stated in the purpose of the research. If you would like to be informed of any results 
from this study, please contact the researchers using the contact information above.  
 
I have read this consent form and have been given the opportunity to ask questions.  I will also be 
given a copy of this consent form for my records.  I hereby give my consent to participate in the 
research described above.  
 
 
I voluntarily agree to take part: 
 
Name of Volunteer Participant (signed) _________________________ Date ___________ 
 
Name of Volunteer Participant (printed) _________________________ 
 
Signature of Researcher ______________________________________Date____________ 
 
 
 
Thumbprint: _______________________________________ 
 
 
 
DATE STUDY ID NAME SIGNATURE, 
INITIALS, OR 
THUMPRINT 
   
 
 
   
  
 
   
  
 
   
 
 
    
 
 
    
 
 
   
 
 
   
 
 
